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GENERAL INTRODUCTION AND OUTLINE
Introduction
Hereditary spastic paraplegia (HSP) refers to a heterogeneous group of inherited dis-
orders with an estimated prevalence of 3.3-6.6/100,000 individuals 7. Patients with 
HSP are clinically characterized by progressive lower extremity spasticity, and to a 
lesser extent, muscle weakness and sensory loss 8,9. In addition, many patients ex-
perience urinary problems related to a spastic bladder. The common pathological 
feature in HSP is retrograde axonal degeneration of the corticospinal tracts, poste-
rior spinal columns, and to a lesser extent the spinocerebellar fibers 10,11. The axonal 
degeneration is presumably due to abnormal axonal membrane trafficking process-
es, which primarily affect the distal parts of axons but additional pathophysiological 
mechanisms are involved 12. 
HSP is characterized by autosomal dominant, autosomal recessive, X-linked or ma-
ternal patterns of inheritance. The genetic classification for HSP is based on sequen-
tial numbering of genetic loci, according to the order of discovery, using a spastic 
paraplegia gene (SPG) designation 13. To date, up to 80 SPG genes have been iden-
tified. Still, a genetic diagnosis cannot be not made in 51–71% of all suspected cases 
14-18, indicating an even larger genetic heterogeneity. HSP can be divided into pure 
(uncomplicated) and complicated forms, depending on the presence or absence of 
other neurological symptoms in addition to spastic paraparesis. Complicated phe-
notypes may include symptoms such as dementia, ataxia, severe amyotrophy, optic 
atrophy, mental retardation, extrapyramidal signs, deafness, peripheral neuropathy 
and/or epilepsy. In pure HSP, the neurological impairments are mainly restricted to 
lower limb spasticity and bladder involvement. In this thesis, the focus is on patients 
with pure HSP.
Pure HSP may manifest at any age, but the first symptoms and signs mostly occur 
before the age of 40 years 19-21. The first presenting symptoms are subtle with de-
velopment of leg stiffness. As the disease progresses, gait and balance impairments 
develop, which may result in falls and fall-related injuries, and which increasingly 
affect safe and independent mobility. Several reports on pure HSP indicate the pres-
ence of gait and balance impairments and subsequent increased fall risk as the most 
prominent functional consequences of HSP 9,22-24. Gait abnormalities in HSP patients 
are typically described as “foot drag”, “crouch gait” and/or “scissoring” 11,25,26. Yet, the 
role of spasticity in gait and balance impairments remains poorly understood. Un-
fortunately, curative treatments for HSP do not exist. As a consequence, current 
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treatments aim at supportive measures and symptomatic relief. One of the primary 
treatments to reduce focal spasticity is injection of botulinum toxin type-A (BTX-A; 
Box 1), but very little is known about the functional effects of this treatment on bal-
ance and gait. Hence, it is important to get insight in the functional complaints and 
problems of patients with pure HSP and to investigate the underlying mechanisms 
and possible treatments of their balance and gait problems. 
Outline of the thesis
 
The overall aim of this thesis is to gain more insight into the motor control deficits of 
patients with pure forms of hereditary spastic paraplegia (HSP) that underlie their gait 
and balance problems and into the effects of treatment with BTX-A. 
Part 1 of this thesis focuses on the daily life problems encountered by patients with 
HSP. Chapter 2 starts with an overview of the pathophysiology, diagnostic workup 
and management of balance impairments in HSP. In chapter 3, the results of an 
online survey are provided that was designed to investigate the influence of muscle 
spasticity on experienced complaints, activity limitations and loss of motor capacities 
in patients with HSP.
Part 2 is focused on the underlying mechanisms of motor control in patients with 
pure HSP. In chapter 4, the role of hyperexcitable short-latency stretch reflexes in 
balance control is investigated by exposing patients to toes-up and toes-down per-
turbations. These balance perturbations are imposed by the Radboud Falls Simulator 
(Box 2). It is expected that exaggerated short-latency reflexes in the triceps surae lead 
to difficulties in sustaining toes-up perturbations. 
BOX 1. Botulinum toxin type A
Botulinum toxin type A (BTX-A) inhibits the acetylcholine release from the presynap-
tic neuromuscular terminals. Local BTX-A injections are used to selectively reduce 
neural activation of targeted muscles 4, with the degree of reduction depending on 
the dosage 5. In neurology and rehabilitation medicine, BTX-A injections are mainly 
used to treat overactive muscles, such as in dystonia and spasticity. BTX-A injection 
is therefore one of the spasmolytic treatment options.
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BOX 2. Balance and gait analysis
In this thesis, the Radboud Falls Simulator (RFS; BAAT, Enschede, The Netherlands 6) 
is used to investigate balance control. The RFS is a motorized platform of which the 
support surface (upon which the subject is standing) can suddenly translate or rotate 
by powerful torque motors that assure standardized delivery of perturbations (figure 
1). During gait assessments, participants walk across a 10 meter walkway (figure 2). 
During both balance and gait assessments, body segments are identified by attach-
ment of reflective markers and tracked by a 3D motion analysis system (Vicon Motion 
Systems, Oxford, United Kingdom) in order to analyze kinematics. In addition, forces 
are obtained from force platforms (AMTI® force plate, Watertown, United States) 
and muscle activation patterns are recorded using surface-based electromyography 
(EMG) (ZeroWire, Aurion, Italy). 





In chapter 5, we examine whether the reticulospinal tract can be utilized to con-
trol voluntary whole-body movements by applying the StartReact paradigm (Box 3) 
during gait initiation. It is expected that the reticulospinal tract is able to play a com-
pensatory role in such voluntary control. 
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BOX 3. StartReact
StartReact is the phenomenon that reaction times are accelerated when a startling 
stimulus is presented simultaneously with an imperative stimulus for executing the 
requested movement. Although the exact neural structures that are involved in the 
StartReact effect are not uncontested, there is ample evidence that the accelerated 
motor responses are due to the startling stimulus directly releasing a subcortically 
pre-prepared movement, which is then conveyed by the reticulospinal tract 1-3. 
Part 3 consists of clinical studies that aim to gain insight in the effects of BTX-A on 
balance and gait. In chapter 6, we address the question how ankle kinematics and 
kinetics during gait are modified by BTX-A injections in the calf muscles. A previous 
study from our group showed a decrease in calf muscle tone and a slight decrease 
in calf muscle strength resulting in an increased gait velocity 9. It is expected that 
a decrease in negative work (due to decreased muscle tone) outweighs a possible 
decrease in positive work (due to decreased muscle strength). In chapter 7, we ex-
plore the functional effects of BTX-A treatment and subsequent stretching of the 
spastic hip adductors on gait and lateral balance control. It is expected that reduced 
spasticity following treatment translates into an increased gait width and improved 
lateral stepping capacity. 
A summary and general discussion in chapter 8 finalize this thesis. 

PART 1
DAILY PROBLEMS OF LIVING WITH HSP

Pathophysiology, diagnostic work-up, and  
management of balance impairments and falls in  
patients with hereditary spastic paraplegia.
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BALANCE AND FALLS IN PATIENTS WITH HEREDITARY SPASTIC PARAPLEGIA
Abstract 
 
Balance impairments are common in patients with hereditary spastic paraplegia 
(HSP) and among the most debilitating symptoms, as they frequently result in falls 
and fall-related injuries. Several features of HSP contribute to balance impairments 
and multiple treatment options exist. However, an overview of these underlying 
mechanisms and their treatment is currently lacking. We review the pathophysiology, 
diagnostic workup, and management of balance impairments in HSP. Recommen-
dations are based on scientific evidence, when available, and otherwise reflect prac-
tice-based evidence supported by clinical experience. We argue that through diligent 
history taking and thorough clinical examination, followed by multidisciplinary treat-
ment tailored to the identified underlying mechanisms, balance capacities in patients 
with HSP can be improved and at least a proportion of falls can be prevented. 
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Introduction
 
Hereditary spastic paraplegia (HSP) is a diverse group of inherited disorders that are 
clinically characterized by progressive spasticity, muscle weakness and reduced 
proprioception in the lower extremities 27,28. In addition, many patients experience 
urinary problems related to a spastic bladder. The common underlying mechanism 
of these symptoms is retrograde axonal degeneration of the corticospinal tracts, 
posterior spinal columns, and to a lesser extent the spinocerebellar fibers 10,11. HSP 
can be divided into pure (uncomplicated) and complicated forms, depending on 
the presence of other neurological symptoms, such as ataxia, optic atrophy, men-
tal retardation, extrapyramidal signs, dementia, deafness and epilepsy 28. The first 
presenting symptoms and signs of HSP are subtle with development of leg stiffness 
and minor gait impairments. Although the disease may manifest at any age, the first 
symptoms and signs mostly occur before the age of 40 years 19-21. As the disease 
progresses, balance impairments develop, which may result in falls and fall-related 
injuries. Unfortunately, the prevalence of balance impairments and frequency of falls 
in HSP has – to our knowledge – not yet been studied. Moreover, the consequences 
of balance impairments and falls have been mapped insufficiently, but clinical experi-
ence shows that these may seriously impact on daily life, as they result in fall-related 
injuries, fear of falling, reduced mobility (approximately 10% of the patients with pure 
HSP become wheelchair bound 29), loss of independence, and reduced quality of life. 
Most publications about HSP concern its genotypes and the genotype-phenotype 
coupling. Far less publications have considered the functional consequences of HSP, 
and most of these address the (management of) spastic gait impairments such as 
‘foot drag’, ‘crouch gait’, and ‘scissoring’ 11,25,26. Very few publications have been fo-
cused on balance impairments and related falls as specific consequences of HSP 22. 
To fill this gap, we here elaborate on the pathophysiology, diagnostic workup, and 
management of balance impairments and falls in patients with HSP. This review is 
based on scientific evidence when available (see box 1), and otherwise reflects prac-
tice-based evidence supported by clinical experience. 
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BOX 1. Search strategy
We searched PubMed for relevant articles published in English from database incep-
tion to January 1, 2017. Potential papers were identified with the terms ‘hereditary 
spastic paraplegia’, ‘Strumpell-Lorrain disease’, ‘HSP’, ‘balance’, ‘balance impairments’, 
‘falls’ and ‘ treatment’. Selected articles were also obtained from the reference lists of 
papers identified by the PubMed search and from searches of the authors’ own files.
Pathophysiology: Why do patients with HSP fall?
 
In general, falls can be the result of intrinsic or extrinsic risk factors, or a combina-
tion of both 30. An icy pavement, wet bathroom tiles, or loose carpets are examples 
of extrinsic risk factors that may cause a trip or a slip inducing a fall. However, as 
in other neurological conditions such as stroke and Parkinson’s disease 31,32, falls in 
HSP are mainly due to intrinsic risk factors. These intrinsic factors hamper feet-in-
place balance responses and contribute to suboptimal stepping responses when a 
feet-in-place response is no longer sufficient to maintain balance. In HSP, four main 
contributors to balance impairments can be identified.
The first intrinsic risk factor is spasticity, which can have a direct (negative) influence 
on balance responses when fast muscle stretch – induced by active or passive body 
perturbations – results in destabilising muscle responses. This is best documented 
for ‘toes-up perturbations’, during which rotation of the support surface induces fast 
ankle dorsiflexion and backward body perturbation 33. In healthy subjects, stretch-in-
duced calf muscle activity is suppressed during these toes-up perturbations, allow-
ing ventral leg and trunk muscles to pull the body forward and restore balance 34,35. 
However, in patients with HSP, there is insufficient suppression of stretch-induced 
calf muscle activity due to reduced corticospinal inhibition of stretch reflexes, as 
part of the so-called ‘upper motor neuron syndrome’ 22,24. This may result in a desta-
bilising plantar flexion moment at the ankles that counteracts the ventral muscles, 
which pulls the centre of mass (further) backwards, and threatens balance 22. As 
such, toes-up perturbations may cause backward falls in HSP. However, as toes-up 
perturbations in daily life are relatively rare, their potential contribution to actual fall 
risk is probably limited. Moreover, the available evidence suggests that calf mus-
cle spasticity does not contribute to balance impairments in HSP during backward 
balance perturbations induced by forward support-surface translations (when the 
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calf muscles are shortened instead of stretched) or by any type of forward body 
perturbation 22. Hence, the direct contribution of spasticity of distal musculature to 
balance impairments in HSP seems limited. Still, spasticity of proximal musculature 
(e.g. the adductors or hamstrings) may directly contribute to balance impairments 
as it hampers the capacity to make sufficiently fast stepping responses in situations 
where feet-in-place responses do not suffice. For example, hip adductor spasticity 
may reduce the efficacy of balance-correcting side steps upon lateral perturbations 
and hamstrings spasticity may seriously limit the capacity to make a forward step of 
sufficient length upon forward body perturbations. 
Although the direct contribution of leg muscle spasticity to impaired feet-in-pace 
balance may be limited, spasticity can indirectly contribute to balance impairments 
and falls in HSP, because it predisposes to the development of muscle contractures 
and joint deformities (second risk factor), which negatively influences the ability to 
perform feet-in-place balance responses as well as stepping responses. The most 
commonly encountered deformity in patients with HSP is pes equino(varus) due to 
structural shortening of the calf muscles, long toe flexors and/or tibialis posterior 
muscle. Structural pes equinus results in a (severely) reduced base of support, partic-
ularly when the heels do no longer have contact with the ground. This situation pre-
vents the use of normal ‘ankle strategies’ for maintaining feet-in-place balance in the 
sagittal plane, requiring the recruitment of less efficient ‘hip strategies’. In addition, 
patients may adopt compensatory postural adjustments at the knees (e.g. hyperex-
tension), hips (e.g. hyperflexion) and trunk (e.g. forward lean) in order to maintain bal-
ance when standing. In some patients, there is varus deformity at the ankles, which 
can be aggravated by a concomitant pes cavus. As a consequence, the base of sup-
port in the frontal plane will be reduced, which will impair the use of ankle strategies 
during one-legged stance, for example during the single-support phase of gait. Apart 
from a direct influence on balance, pes equinovarus obviously predisposes to gait 
impairments such as ‘foot drag’ and ‘hooking’, which increases the risk of tripping 
over one’s own feet while walking or when making a balance-correcting stepping 
response. Moreover, varus deformity at heel strike and during the stance phase of 
gait will predispose to ankle instability, ankle sprain, and falling sideways. In addition 
to pes equinovarus, knee flexion contractures (due to shortened hamstrings) and 
hip adduction contractures (due to shortened hip adductors) are common in pa-
tients with HSP. In our experience, their impact on balance is – as with spasticity of 
proximal musculature – stronger through impaired stepping responses than through 
impaired (feet-in-place) equilibrium reactions.
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The third intrinsic risk factor for balance impairments and falls in HSP is muscle 
weakness. Indeed, there is evidence that reduced calf muscle strength is associat-
ed with postural instability during forward body perturbations induced by backward 
support-surface translations 22. In contrast, however, the relationship between tibialis 
anterior strength and backward body perturbations (induced by forward support-sur-
face translations) appears to be less clear 22. Generally, muscle weakness does not 
seem to be the major impairment in patients with HSP, even though the name ‘para-
plegia’ suggests otherwise. There is growing support for the notion that muscle 
weakness induced by lateral corticospinal tract dysfunction can be compensated by 
reticulospinal activation originating from the brainstem 36,37. Indeed, there is strong 
evidence for intact reticulospinal control over voluntary and postural leg movements 
in patients with HSP 1,23,38. Hence, compensatory reticulospinal activity may be quite 
effective to produce sufficient muscle strength, although less differentiated in com-
parison to the more selective corticospinal control over muscles 39. However, as with 
other neurological diseases 40, patients with HSP are prone to sarcopenia and loss of 
muscle strength due to ‘disuse’ induced by lack of activity. Lack of activity can have 
several reasons, one of which is fear of falling. Disuse-induced muscle weakness 
commonly induces a vicious circle in which balance impairments become worse, 
resulting in falls and fear of falling, and eventually more disuse. 
A fourth, least known or appreciated risk factor for balance impairments in HSP is re-
duced proprioception, resulting in delayed postural responses. We evaluated balance 
responses to forward and backward body perturbations in patients with pure HSP, 
and found that patients were less stable than healthy aged-matched control subjects, 
as reflected by a larger percentage of trials in which they had to take a corrective 
step or grasp a handrail 23. Moreover, compared to controls, their postural responses 
to backward and forward perturbations were on average delayed by 38 and 34 ms, 
respectively 23. This delay may appear small in absolute terms, but entails a relative 
increase of 25-30% compared to healthy subjects. This delay in postural responses 
could theoretically be the result of a slowness of signals in the afferent (posterior 
spinal columns) or efferent (reticulospinal) tracts, or in a combination of both. By 
combining balance perturbations with an auditory startling stimulus we were able 
to disentangle both mechanisms 1,36,41. The results indicated that delayed postural 
responses in patients with HSP are primarily due to a delay of signals in the posterior 
spinal columns, i.e. due to impaired proprioception 23. 
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Overall, we believe that impaired feet-in-place responses in patients with pure HSP 
are mainly due to delayed postural responses and to the biomechanical influence of 
predominantly distal muscle contractures. In contrast, the contribution of distal mus-
cle weakness and spasticity seems to be restricted to specific types of body perturba-
tions. Nevertheless, spasticity, shortening, and weakness of the proximal leg muscles 
may hamper the capacity to make sufficiently fast and large stepping responses in 
situations where feet-in-place responses do not suffice. Obviously, it should be kept 
in mind that ataxia, extrapyramidal symptoms and/or visual impairments may con-
tribute to balance impairments in patients with complicated forms of HSP. 
 
 
Diagnostic workup: individual identification of fall 
mechanisms in HSP
 
Although balance impairments and falls in HSP are common, the presence and rela-
tive contribution of the various intrinsic and extrinsic risk factors may vary consider-
ably between patients. Therefore, history taking and clinical examination is necessary 
to determine the contribution of each factor to individual balance impairments 30. In 
this diagnostic process, it is important to value each risk factor as well as their possi-
ble interactions, as often multiple factors are relevant for individual patients.
History taking
In both healthy populations and in patients with a neurological disorder, the stron-
gest risk factor for a fall is the presence of a fall-history 42,43. It is therefore essential 
to ask whether the patient has fallen during the last year(s) and, if so, whether he or 
she has fallen recurrently, under which circumstances, and whether any injury has 
ever occurred. In the case of recurrent falls, it is important to establish whether there 
is a typical pattern or direction to the fall 30. Even if the patient indicates not to fall, 
the identification and treatment of risk factors is still important for the prevention 
of future falls. Patients with HSP can usually indicate whether they are easily ‘pulled 
backward’ or whether they fall forward or sideways instead. It is not useful to ask for 
underlying mechanisms (e.g. spasticity, slowness, or contractures), as patients find it 
difficult to judge any of such possible relationships. Yet, fall circumstances, fall pat-
tern, and type of injury can point towards a specific mechanism like ‘backward insta-
bility’. When a patient has fallen, it is important to ask whether he or she recalls hitting 
the floor to exclude loss of consciousness due to head trauma. Because patients 
CHAPTER 2
24
BALANCE AND FALLS IN PATIENTS WITH HEREDITARY SPASTIC PARAPLEGIA
with HSP rarely lose their consciousness when falling, other underlying mechanisms 
such as vasovagal syncope or cardiac arrhythmias should be suspected. As in the 
general population, use of medication – especially polypharmacy – can increment 
fall risk and, thus, an evaluation of prescribed drugs should take place. Benzodiaze-
pines and antidepressants are notorious in this respect 44, in addition to neuroleptics, 
antihypertensive medication, and anti-arrhythmics 45. In addition to intrinsic factors, 
it is important to screen for the presence of extrinsic factors, for example the type of 
footwear and the home situation. It is not uncommon to discover that patients who 
suffer recurrent falls live in a house with loose high carpets and without extra support 
points in the bathroom or toilet. 
Finally, it is informative to inquire about the impact of balance impairments, partic-
ularly fear of falling and a related reduction of in- and outdoor activities. In this way, 
the clinician is also able to screen for disuse. In fearful patients, fall frequency is not 
an adequate measure of balance problems, as these patients have often adjusted 
their lives in such a way that falls hardly occur. The downside of this adjustment is, 
however, a seriously reduced quality of life for both themselves and their relatives as 
well as an enhanced risk of co-morbidity related to immobility, such as cardiovas-
cular disease, osteoporosis and sarcopenia, reinforcing a vicious circle of functional 
incapacity and inactivity. 
Clinical examination
When the patient’s history is suspicious of balance impairments, a thorough clinical 
examination is mandatory to confirm the presence of balance impairments and to 
identify underlying mechanisms. Table 1 provides an overview of useful clinical tests 
of balance, gait and neurological functions.
A useful test to indicate the presence of balance impairments is assessing the ability 
to rise from a chair, to stand on two legs as well as on one leg with the foot flat on 
the ground and eyes opened. An inability to perform such tests without any external 
support strongly suggests the presence of balance impairments. A key element in 
the clinical assessment of postural instability is the retropulsion test, in which the as-
sessor induces a balance perturbation by applying a (preferably unexpected) shoul-
der pull 46. The absence of a balance corrective step or a suboptimal quality of the 
balance corrective step is indicative of postural instability. In patients with HSP, we 
recommend to perturb the patient not only in the backward direction, but also in the 
forward and lateral directions to test the quality of the stepping responses in the oth-
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er directions as well. By sitting on a stool in front of the patient the clinician can easily 
pull the pelvis forward or apply sideways forces to the pelvis, while the patient is able 
to grasp the shoulders of the clinician or the clinician can stop a falling motion when 
needed. As a more elaborate test we advice to perform the mini-BESTest, consisting 
of a 14-item, 3-point rating scale evaluating four sub-items: transitions/anticipatory 
postural control, reactive postural control, sensory orientation, and stability in gait 
47. Another option is the Berg Balance Scale (BBS)48, which is a standardized 14-
item, 4-point rating scale to indicate the presence of postural instability while sitting, 
standing and making postural movements in place. Both the mini-BESTest and the 
BBS include several elements of the tests described above. However, no standard-
ized balance test has yet been validated for patients with HSP. 
TABLE 1. Key elements of the clinical examination in patients with HSP
Tests that help to indicate the presence of balance impairments 
•	 Rising from sit to stance
•	 Two- and one-legged stance
•	 Retropulsion test (plus perturbations in forward and lateral directions)
•	 Mini-BESTest or Berg Balance Scale 
•	 Evaluation of the gait pattern
•	 Standardized gait observation
•	 Observation of tandem gait
Evaluation of the four main intrinsic risk factors for balance impairments in HSP
•	 Evaluation of muscle tone (e.g. Modified Ashworth Scale)
•	 Evaluation of joint mobility (e.g. Debrunner notation)
•	 Evaluation of muscle strength (e.g. MRC-scale)
•	 Evaluation of proprioception 
•	 Vibration sense at lateral malleolus and first metatarsophalangeal joint
•	 Romberg’s test
•	 Gait with and without a walker or ‘finger support’
Balance capacity while walking can be assessed by testing tandem gait (i.e., the ability 
to take 10 consecutive steps along an imaginary line without one or more side steps). 
This test is very sensitive for subtle balance impairments and often no longer possible 
in patients with HSP. Of course, the gait pattern should be observed for the identifi-
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cation of specific gait impairments that increase the risk of tripping and falling, such 
as foot drag, hooking of the feet, and excessive scissoring with collision of the knees. 
The four main risk factors for balance impairments in HSP must always be identi-
fied by a systematic evaluation. We recommend to assess muscle tone of distal and 
proximal leg musculature using the Modified Ashworth Scale (MAS) 49, to evaluate 
joint mobility with goniometry using the Debrunner notation 50, and to assess muscle 
strength using the Medical Research Council (MRC) scale 51. Although both the MAS 
and the MRC scales have been criticized for their lack of reliability and sensitivity 
52, alternative clinical tools for measuring muscle tone (e.g. the Tardieu scale 53 and 
strength (e.g. hand-held dynamometry) are quite time-consuming to be applied to 
all joints of the lower limbs and do not necessarily provide more reliable information. 
Importantly, with regard to management, the clinician should try to carefully discrim-
inate loss of muscle length (contracture) from increased muscle tone (spasticity) us-
ing goniometry for all relevant muscle groups, with the calves evaluated with both an 
extended (gastrocnemius) and flexed (soleus) knee, preferably in a supine position. 
Regarding the evaluation of proprioception, it is useful to evaluate vibration sense at 
the lateral malleolus and at the first metatarsophalangeal joint. An easy way to evalu-
ate the contribution of impaired proprioception to balance impairment is Romberg’s 
test, in which the clinician evaluates body sway and the presence of balance cor-
rective movements of the head, trunk and arms while the patient stands erect with 
the feet together and the hands by the side. This test is performed with eyes opened 
and closed and is considered positive when body sway increases to the extent that 
a patients tends to fall with the eyes closed compared to when they are opened. A 
positive test is indicative of balance impairments due to sensory dysfunction and, 
thus, useful to find proof of impaired leg somatosensation in HSP. Nevertheless, a 
false-positive outcome may occur due to uncertainty or fear, while a false-negative 
outcome may be due to insensitivity to subtle sensory deficits. One study did not 
find increased postural sway in four patients with HSP compared to controls (18), but 
future studies are needed to further map postural sway in patients with HSP, both in 
mildly and severely affected patients. 
Another functional test that is sensitive to somatosensory deficits is comparing com-
fortable gait speed with and without a walker. Although a walker may provide me-
chanical support and increases the base of support while walking, its most important 
influence is often the provision of sensory feedback through the upper extremities 
especially in patients that do not really lean on the walker. When such patients walk 
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much faster with a walker than without, this finding is suspicious of impaired leg 
somatosensation. In the same vein, providing ‘a fingertip’ of support to the hand of a 
patient while standing or walking is also a strong indicator of reduced somatosensa-
tion54, if it leads to better postural stability and higher gait speed.  
As outlined in the introduction, patients with a complicated form of HSP can have 
a wide variety of other symptoms in addition to their spastic paraparesis, such as 
ataxia, signs of parkinsonism or visual disorders. As these symptoms may significantly 
contribute to the balance impairments, it is important to screen and monitor them 
and, if present, to manage treatable symptoms accordingly (this will not be covered 
in the management section of this paper). 
Ancillary testing
In most patients, history taking and clinical examination will be sufficient to obtain a 
good general overview of the presence and severity of the balance impairments and 
of the underlying risk factors. Yet, a more in-depth evaluation of balance impairments 
may be conducted with posturography. 
Using ‘static posturography’ equipment for recording quiet standing6, body sway 
can be quantified and compared to reference values obtained from healthy, age-
matched individuals. In addition, the Romberg quotient can be determined, which is 
the ratio between the body sway assessed with eyes closed divided by the sway as-
sessed with eyes opened 55. Such an instrumented Romberg quotient is much more 
sensitive than the clinical Romberg’s test, but the necessary equipment may not be 
available in many clinical practices. 
So-called ‘dynamic posturography’ is a technique that employs physical perturba-
tions of stance (often by a motorized balance platform) to systematically and quan-
titatively evaluate both feet-in-place balance responses and stepping responses. Al-
though this technique has proven its value for research purposes, it has so far no 
clear additional value for clinical practice in comparison to the tests described above 
6. However, when balance impairments and gait impairments coincide, or when gait 
impairments frequently result in falls, instrumented assessment of the kinematics 
(joint motion), kinetics (joint moment of force and power) and muscle activations 
(electromyography) during walking (instrumented ‘gait analysis’) can be useful to 
analyse specific gait impairments to indicate the need for well targeted interventions 
(e.g. focal spasmolysis, ankle-foot orthosis) 56,57.
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Management: how to prevent patients with HSP from falling?
Adequate management of balance impairments and falls in patients with HSP will 
greatly depend on the identification of risk factors as described above. In this para-
graph, we will discuss the treatment options based on each of these factors. The 
evidence for these treatment options is sparse, because very few studies have been 
performed and the available studies are non-randomised. In addition, the evidence 
of these interventions on balance performance in other patient groups with an upper 
motor neuron syndrome is also sparse, as most studies evaluated the effect on gait 
and not on balance control or the prevention of falls 57-59. Hence, most treatment 
options are based on expert opinion. 
Spasticity 
If a patient’s history and clinical examination is indicative of calf muscle spasticity 
contributing to a tendency to fall backwards, focal spasmolysis of the calf muscles 
must be considered. The main treatment option is neuromuscular blockade by the 
administration of bilateral botulinum toxin type A (BTX-A) injections in the gastroc-
nemius and soleus muscles to reduce the amplitude of the balance destabilizing 
responses. The efficacy of these injections has, however, not yet been proven. We 
found 10% improvement of comfortable gait speed after such injections in patients 
with HSP, but no improvement on the BBS, dynamic posturography, or the Activi-
ties-specific Balance Confidence scale (ABC)9. Despite the absence of a significant 
effect at group level on all balance-related outcomes, it is our clinical experience 
that well-selected individual patients with destabilizing calf muscle spasticity and a 
relative mild pes equinus contracture may profit from focal spasmolysis and subse-
quent stretching exercises of the calf muscles with regard to their backward postural 
stability. This notion is supported by a recent retrospective study reporting that fo-
cal spasmolysis with BTX-A combined with physiotherapy aimed at optimizing joint 
mobility of the treated segments helps to acquire an adequate postural alignment 
in patients with HSP 60. In addition to intramuscular injections with BTX-A, chemical 
or thermal neurolysis of the tibial nerve and selective surgical neurotomy of specific 
branches of the tibial nerve are techniques to reduce disabling calf muscle spasticity 
61,62. However, chemical or thermal neurolysis carries the risk of inducing sensory 
deficits and/or neuropathic complaints, while selective neurotomy is complex and 
performed only by very few expert teams worldwide. 
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As mentioned above, spasticity of the proximal muscles may hamper stepping re-
sponses in both the sagittal and frontal planes. As such, it would intuitively be right 
to apply focal spasmolysis by intramuscular BTX-A injections (followed by stretching 
exercises) for instance in the hamstrings to improve forward stepping and in the hip 
adductors to improve lateral stepping in individual patients with HSP. Currently, we 
are conducting an uncontrolled pre-post trial to study the efficacy of bilateral BTX-A 
injections in the hip adductors to improve spontaneous gait width as well as side 
stepping responses upon lateral body perturbations in patients with HSP and hip 
adductor spasticity (Toetsingonline.nl: NL5353904.091.15). 
The use of oral spasmolytic drugs is usually not effective to obtain focal results in 
specific muscles 63 and carries the risk of systemic side effects, such as nausea, 
drowsiness, loss of (leg) muscle strength, and dizziness. Yet, oral spasmolytic drugs 
(e.g. baclofen, tizanidine or tolperison) should be considered when there is severe 
‘lower body’ spasticity affecting several distal and proximal leg muscles, hampering 
effective stepping responses. When effective, such patients will probably also profit 
from this medication with regard to their gait capacity. If oral spasmolytic drugs are 
insufficient (and multilevel intramuscular BTX-A injections not feasible or impracti-
cal), intrathecal baclofen therapy (ITB) should be considered for this relatively severe 
subgroup of patients. ITB has shown to reduce spasticity-related complaints and 
improve walking capacity in these patients 64, but its effect on balance capacity has 
not yet been shown. 
Contracture and deformity
As stated above, pes equino(varus) is the main and often first deformity seen in pa-
tients with HSP due to shortening of the dorsal leg muscles. In addition to muscle 
contracture, spasticity may contribute to this deformity when spastic muscles are 
no longer able to fully relax. From this perspective, focal spasmolysis of the calf 
muscles, tibialis posterior and/or long toe flexors may also be indicated to reduce 
ankle deformity, but such treatment should always be accompanied by intensive 
stretching exercises to improve muscle length and inhibit muscle tone. Especially 
selective BTX-A injections in the tibialis posterior muscle may be effective to reduce 
varus deformity, unless fixed varus contracture has developed. In the case of a fixed 
contracture, ankle deformity can be compensated by providing orthopaedic foot-
wear but the effectiveness of such footwear to improve balance capacity in patients 
with HSP has not yet been studied. The main goal of orthopaedic footwear is to re-
store a full base of support in both the antero-posterior and medio-lateral directions 
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and to provide ankle stability in the case of structural varus deformity. When there 
is concomitant pes cavus, a well adjusted insole can accommodate for this latter 
deformity. Orthopaedic footwear should always be as light-weighted as possible and 
allow sufficient mobility at the talocrural (superior) ankle joint for optimal use of ankle 
strategies and for an optimal roll-off motion during gait. In addition, the external sole 
should not aggravate any tendency towards foot drag. 
Another option for restoring a normal base of support is to surgically lengthen the 
shortened dorsal muscles of the lower leg, particularly for more severe contrac-
tures and for those patients that do not want to rely on adjusted footwear. Usually, 
percutaneous Achilles tendon (AT) lengthening is sufficient to correct pes equinus. 
Interestingly, it is our experience that AT lengthening will often reduce the degree 
of post-operative calf muscle spasticity as well. Tenotomy of the tibialis posterior 
muscle may be effective to correct pes varus, but an (complementary) arthrodesis of 
the talonavicular joint may be a more viable treatment option. In addition, tenotomy 
of the long toe flexors may be necessary for the AT lengthening to be truly effective. 
Osteotomy of the first metatarsal bone can be performed to correct a concomitant 
severe and structural pes cavus.   
Any treatment that is able to reduce equinovarus deformity at the ankle joints will 
eventually be beneficial for static and dynamic balance by allowing better use of 
ankle strategies in both planes and by a reduced risk of tripping, hooking, ankle insta-
bility or ankle sprain. Redression of equinovarus deformity will also improve standing 
posture by requiring less postural adjustments at the knees, hips, and trunk.
Knee flexion and hip adduction contractures must preferably be treated by an in-
tensive stretching regime, supported by BTX-A injections in the hamstrings and hip 
adductor muscles, respectively. As for the hip adductors, the adductor magnus, ad-
ductor longus, and gracilis are the most relevant target muscles given their anatom-
ical lever with respect to the hip joint 65. In our experience, the medial hamstrings 
are a better target than the lateral hamstrings if there is a tendency towards internal 
rotation at the hips. Besides passive stretching exercises, active stepping and agility 
training is recommended to incorporate improved joint range of motion into the 
motor programs used for standing and walking. 
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Muscle weakness 
As indicated above, muscle weakness does not seem to be the major determinant 
of balance impairments in HSP. This is probably related to reticulospinal compensa-
tion originating from the brainstem 1. Exercise training to improve muscle strength 
is therefore not very likely to improve balance capacity in most patients with HSP. 
However, patients with HSP are prone to ‘disuse’ phenomena due to lack of activ-
ity and fear of falling. So if a patient’s history and/or clinical examination indicates 
disuse, a comprehensive physical training program, guided by a physical therapist is 
recommended. As prolonged walking frequently leads to increased leg muscle tone, 
this may not be the optimal training activity for patients with HSP. We therefore ad-
vice to regularly perform cycling exercises, preferably under natural circumstances 
using a (adapted) bicycle, or otherwise a home trainer. Most patients experience a 
beneficial effect of cycling exercises not only on their muscular and cardiopulmo-
nary endurance, but also on their leg muscle spasticity and stiffness during walking. 
Usually, this kind of aerobic training can be done at home or in a community-based 
fitness practice and needs merely remote guidance from a physical therapist. The 
effectiveness of regular (cycling) exercises to prevent disuse phenomena, to improve 
muscular and cardiopulmonary endurance, and to reduce leg muscle spasticity in 
HSP is an important topic for future research.       
Impaired proprioception 
Unfortunately, it is not possible to restore impaired proprioception in patients with 
HSP. Management should therefore focus on the use of optimal compensation strat-
egies. Compensation involves an increased reliance on other sensory resources 
than proprioceptive information from the feet and lower legs (such as visual input 
or somatosensory information from the upper legs or provided by a walking aid). To 
train this type of compensation, we recommend patients with HSP to perform daily 
balance exercises at home, e.g. by alternately standing on one leg, in front of a high 
table or low cupboard, while gradually reducing the amount of hand/finger contact 
with the object. In our clinical practice, all patients are taught how to perform these 
exercises by an expert physical therapist during one treatment session.
When balance impairments are so severe that falls occur regularly, the use of walk-
ing aids cannot be avoided. Preferably, patients should use such aids not to lean on, 
but to obtain extra somatosensory information through the upper extremities. Thus, 
Nordic Walking sticks are preferred above conventional canes or crutches. Some pa-
tients prefer to use a walker, as these devices often provide additional comfort such 
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as a seat and basket. Even when patients start to rely on walking aids, they must be 
challenged to maintain their balance capacity by continuing the daily performance 
of balance exercises to avoid the detrimental consequences of disuse. Eventually, 
some patients may need to rely on a wheelchair, even to cross short distances, de-
pending on the age of onset and the progressiveness of the disease. We recommend 
consultation of an occupational therapist for offering advice on suitable wheelchairs. 
 
 
Conclusion and future perspectives
Balance impairments are an important and ‘independent’ functional consequence 
of HSP. Inadequate feet-in-place responses are predominantly due to progressively 
delayed balance responses and contractures of distal musculature. In addition, spas-
ticity, contractures and, to a lesser extent, weakness of proximal leg muscles result in 
suboptimal stepping responses. Falls are a threatening consequence of balance im-
pairments and many clinicians perceive falls in HSP as untreatable. However, it is our 
experience that diligent history taking and thorough clinical examination, followed 
by a multidisciplinary treatment tailored to the identified underlying mechanisms, is 
able to ameliorate balance capacities in patients with HSP and to prevent at least a 
proportion of these falls. Many treatment options that we have discussed need to be 
validated by further research. We conclude this review with some examples of topics 
for future studies. We have already highlighted the need for studying the effect of fo-
cal spasmolysis by intramuscular BTX-A injections followed by stretching exercises in 
proximal musculature to improve stepping responses. With respect to contractures, 
future studies need to investigate the timing of soft-tissue surgery. We hypothesize 
that timely surgical treatment, for example of a pes equino(varus) deformity, will 
improve balance capacities and prevent falls in comparison to prolonged treatment 
with orthopaedic shoes. 
With respect to functional balance training, the use of new technological tools 
should be investigated. One example is C-mill training, during which a diversity of 
visual targets is projected on a treadmill that need to be hit (or avoided) with various 
degrees of complexity, while safety is ensured by two parallel bars that patients can 
grasp in case of balance loss. The type and complexity of the visual targets can be 
individually adjusted, which makes it possible that every patient can train at his own 
level and can experience both benefit and reward. In our centre, we regularly provide 
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10 sessions of C-mill training (2 sessions per week, during 5 weeks) to patients with 
HSP for improving their dynamic balance. Such a training has been shown to be 
effective for patients with stroke 66 and for patients with hereditary forms of (spino)
cerebellar ataxia67, but studies in patients with HSP have yet to be performed. Anoth-
er potentially useful type of functional exercise is robotic training using the Lokomat, 
a robotic gait orthosis combined with a harness-supported body weight system. In 
an uncontrolled study of 13 patients with pure HSP 68, a six-week robot-aided gait 
training significantly improved balance performance assessed with the BBS. Future 
work is needed to investigate whether these promising results can be replicated by 
controlled studies. 
With respect to the organization of multidisciplinary treatment for balance impair-
ments in HSP, we expect that in the near future, patients will be supported by specif-
ically designed e-health systems, monitoring their individual condition and connect-
ing them to their primary healthcare providers. The feasibility and clinical value of 
such e-health systems needs to be evaluated by future studies as well. 
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Hereditary spastic paraplegia (HSP) is a group of inherited disorders characterized by 
progressive spastic paresis of the lower limbs. Treatment is often focused on reducing 
spasticity and its physical consequences. To better address individual patients’ needs, 
we investigated a broad range of experienced complaints, activity limitations, and loss 
of motor capacities in pure HSP. In addition, we aimed to identify patient characteris-
tics that are associated with increased fall risk and/or reduced walking capacity. 
Methods
We developed and distributed an HSP-specific online questionnaire in the Netherlands. 
A total of 109 out of 166 questionnaires returned by participants with pure HSP were 
analyzed.
Results
Participants experienced the greatest burden from muscle stiffness and limited stand-
ing and walking activities, while 72% reported leg and/or back pain. Thirty-five and 46% 
reported to use walking aids (e.g. crutches) indoors and outdoors, respectively; 57% re-
ported a fall incidence of at least twice a year (‘fallers’); in 51% a fall had led to an injury 
at least once; and 73% reported fear of falling. Duration of spasticity and incapacity to 
rise from the floor were positively associated with being a ‘faller’, whereas non-neuro-
logical comorbidity and wheelchair use were negatively associated. Higher age, expe-
rienced gait problems, not being able to stand for 10 minutes, and incapacity to open a 
heavy door showed a negative association with being a ‘walker without aids’ (>500m).
Conclusions
Our results emphasize the large impact of spastic paraparesis on the lives of people 
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Background
 
Hereditary spastic paraplegia (HSP) is a group of inherited disorders, characterized by 
progressive bilateral lower limb spasticity and, to a lesser extent, muscle weakness 27. 
HSP can be classified as ‘pure’ (‘uncomplicated’) or ‘complicated’, depending on the 
presence of other neurologic abnormalities such as ataxia, seizures, cognitive impair-
ment, and/or involvement of the upper extremities and speech 10,19,28,69. In patients 
with pure HSP, the main neurological feature is a progressive spastic paraparesis 
(SP). As HSP cannot be cured, treatment is often focused on reducing or stabilizing 
spasticity and its physical consequences. However, rehabilitation strategies should 
focus on a broad range of experienced complaints and limitations to address the 
needs of patients. Thus, gaining more knowledge of SP-related complaints, activity 
limitations, and loss of motor capacities as experienced by patients is important for 
better disease management and tailoring interventions to individual patients’ needs.
In various patient groups with lower limb spasticity (e.g. stroke, spinal cord injury and 
multiple sclerosis), spasticity appears to be a significant contributor to experienced 
complaints, activity limitations, and loss of motor capacities 70-72. Recently, an inter-
national survey in patients living with spasticity was conducted that emphasized the 
large impact of spasticity on daily life and the need for better collaboration, commu-
nication and sharing of information between patients and their healthcare providers 
to fulfill individual needs 73. Yet, patients with pure HSP may differ from the population 
with spastic paraparesis at large, as their condition is inherited and slowly progres-
sive. Existing reports on pure HSP typically indicate the presence of gait and balance 
impairments and an increased risk of falling as the most prominent functional con-
sequences 9,22,23,69,74,75. In addition, some studies mentioned the occurrence of pain, 
fatigue, urinary symptoms, sleeping problems, unpredictable day-to-day fluctuations, 
activity limitations and participation restrictions. However, these studies included ei-
ther small patients samples 76,77 or lumped patients with pure and complex HSP 78-80. 
Against this background, we developed a disease-specific online questionnaire to 
investigate the experienced complaints, activity limitations, and loss of motor ca-
pacities as well as the experienced healthcare needs in a large, representative group 
of patients with pure HSP in the Netherlands. In the current study, we specifically 
focus on SP-related complaints, activity limitations and loss of motor capacities to 
better understand the impact of the disease. Besides motor problems, we includ-
ed autonomic (micturation, defecation, and sexual) dysfunctions, as we expected 
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that the latter might be related to spasticity as well. In addition, as balance and gait 
impairments are considered key problems in HSP, we aimed to identify specific de-
mographic, clinical and functional characteristics that are associated with increased 
fall risk and/or reduced walking capacity. Data on the experienced needs will be 
reported in a separate publication.
Methods
Recruitment and inclusion of participants
Participants were recruited through the national patient organization for neuromus-
cular disorders in the Netherlands (“Spierziekten Nederland”; www.spierziekten.nl). 
On our request, they sent all the members of the HSP working group an e-mail 
with information about the web-based survey. In addition, all patients with pure HSP 
known at the national expertise center for inherited movement disorders of the 
Radboud university medical center in Nijmegen were sent a letter with information 
about the survey. People could participate if they had genetically confirmed HSP, or 
were very likely to have HSP based on their clinical symptoms and family history. In 
addition, participants had to be 18 years or older. Persons with HSP and their rela-
tives were requested to contact the primary researcher (BvL) by e-mail if they were 
willing to participate. After receiving an e-mail, the primary researcher sent a unique 
link to the web-based questionnaire to each patient who had indicated willingness 
to participate. This study was approved by the regional medical ethics committee 
“Commissie Mensgebonden Onderzoek Arnhem-Nijmegen” (number 2016-2922) 
and conducted according to the declaration of Helsinki.
Web-based questionnaire
The structure and content of the web-based survey were designed by a team of expert 
physicians, researchers, physical therapists, and persons with HSP. Part of the question-
naire was based on a previous international survey of patients living with spasticity 73, 
while other questions were based on a qualitative study in patients with pure HSP who 
were interviewed about the daily life consequences of spastic paraparesis and their re-
lated healthcare needs (note: data on healthcare needs are reported elsewhere) 77. The 
structure and formulation of the questions and predefined answering options were 
improved during an iterative process, until all authors agreed on the final questionnaire. 
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Completion of the questionnaire by participants was estimated to take about 20 min-
utes, but there was no set time limit. Participants were able to pause the questionnaire 
and continue later. To some extent, the amount of questions was variable for each 
participant, depending on his/her answer to a preceding question. Answering options 
were based on multiple choice, but some questions included a text entry as one of 
the options. Overall, the questions in this study were grouped into three response 
categories: A. ‘participant characteristics’, B. ‘complaints and activity limitations’, and 
C. ‘loss of motor capacities’ (see Appendix). Whereas the questions in category B were 
focused on the problems participants experienced when performing certain daily life 
activities, the questions in category C were focused on the self-rated capacity to ex-
ecute specific activities. To obtain a homogeneous sample of persons with pure HSP, 
specific questions were included to identify patients with neurological comorbidity 
and/or a complicated form of HSP.
Data analysis
Patients were excluded from further analysis if they indicated that they had a compli-
cated form of HSP (or a genetic defect invariably associated with a complicated form 
of HSP); experienced upper limb paresis, speech problems, or cognitive problems; or 
reported any neurological comorbidity that could influence spasticity, motor control, 
physical fitness, or activity. As we were interested in SP-related complaints, activity 
limitations, and loss of motor capacities, participants who reported that they did not 
experience spasticity (or had spasticity for less than 1 year) were also excluded from 
further analysis.
Statistical analysis
Descriptive statistics were used to analyze the primary data obtained from the ques-
tionnaires. In addition, univariate logistic regression analyses were performed on two 
dependent variables: being a ‘walker without aids’ (i.e., self-report of walking distance 
without crutch or walker > 500m), and being a ‘faller’ (i.e., self-report of at least two 
falls a year). The threshold of at least two falls a year was chosen to make sure that 
subjects were not classified as a ‘faller’ based on a single (perhaps coincidental) fall. 
To prevent overfitting of the model in case of many correlations between possi-
ble determinants and dependent variables, we continued with multivariate logistic 
forward regression analyses. Thus, possible determinants from each of the three 
response categories that were associated with a specific dependent variable in the 
univariate analyses (p<0.10) were entered in a multivariate logistic forward regression 
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A total of 194 respondents requested to participate, of which 166 persons returned a 
fully completed questionnaire. Subsequently, 57 respondents not meeting the crite-
ria outlined above were excluded (n=16 established complicated form of HSP; n=12 
upper limb paresis; n=21 speech problems; n=19 cognitive problems; n=15 neuro-
logical comorbidities; n=4 spasticity < 1 year). Finally, 109 respondents were included 
for further analysis. The participants showed an equal sex distribution (49.5% male 
and 50.5% female) and had a mean age of 52.8 years (age range 19-84 years). Most 
participants (83%) indicated a positive family history for pure HSP and 53% reported 
that HSP was also genetically confirmed. Participants without a positive family history 
or genetic diagnosis (n=7) were e-mailed by the primary investigator to confirm that 
the clinical diagnosis of pure HSP was made by a neurologist. All participant charac-
teristics are summarized in table 1.
B. Complaints and activity limitations
Experienced complaints and activity limitations were scored on a numeric scale 
(range 0-10; 0: no burden/hindrance, 10: extreme burden/hindrance). Overall, the 
participants experienced the greatest burden or hindrance from their muscle stiff-
ness and from problematic standing and walking activities (figure 1). They also re-
ported to experience a substantial burden from both physical and mental fatigue. 
Sleeping problems, self-care problems, and emotional problems were relatively mild.
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TABLE 1. Demographic and clinical characteristics
    N=109
Patient characteristics n mean (SD)
Sex (male/female) 54/55
Age (years) 52.8 (14.2)
















First degree relatives 83
Other family members 47









  Other non-neurological comorbidities 7  
*Rheumatism and osteoarthritis were given as examples to participants. Patients were 
instructed that this category did not include non-specific back complaints.
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FIGURE 1. Median, interquartile range, and total range of the level of burden/hindrance that 
participants experienced in various categories (Questions B1-B13) (0: no burden/hindrance, 10: 
extreme burden/hindrance). +: outlier.
 
Seventy-two percent of the participants reported pain. Fifty-five participants (50%) 
reported back pain, predominantly in the lower back, and 59 participants (54%) re-
ported leg pain. The majority described leg pain as nerve pain (i.e., burning or tingling 
pain; n=25), cramps (n=32), or restless legs (i.e., strong urge to keep the legs moving; 
n=33). 
Autonomic dysfunctions
Forty-nine (50%) and 21 (19%) of the participants reported micturation and de-
fecation problems, respectively. These problems were related to extreme urge 
(n=22 and n=11, respectively), impaired sphincter control (n=45 and n=14, res-
pectively), or slowness of gait (n=30 and n=11, respectively). Forty-three of the 
participants (39%) reported sexual problems, whereas 46 (42%) experienced no 
sexual problems and 20 (18%) did not know. The most frequently reported rea-
sons for sexual problems were related to spasticity (n=26) and pain (n=14). Some 
men reported ejaculation problems (n=4) or erectile dysfunction (n=8), whereas 
some women experienced vaginal dryness (n=5). Eleven participants reported 
other sexual problems, among which difficulties with having an orgasm (n=6). 
C. Loss of motor capacities
Table 2 provides an overview of the devices applied for supporting functional mo-
bility. The devices were categorized into orthoses (including orthopedic footwear), 
CHAPTER 3
43
SURVEY: EXPERIENCED PROBLEMS IN PATIENTS WITH PURE HSP
walking aids, and wheelchairs. The most often used devices were walking aids, such 
as canes or crutches: 35% reported to use walking aids indoors, whereas 46% used 
walking aids outdoors. Outdoors, an (electric) wheelchair was often applied as an 
alternative for walking. 
TABLE 2. Use of mobility-supporting devices (N=109)
n (%)
Type of device Indoors Outdoors
Orthoses 32 (29%) 44 (40%)
Ankle-foot orthosis 13 (12%) 19 (17%)
Orthopedic footwear 28 (26%) 34 (31%)
Walking aids 38 (35%) 50 (46%)
Walker 26 (24%) 30 (28%)
Cane/Crutch 28 (26%) 41 (38%)
Wheelchairs 23 (21%) 50 (46%)
Wheelchair 22 (20%) 43 (39%)
Electric wheelchair 7 (6%) 29 (27%)
Other 11 (10%) 10 (9%)
None 44 (40%) 23 (21%)
 
Without a walking aid, the majority of the participants was either unable to walk (28%) 
or walk up to 100 meters (28%), or was able to walk more than 1000 meters (32%). 
Only 12% reported to be able to walk between 100 and 1000 meters without a walk-
ing aid. With the use of walking aids, there was a more equal distribution of walking 
capacity due to a general shift from very short to longer distances (figure 2). Indeed, 
a total of 45 participants (41%) was able to walk further with than without the use of 
a walking aid. Many participants described their gait pattern as characterized by drop 
foot (75%), scissoring (30%), and/or crouch gait (13%).
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FIGURE 2. Walking distance with and without aids.
As shown in figure 3, relatively few participants were not able to sit for 30 minutes 
or to open a (heavy) door. In contrast, stair walking, picking something up from the 
floor, squatting and rising, rising from the floor, and walking with a heavy bag was 
difficult or even impossible for the majority of the participants. 
 
FIGURE 3. Percentage of participants that responded to be able to execute specific motor 
capacities with ease, with difficulty, or not at all.
Falls
Since the onset of spasticity symptoms, 93 of the participants (85%) had fallen at 
least once, which had occurred within 5 years of symptom onset in 63 of 93 subjects 
(68%). Most participants (67%) reported a fall incidence of at least once a year; 57% 
reported to fall at least twice a year (‘faller’) (figure 4). In 56 participants (51%) a fall 
had led to an injury at least once, such as a skin injury (n=34), bruise (n=33), and/or 
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bone fracture (n=13). Only 29 of the participants (27%) reported not to be afraid of 
falling, whereas 66 (60%) were moderately afraid and 14 (13%) were very afraid to fall.
 
FIGURE 4. Self-reported fall frequency of participants.
 
Regression analyses
Univariate logistic regression analyses (n=109) revealed nine determinants that were 
associated with being a ‘faller’. These determinants were entered into a multivariate 
forward regression analysis (table 3, upper part). In the final model, duration of spas-
ticity symptoms and the incapacity to rise from the floor were positively associated 
with being a faller, whereas non-neurological comorbidities and the use of a wheel-
chair were negatively associated. The overall explained variance was 45%.
The 27 participants who were not able to stand for 10 minutes or who were not 
able to open a heavy door, were never able to walk more than 500 meters without 
walking aids. These participants could not be included in the (multivariate) logistic 
regression, because of the 1:1 associations. Univariate logistic regression analyses of 
the remaining participants (n=82) yielded 29 determinants that were associated with 
being a ‘walker without aids’. These determinants were entered into a multivariate 
forward logistic regression analysis (table 3, lower part). In the final model, difficulties 
with standing for 10 minutes and with opening a heavy door showed a strong nega-
tive association with being a ‘walker without aids’, whereas age and experienced gait 
problems showed a small to moderate negative association, respectively. The overall 
explained variance was 58%.
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TABLE 3. Multivariate forward logistic regression analyses
Dependent variable: ‘faller’ (self-report of at least two falls a year) (n=109)
Cofactor Level of cofactor n OR (95 % CI) p-value
Duration of spasticity 
symptoms










Comorbidity Reference: No 101
Yes 8 0.162 (0.052-0.509) 0.002
Walking aids indoors Reference: No wheelchair 87
Wheelchair 22 0.130 (0.029-0.577) 0.007
Rise from floor Reference: Yes, with ease 12








 Overall explained variance R2 = 0.450
Dependent variable: ‘walker without aids’  
(self-report of walking distance without crutch or walker > 500 m) (n=82)
Cofactor Level of cofactor n OR (95 % CI) p-value
Age 19-84 82 0.944 (0.899-0.994) 0.030
Gait problems 0-10 82 0.604 (0.400-0.911) 0.016
Standing (10 min) Reference: Yes, with ease 40
Yes, with difficulty 42 0.286 (0.085-0.970) 0.045
Open heavy door Reference: Yes, with ease 41
Yes, with difficulty 41 0.165 (0.049-0.564) 0.004
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Discussion
Given the estimated prevalence of 800 persons with pure HSP in the Netherlands 
81, this web-based survey probably included a fairly representative sample of 109 
persons who showed an equal sex distribution, a wide age range, a large variation in 
duration of spasticity symptoms, and an expected (skewed) distribution of underlying 
genetic defects. This study sample reported many subjective complaints and activity 
limitations, of which muscle stiffness and problems with performing standing and 
walking activities were most severe (medians ≥ 7 on a numeric rating scale 0-10). 
Balance, gait and falls
Several studies have reported problems with performing standing and walking activi-
ties and an increased fall risk in patients with HSP 9,19,22,23,75, but the published data on 
severity or prevalence of these problems are still very limited. Only one survey report-
ed that 47% of the participants with HSP had fallen at least once over the past three 
months 79, yet this estimate also included patients with complicated forms of HSP. 
In the current survey, both the reported severity of the balance and gait problems, 
fear of falling, and the high prevalence of falls and fall-related injuries indicate that 
safe and efficient postural and ambulatory control is a major problem in people with 
pure HSP. The observed proportion of 67% of people who reported at least one fall 
per year seems to be comparable to other patients with spastic paraparesis caused 
by, for instance, multiple sclerosis, tropical spastic paraparesis or spinal cord injury of 
whom 50-75% report at least one fall per year 82-91. 
Unfortunately, the present data do not allow us to make inferences on the effect 
of walking aids on falls, but many participants reported the use of different types of 
walking aids to increase their walking distance. Without a walking aid, 63% indicated 
that they could not walk at least 500 meters, while 28% were not able to walk at 
all. Besides walking aids, several participants used some type of ankle-foot ortho-
sis or orthopedic footwear to improve their walking capacity, probably to prevent 
foot drag during the swing phase and/or optimize ankle stability during the stance 
phase. Based on the results of this study, it is not possible to conclude which walking 
aid and/or orthosis is generally most effective. Our experience has learned that a 
thorough individual clinical assessment, sometimes supported by an instrumented 
gait analysis, is the best way to provide an individually tailored advice for the use of 
medical devices. This advice should take into account both the gait pattern (e.g., foot 
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drag, crouch, scissoring) and the execution of other daily life activities than upright 
standing and walking, such as stair climbing, squatting, cycling, driving a car etc. 75. 
Several interventional studies have provided indications of improved gait capacity 
by robotic training 68, botulinum toxin injections in spastic calf muscles or hip ad-
ductors 65,92-94, and intrathecal baclofen 64. However, these studies mainly focused 
on gait speed and/or gait pattern as outcomes, and not on walking distance, perfor-
mance of daily life activities, or falls. Studies on surgical interventions in HSP have 
not been conducted yet. Overall, it is fair to conclude that there is an urgent need 
for future studies in people with HSP that investigate the underlying mechanisms 
of their balance and gait problems and increased fall risk in order to develop nov-
el and convenient intervention strategies to preserve life-long ambulatory capacity 
and gait-related activities, and prevent falls. Remarkably, even sitting for 30 minutes 
appeared to be a problem for 30% of the participants, perhaps due to back pain or 
severe stiffness. Further research on sitting problems is necessary, particularly re-
garding wheelchair mobility.
Muscular and non-motor symptoms
Unsurprisingly, muscle stiffness, muscle cramps and weakness appeared to be signif-
icant problems in our participants. Usually stiffness and cramps are treated with mus-
cle relaxant medication, but apparently these symptoms are still very troublesome for 
many patients. Our results further showed that pain, fatigue, and autonomic prob-
lems are major (non-motor) symptoms in patients with pure HSP. Only few previous 
studies have mentioned pain as an important problem in this population 76,77,79,95, even 
though pain in the legs and/or back was reported by 72% of our participants. This 
number was similar to the reported frequency in previous studies 76,79. The nature of 
leg pain was most often described as nerve pain, cramping pain or restless legs. Back 
pain was most prevalent in the lower back. In our clinical experience, low back pain 
often has a continuous character, possibly related to postural deviation (i.e., anterior 
pelvic tilt with lumbar hyperlordosis). On average, the severity of pain yielded a me-
dian score of 4 on a numeric rating scale (0-10), but from a recent qualitative study, 
using semi-structured interviews in 14 patients with pure HSP, we learned that, in 
individual patients, pain may be severe enough to seriously affect their quality of life 
77. Besides pain, many participants experienced fatigue, both physically and mental-
ly, with median severity scores of 6 and 5, respectively. From our recent qualitative 
study it became clear that spasticity and muscle stiffness impact on physical fitness, 
while the high levels of attention needed to cope with balance and gait problems 
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seem to cause mental fatigue 77. Generally, fatigue and pain are serious problems 
in many types of chronic neurological disorders such as spinal cord injury, stroke, 
Parkinson’s disease, multiple sclerosis, and neuromuscular disease, which require 
specific clinical attention and treatment 91,96-100. Our results indicate that people with 
HSP form no exception to this rule, and probably remain undertreated in these re-
spects. The present results confirm previously described micturation and defecation 
problems in people with pure HSP 101,102. As underlying causes for these problems our 
data indicate, on the one hand, extreme urge and problematic sphincter control 80 
and, on the other hand, problems to reach the toilet in time. The latter problems may 
well be primarily related to the gait disorder due to the spastic paraparesis. Whereas 
urological consultation is needed in the case of bladder and sphincter abnormalities, 
adequate treatment of spasticity and gait problems may be additionally helpful to 
reduce micturation and defecation problems. Sexual problems were also frequently 
mentioned by our participants. This result confirms a previous study reporting sexual 
complaints in 7 out of 11 patients with pure HSP, indicating pain and spasticity as 
most important underlying causes 102. Hence, also for sexual problems, a combina-
tion of urological / gynecological consultation and adequate spasticity management 
seems to be crucial.
Predicting unsupported walking capacity and falling
The duration of spasticity symptoms appeared to be a strong predictor of being 
a faller. However, unexpectedly, people with an intermediate duration of spasticity 
symptoms (6-10 years) showed the highest risk, much higher than those with a short-
er duration (1-5 years), and also higher than those with a duration of more than 15 
years. A possible explanation for this finding may be that in this stage of the disease 
(6-10 years) people are becoming increasingly affected by spastic paraparesis, while 
they are still trying to remain as active as possible in terms of standing and walking 
activities. This discrepancy might bring about an increased fall risk. In the next phase 
(11-15 years symptom duration), there seems to be a marked drop in fall risk, which 
might be related to a gradual adjustment of the activity pattern, increased careful-
ness, and perhaps the use of walking aids. Symptom duration longer than 15 years 
seems to increase fall risk again, perhaps due to the severity of the balance problems, 
affecting basic activities such as rising to stance, sitting down, and making transfers. 
Unfortunately, our data do not allow more detailed interpretation of the observed 
risk pattern, which warrants further investigation. Difficulty or inability to rise from the 
floor was another important risk factor of being a faller, which is an intuitive finding, 
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as rising from the floor requires both sufficient lower extremity strength and basic 
balance capacity. Testing the individual capacity to independently rise from the floor 
may, therefore, be an interesting clinical test to assess increased fall risk. The use of 
a wheelchair and the presence of non-neurological comorbidities appeared to be 
strong ‘protectors’ against being a faller. The remarkable result of non-neurological 
comorbidities being negatively associated with falling may be related to a lower level 
of standing and walking activities in these people, which may lead to a reduced fall 
risk. However, further research should shed more light on these findings.
With regard to walking, higher age was associated with a lower chance of being 
able to walk without aids for at least 500 meters, which probably results from a 
combination of normal ageing and disease progression. The observed odds ratio 
of 0.944 implies that, with every year, the chance of being a walker without walking 
aids decreases by a factor 0.944. Over 30 years, the chance of being a walker with-
out aids would thus decrease to a mere 17.8% (0.94430). Experienced problems with 
gait-related activities also appeared to be a strong predictor of the inability to walk 
without aids. Lastly, the inability (or difficulty) to stand for 10 minutes and/or open 
a heavy door were also very strong predictors. This points towards the notion that 
standing balance capacity is an important prerequisite for independent walking. Ask-
ing patients in clinical practice whether they can easily stand for 10 minutes and/or 
open a heavy door may, thus, provide a good indication of their independent walking 
capacity. Again, further research should provide more insight in these relationships. 
Strengths and limitations
A limitation inherent in using questionnaires is the subjective nature of the results and 
the lack of physical examination data, which is why we emphasized that our data re-
flect the experienced complaints, activity limitations, and loss of motor capacities in 
people with HSP. Still, experiences may reveal problems that remain unnoticed when 
focusing on objective assessments. In addition, the design process of the question-
naire was not unbiased, as it was based on professionals’ preconception of what im-
portant aspects of HSP might be. Yet, although participants often had the option to 
provide additional information next to the predefined multiple choice options, they 
used this option only sparsely. 
Another limitation is that only the subjects without a positive family history or genetic 
diagnosis were checked for a formal diagnosis of pure HSP made by a neurologist. 
By including and excluding subjects based on specific questions, we tried to obtain 
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a homogeneous sample with pure HSP, but it is possible that some people were 
incorrectly enrolled or excluded. Our study sample was limited in absolute numbers, 
which precluded subgroup analyses based on for instance genetic defect, or dura-
tion of spasticity symptoms. Nevertheless, our study is the largest survey in people 
with pure HSP until now. In addition, our participants showed an equal sex distribu-
tion, wide age range, and a large variation in SP-related symptoms, which supports 
their representativeness of the Dutch population with pure HSP, of which we prob-
ably included about 15% 81. Since we excluded patients with complicated forms of 
HSP, our results cannot be generalized to the entire population with HSP. 
Conclusion
The results of this web-based survey indicate that people with pure HSP experience 
many physical complaints, activity limitations, and loss of motor capacities. Of these, 
muscle stiffness, limited standing and walking activities, and increased fall risk are 
most prominent, but also pain, fatigue, autonomic dysfunctions, fear of falling, and 
problems with performing working and hobby activities are relevant symptoms and/
or areas of disability with an inherent loss of quality of life. Future research, using 
objective next to subjective measures, is needed to better understand the full func-
tional impact of HSP on the daily lives of patients, to study underlying mechanisms 
of disabling symptoms, and to find new roads to interventions that are able to pre-
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Appendix
APPENDIX 1.  Overview of variables and answers
 Variable Description N Answer (n) / mean ± 
SD / median [IQR]
A Participant characteristics
1 Age Age of participants 109 52.81 ± 14.22










Genetic defect  




Duration of LLS 
symptoms

























8 Gene Genetic defect causing HSP 109 SPG2 (1)
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9 HSP in family*
Relatives with known  
or presumed HSP
109 First degree (83)




B Complaints and activity limitations
1 Muscle stifness
Score on hindrance/burden 
of muscle stiffness (0-10)
109 7 [3]
2 Muscle cramps
Score on hindrance/burden 
of muscle cramps (0-10)
109 4 [4]
3 Pain




Score on hindrance/burden 
of muscle weakness (0-10)
109 5 [4]
5 Physical fatigue
Score on hindrance/burden 
of physical fatigue (0-10)
109 6 [4]
6 Mental fatigue
Score on hindrance/burden 
of mental fatigue (0-10)
109 5 [6]
7 Sleeping problems
Score on hindrance/burden 
of sleeping problems (0-10)
109 2 [4]
8 Emotional problems
Score on hindrance/burden 




Score on hindrance/burden 
of balance problems (0-10)
109 7 [3]
10 Gait problems
Score on hindrance/burden 
of gait problems (0-10)
109 8 [2]
11 Fear of falling
Score on hindrance/burden 
of fear of falling (0-10)
109 5 [5]
12 Self-care
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14 Sleeping problems
Experience of sleeping 
problems
109 No (56)
Only falling asleep (6)
Only sleeping through 
(32)
Both (15)
15 Pain* Experience of pain 109 No (30)
Back pain (55)
Leg pain (including 
restless legs) (59)
Other (18)
16 Location back pain* Location of back pain 55 Lower back (55)
Middle back (10)
Higher back and neck 
(16)
17 Lower back pain
Pain score in the lower  
back (0-10)
55 6 [2]
18 Middle back pain
Pain score in the middle 
back (0-10)
10 5 [4]
19 Higher back pain
Pain score in the higher 
back/neck (0-10)
16 6 [4]













Score of experienced  
restless legs (0-10)
33 6 [4]
24 Sport Capacity to perform sports 109 No (47)
Yes (62)
25 Sport adaptations
Need of adaptations  




Reason of sport 
disability
Reason why not being 















Reason of difficulty to reach 
the toilet for micturation










Reason of defecation 
problems *
Reason of difficulty to reach 
the toilet for defecation











Reason of sexual 
problems*










































3 Distance without aids







4 Distance with aids








Capacity to walk up a  
normal staircase
109 No (16)
Only when holding 
rail(s) (75)
Without holding rail(s) 
(18)
6 Walk downstairs
Capacity to walk down a 
normal staircase
109 No (17)
Only when holding 
rail(s) (79)




of the gait pattern




Inability to walk (8)
8 Pick something up
Capacity to pick up some-
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With ease (16)
9 Sitting (30 min)





10 Standing (10 min)





11 Squat and rise





12 Rise from floor





13 Open heavy door





14 Walk with heavy bag
Capacity to walk with a 









16 Time until first fall
Time in years of first fall 
since onset symptoms




17 Fall frequency Estimate of fall frequency 109 Weekly (6)
Monthly (11)
Every 3 months (23)
Every 6 months (22)
Yearly (11)
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Never (19)
18 Fall location




Both just as often (31)
19 Fall injury Injury after a fall 93 No (37)
Once (27)
More than once (29)




21 Fear of falling Afraid to fall (again) 109 No (29)
A little (66)
    Very much (14)
 
*Multiple answers allowed #no frequence of use was stated. Participants were asked which 
mobility supportive devices they used indoors and outdoors
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PART 2
MOTOR CONTROL MECHANISMS IN PATIENTS  
WITH HSP 

Excessive short-latency stretch reflexes in the calf 
muscles do not cause postural instability in patients 
with hereditary spastic paraplegia.
PUBLISHED AS
van Lith BJH*, de Niet M*, van de Warrenburg BPC, Geurts AC, Weerdesteyn V. Excessive short-
latency stretch reflexes in the calf muscles do not cause postural instability in patients with hereditary 
spastic paraplegia. Clin Neurophysiol. 2019 Aug;130(8):1188-1195.








To identify the role of hyperexcitable short-latency stretch reflexes (SLRs) on balance 
control in people with hereditary spastic paraplegia (PwHSP). 
Methods
Sixteen PwHSP with triceps surae spasticity and 9 healthy control subjects were sub-
jected to toes-up support-surface perturbations. EMG data were recorded from gas-
trocnemius, soleus and tibialis anterior. Furthermore, center-of-mass trajectories were 
recorded.
Results
PwHSP were less able to withstand the perturbations. Triceps surae SLRs (40-80ms post 
perturbation) in PwHSP were increased compared to healthy subjects. Furthermore, a 
sustained triceps surae EMG activity at 220-320ms post perturbation was observed in 
PwHSP, whereas control subjects demonstrated suppression of triceps surae activity. 
Center of mass trajectories started to diverge between PwHSP and controls only after 
~500ms, with greater excursions being observed in the PwHSP.
Conclusions
The present results confirm that balance control is impaired in PwHSP. However, the 
late instant of center of mass divergence argues against a direct, causative role of 
hyperexcitable SLRs in the triceps surae.
Significance 
We postulate that enhanced short-latency stretch reflexes of the triceps surae do not 
underlie poor balance control in PwHSP. Instead, we suggest the lack of suppression of 
later triceps surae activity to be the main cause.
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Introduction
 
Hereditary spastic paraplegia (HSP) describes a heterogeneous group of neurodegen-
erative disorders characterized by slowly progressive leg muscle spasticity and muscle 
weakness 11,28,103 The main neuropathological feature is axonal degeneration of the lon-
gest descending and ascending nerve fibres (i.e. crossed and uncrossed corticospinal 
tracts to the legs, fasciculus gracilis fibers and, to a lesser extent, spinocerebellar fibers 
11). HSP can be phenotypically classified into pure and complicated forms. Complicat-
ed phenotypes include symptoms such as dementia, ataxia and peripheral neuropathy, 
in addition to leg muscle spasticity. In contrast, people with pure HSP (PwHSP) mainly 
experience lower limb spasticity with relatively preserved muscle strength, motor se-
lectivity and proprioception 11,56,104. The spasticity in the lower extremities causes the 
typical gait abnormalities observed in PwHSP, which include forefoot landing, foot 
drag during swing, and increased hip adduction (‘scissoring’ gait). Furthermore, it be-
comes increasingly evident that PwHSP also suffer from impaired balance control (e.g. 
de Niet et al. (2013) 22, de Niet et al. (2015) 9, Nonnekes et al. (2013) 23 and Nardone et 
al. (2001) 24). However, the mechanism underlying these balance impairments – and in 
particular the role of leg muscle spasticity - is yet poorly understood.
Spasticity is commonly defined as the velocity-dependent hyperexcitability of spi-
nal stretch reflexes 105. Nardone et al. (2001) 24 have shown that patients suffering 
from calf muscle spasticity indeed exhibit exaggerated short latency stretch reflex-
es (SLR) in the triceps surae following a sudden rotation in toes-up direction, im-
posed by a moveable platform (inducing ankle dorsiflexion movements). Toes-up 
rotations induce backward falls. To overcome this perturbation, the tibialis anterior 
muscle has to generate a corrective ankle dorsiflexion torque to pull the center of 
mass in the forward direction. Muscle activity of the antagonist muscles - i.e. the 
triceps surae – may thus be detrimental for balance recovery following toes-up per-
turbations. An earlier study of our group 22 suggested a detrimental effect of triceps 
surae spasticity on postural stability. The maximal magnitude of rotational toes-up 
perturbations that PwHSP could sustain without stepping (i.e. stepping threshold) 
was associated with clinical scores of triceps surae spasticity; patients with more 
severe spasticity had lower stepping thresholds. The latter result may seem to con-
cur with a destabilizing effect of hyperexcitable stretch reflexes of the triceps surae. 
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However, it is questionable whether the SLR can generate sufficiently large torques 
at the ankle joint to induce a loss of balance 106. Some previous studies suggested 
that increased SLRs as a result of spasticity contributed to functional impairments in 
both balance and gait 22,107-110, whereas other studies suggested there was no evident 
functional consequence of an increased SLR 24,111,112. Hence, is it important to further 
investigate the effects of excessive SLRs on balance control. Furthermore, it cannot 
be excluded that later phases of the postural response may also be defective in 
PwHSP.
The purpose of the current study was to gain further insight into the mechanisms un-
derlying impaired balance control in PwHSP. To address this aim, toes-up support-sur-
face balance perturbations at several intensities, imposed by a rotational platform, were 
applied in PwHSP and healthy control subjects. Previous research from our lab showed 
that after such toes-up perturbations, PwHSP overall had lower success rates, com-
pared to healthy controls 9. However, to provide insight in the underlying mechanisms, 
success rates for different intensities, electromyographic (EMG) responses from the 
triceps surae, and the time course of center-of-mass (CoM) excursions and velocities 
following perturbations were investigated in the current study. The instant where CoM 
trajectories start to diverge between PwHSP and controls provides crucial information 
on the causal role of hyperexcitable stretch reflexes in the impaired ability of PwHSP to 
withstand these toes-up perturbations. We hypothesized that exaggerated SLRs in the 
triceps surae of PwHSP would lead to difficulties in sustaining toes-up perturbations. 
This would be reflected by an early divergence (<200ms post perturbation) of their 




For addressing the present research question, we used the baseline data as obtained 
in the FEBOCH-I study 9. The FEBOCH-I study aimed to assess the effects of bot-
ulinum toxin injections in the triceps surae, with success rates of balance recovery 
to multidirectional translational and rotational perturbations as secondary outcomes. 
These were assessed at baseline and at 4 and 18 weeks post intervention. The baseline 
assessment also included EMG measurements, which allowed us to conduct this addi-
CHAPTER 4
67
THE ROLE OF EXCESSIVE SHORT-LATENCY STRETCH REFLEX ON BALANCE CONTROL 
tional mechanistic study on the role of excessive stretch reflexes in recovering balance 
following rotational ‘toes-up’ perturbations.
Participants
Participants were recruited from all symptomatic PwHSP who visited the Rehabilita-
tion and/or Neurology outpatient clinics of our university hospital during a period of 
one year. In addition, active recruitment took place through advertisements and oral 
presentations for the national patient council (Spierziekten Nederland). PwHSP could 
be included if they were (1) having autosomal dominant pure HSP (either genetically 
proven or based on family history), (2) having clinical symptoms of spasticity (e.g. 
clonus, stiffness, muscle cramps pain), and (3) being a community ambulator (Func-
tional Ambulation Categories (FAC) score 5 113). Exclusion criteria were (1) Modified 
Ashworth Scale (MAS) score of the calf muscle with the knee flexed or extended 
greater than 2 49, (2) passive ankle range of motion with an extended knee less than 
10° dorsiflexion, (3) leg muscle strength (both calf and tibialis anterior muscles) lower 
than 4 on the Medical Research Council (MRC) scale 114, and (4) motor selectivity 
lower than stage 5 of the Brunnström stages, all on either side of the body 115. After 
screening 32 PwHSP, 16 PwHSP met the inclusion criteria and were included in this 
study. Demographics and clinical characteristics of the included PwHSP are listed in 
Table 1. In addition, 9 healthy controls of similar age were recruited. The study was 
approved by the regional medical ethics committee and was conducted in accor-
dance with the Declaration of Helsinki. All subjects gave written informed consent 
before the experimental procedures. 
Balance assessment
Subjects stood barefoot on a moveable platform with their knees extended and their 
feet at shoulder width. They wore a safety harness, which was attached to the ceiling, 
and prevented them from falling. The platform imposed rotational (toes-up and toes-
down) and translational (forward and backward) perturbations. Perturbations were ap-
plied at four intensity levels (3, 5, 7 and 9 degrees rotation; translations at 0.25, 0.50, 
0.75 and 1.00 m·s-2). For detailed specifications of the perturbations and the platform, 
see de Niet et al. (2013) 22.
The protocol consisted of four familiarization trials of each of the four perturbations 
at the lowest intensity (i.e. 3 degrees rotation or translation at 0.25 m·s-2) to familiarize 
the participants with the experimental setup. Thereafter, a total number of 64 perturba-
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tions were imposed in random order with four perturbations at each intensity level for 
each type of perturbation (e.g. 4 types x 4 intensities x 4 repetitions). Participants were 
instructed to respond to the perturbations without stepping or grabbing for support. 
For each trial it was determined whether the participant was successful in recovering 
balance with the requested feet-in-place response. This resulted in a success rate (pro-
portions of successfully performed trials) for each type of perturbation. In this paper, 
only the results for the toes-up rotations are reported, as those perturbations applied 
a rapid stretch to the triceps surae and were thus related to stretch-related activity.
Kinematics and EMG
Three-dimensional kinematic data of the lower limbs and the trunk were collected using 
a motion capture system (Vicon Motion Systems®, Oxford, UK) at a sample frequency 
of 100 Hz. Twenty-one reflective markers were placed on the trunk and lower limbs ac-
cording to the full-body PlugInGait configuration (Vicon Motion Systems®, Oxford, UK). 
Furthermore, bilateral muscle activity was recorded by surface electromyography at a 
sample frequency of 1000 Hz from the medial head of the gastrocnemius (GM), soleus 
(SOL) and tibialis anterior (TA) muscles with electrodes (Ag-AgCl, ARBO ECG electrodes, 
Tyco Healthcare, Neustadt, Germany) placed according to SENIAM guidelines. 
Data processing and analysis
The marker data were processed using the PlugInGait model in Vicon Nexus (Vicon 
Motion Systems®, Oxford, UK; 116). Based on the hip markers and anthropologic data, 
the Vicon system determined a virtual CoM according to the PlugInGait model. Subse-
quently, CoM position data were low-pass filtered at 10 Hz (2nd order zero-lag Butter-
worth filter) and CoM velocity data were derived from CoM position data. EMG signals 
were band-pass filtered (10-499 Hz, 2nd order zero-lag Butterworth filter), rectified and 
low-pass filtered with 100 Hz. Thereafter, the EMG signal was normalized (i.e. expressed 
as a percentage of the background EMG activity averaged over 100ms prior to onset 
perturbation). For each subject and perturbation intensity, kinematic and EMG data were 
ensemble averaged across trials and across the left and right leg. We determined the 
mean (normalized) EMG amplitude over four time windows following the start of the 
perturbation; 40-80ms (short-latency response, SLR), 80-120ms (medium latency re-
sponse, MLR), 120-220ms (long latency responses, LLR) and 220-320ms (post-LLR, 109,117).
Statistical analysis
The success rates of balance recovery without stepping were compared between the 
PwHSP and controls using a factorial ANOVA with group as between-subjects factor 
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and perturbation intensity as within-subjects factor. Post-hoc analysis involved bonfer-
roni-corrected independent t-tests. 
The (normalized) EMG amplitudes were compared between the PwHSP and controls 
for each time window of interest (i.e. SLR, MLR, LLR and post-LLR) by means of a re-
peated-measures ANOVA with group as between-subjects factor and perturbation in-
tensity as within-subjects factor. An independent students t-test was used to compare 
background activity between PwHSP and controls. Finally, to determine the instant 
that CoM trajectories started to diverge between PwHSP and controls, we compared 
the CoM excursions and velocities for each intensity of perturbation using consecutive 
one-sided independent t-tests at time intervals of 10ms following the onset of the per-
turbation. The α-level was set at 0.05 for all analyses.
Results
 TABLE 1.  Demographic and clinical characteristics of patients with autosomal dominant  
hereditary spastic paraplegia and control subjects
   HSP Healthy controls
N 16 9
Age (mean ± SD) 48.8 ± 12.8 47.3 ± 11.8 







SOL 1 (n=6); 2 (n=10)
GM 1 (n=8); 2 (n=8)
MRC calf muscle‡ 5 (n=10); 4 (n=6)
MRC dorsiflexion‡ 5 (n=16)
Vibration sense (mean ± SD)* 4.0 ± 2.0  
HSP, Hereditary Spastic Paraplegia; MAS, Modified Ashworth Scale; MRC, Medical Research 
Council; ‡ Left and right leg scored equally, *Assessed with Rydel-Seiffer tuning fork
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For the most severely affected PwHSP (n=4) it was too demanding - both in terms of 
fatigue and safety - to undergo the total number of perturbations (64 trials). Therefore, 
the perturbations at the highest intensity of each type were omitted, leaving 48 per-
turbations for these participants. In the remainder of the paper, the EMG results for 
the three levels of perturbation intensities that could be collected in all PwHSP will be 
reported. Yet, subgroup analysis for the 12 PwHSP who underwent the full number of 
perturbations yielded a similar pattern of results (appendix). 
Success rates following toes-up perturbations
PwHSP were less capable of withstanding toes-up perturbations without stepping or 
grabbing for support (main effect of group, t(23)=5.439, p<0.001). PwHSP exhibited a 
large decrement in performance at higher perturbation intensities, whereas the controls 
barely failed to recover balance at all (group*intensity, F(3,69)=10.141, p<0.001, figure 1). 
Post-hoc tests yielded significant differences between the groups at perturbations of 5° 
(t(23)=4.000, p=0.001), 7° (t(23)=4.251), p<0.001), and 9° (t(23)=8.326, p<0.001), whereas 
success rates at perturbations of 3° did not differ (t(23)=1.661, p<0.001). 
FIGURE 1. Mean success rates (SD) of PwHSP (black) and control subjects (grey) at the three 
intensities of rotational toes-up perturbations. Asterisks mark significant differences between 
the groups.
 
EMG responses – between-group differences
Mean SOL, GM and TA EMG traces of a representative control subject and participant 
with HSP during toes-up perturbations are shown in figure 2. All EMG results of each 
muscle per time interval are presented in table 2. The average background activity pri-
or to perturbation was not significantly different between PwHSP and controls in GM 
(t(9.6)=2.2124, p=0.052), SOL (t(23)=0.440, p=0.664), or TA (t(22.2)=-1.509, p=0.145).
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TABLE 2. EMG outcome measures per time window for PwHSP and healthy controls
















p=0.045Control 136 ± 31 139 ± 29 176 ± 59
MLR





p=0.907Control 218 ± 146 197 ± 92 243 ± 139
LLR





p=0.780Control 147 ± 104 152 ± 104 176 ± 107
Post-LLR





p=0.047Control 68 ± 47 58 ± 31 67 ± 34
GM
SLR






p=0.038Control 127 ± 51 138 ± 43 178 ± 92
MLR






p=0.906Control 206 ± 92 219 ± 122 268 ± 172
LLR






p=0.453Control 179 ± 85 174 ± 104 277 ± 294
Post-LLR





p=0.012Control 71 ± 48 65 ± 36 87 ± 54
TA
SLR






p=0.076Control 111 ± 20 97 ± 13 100 ± 17
MLR






p=0.510Control 228 ± 111 333 ± 481 232 ± 130
LLR






p=0.762Control 1402 ± 750 1223 ± 762 1669 ± 658
Post-LLR






p=0.665Control 1731 ± 937 1859 ± 1171 2714 ± 1214
* Sphericity not assumed, Greenhouse-Geisser test used. SOL, Soleus; GM, Gastrocnemius; TA, 
Tibialis anterior; SLR, short-latency reflex; MLR, medium-latency reflex; LLR, long-latency reflex
CHAPTER 4
72
THE ROLE OF EXCESSIVE SHORT-LATENCY STRETCH REFLEX ON BALANCE CONTROL 
FIGURE 2. Representative rectified raw EMG traces of a control subject (left column) and an 
participant with HSP (right column) after a 7 degrees toes-up perturbation. Time zero is the 
time of the perturbation onset. SLR and post-LLR responses in SOL and GM compared to the 
control subject. SOL, Soleus; GM, Gastrocnemius.
 
 
In figure 3, the SOL, GM and TA responses (normalized to background activity) fol-
lowing perturbations are shown for PwHSP and controls. SLR amplitudes were larger 
in PwHSP than in controls in both the SOL (figure 3a, F(1,23)=4.516, p=0.045) and 
GM muscle (figure 3b, F(1,23)=4.847, p=0.038). In contrast, the response amplitudes 
in both the MLR and LLR time windows did not differ between the groups in either 
calf muscle. In the post-LLR time window, however, the PwHSP demonstrated great-
er muscle activity again compared to controls in GM (F(1,23)=7.429, p=0.012) and 
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SOL (F(1,23)=4.394, p=0.047). The response amplitudes in the TA muscle were not 
different between the groups in any of the time windows (figure 3c). 
 
FIGURE 3. Overall EMG activity (averaged over 3 intensities) for each post-perturbation time 
window in (A) SOL, (B) GM and (C) TA. Black bars represent data of PwHSP, grey bars of the 
control group. Asterisks mark significant differences between the groups. SOL, Soleus; GM, 
Gastrocnemius; TA, Tibialis anterior.
EMG responses – effects of perturbation intensity
In the SOL, no effects of perturbation intensity were shown in any of the response 
amplitudes. For the GM, greater post-LLR amplitudes were observed at higher per-
turbation intensities (F(2,46)=6.190, p=0.004), whereas there was no perturbation 
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intensity effect in SLR, MLR and LLR response amplitudes. For TA, post-LLR response 
amplitudes increased with increasing perturbation intensities (F(1.552,35.675)=8.778, 
p=0.002), which effect was not present in the other TA response windows. None of 
the intensity * group interaction effects reached significance. 
Center-of-mass displacement
The averaged CoM displacements and velocities of the groups are depicted at each 
intensity of perturbation (figure 4). 
FIGURE 4. Average CoM excursion (left) and CoM velocity (right) patterns of PwHSP (dashed 
line) and controls (solid line) for (A,B) 3 degrees perturbations, (C,D) 5 degrees, (D,E) 7 degrees 
and (F,G) 9 degrees. The onset of perturbation is at 0 ms. Points of divergence based on signif-
icance of independent t-test are marked with grey solid vertical line. CoM, Center of Mass.
 
The CoM trajectories were very similar between individual participants and between 
the groups in the first ~300ms post perturbation. From ~500ms onwards, the vari-
ability in trajectories between subjects increased considerably, which was particular-
ly evident in the HSP group. As shown in figure 4a, no point of divergence of CoM 
excursions could be identified up to 1000ms for perturbations of 3°. The statistical 
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points of divergence between the CoM excursions of both groups were at 520ms 
(t(23)=1.777, p=0.044), 490ms (t(23)=1.785, p=0.043) and 460 ms (t(19)=1.767, 
p=0.047) for perturbations of 5°,7° and 9°, as shown in figure 4c, 4e and 4g respec-
tively. The statistical points of divergence between the CoM velocities of both groups 
were detected at 430 ms (t(23)=1.793, p=0.043) , 420 ms (t(23)=2.012, p=0.028), 
400 ms (t(23)=1.857, p=0.038) and 410 ms (t(19)=1.780, p=0.046) for the 3°, 5°, 7° 




The main aim of this study was to identify whether hyperexcitability of triceps surae 
short-latency stretch reflexes (SLRs) is a key determinant of the poor balance control 
in PwHSP in response to toes-up support-surface rotations. In line with their pro-
nounced leg muscle spasticity, we indeed observed increased SLRs in the triceps 
surae of the PwHSP compared to healthy controls. The great difficulty that the PwHSP 
experienced in sustaining the perturbations was evident from their lower success 
rates and greater CoM excursions and velocities in comparison to the controls. The 
PwHSP also demonstrated enhanced triceps surae activity in the post long-latency 
reflex (LLR) time window (220-320ms) compared to the controls, whereas the MLR 
and LLR response amplitudes did not differ. For TA activity, no differences between 
the groups were found in any of the time windows. 
The present results confirm previous findings of impaired balance control and in-
creased short-latency stretch reflexes in spastic triceps surae upon sudden toes-up 
support-surface rotations 22,24. Yet, studies on the significance of leg muscle spastic-
ity for defective balance control are yet sparse and the results disparate. This lack 
of knowledge might be due to the fact that spasticity in patients with upper motor 
neuron syndromes often coexists with other impairments (e.g. paresis, sensory loss, 
contractures, involvement of other structures relevant for balance control). HSP, 
however, is mainly characterized by spasticity, whereas muscle strength, somato-
sensation and range of joint motion are relatively well preserved. HSP thus provides 
a ‘naturalistic model’ for studying how spasticity contributes to impaired balance 
control. Our study adds to the existing knowledge on the impact of leg muscle spas-
ticity in balance control as, contrary to our hypothesis, the results demonstrate that 
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there does not seem to be a direct, causative relationship between hyperexcitable 
SLRs in triceps surae and poor balance performance. Furthermore, we here report a 
yet unidentified abnormality in the spastic triceps surae (i.e. sustained activity in the 
post-LLR window), which potential significance will be further eluded on. 
The PwHSP had more difficulties to recover from the perturbations without stepping 
than the control subjects. Indeed, the PwHSP demonstrated greater CoM excursions 
and velocities compared to controls, which became apparent in the statistical analy-
ses of CoM velocities at 400-430ms post perturbation. People recover from “toes-up” 
rotational balance perturbations by generating corrective ankle dorsiflexion torques, 
through MLR and LLR responses at onset latencies of ~100-115ms (Allum et al. , 2002, 
Campbell et al. , 2009). In a previous study on toes-up rotational balance perturbations 
in people with leg muscle weakness, it was demonstrated that distal weakness (i.e. a 
reduced capacity to generate large corrective torques) resulted in evident divergence of 
COM velocity from that of healthy subjects at ~225 ms post perturbation (Horlings et al. 
, 2009). These results point at a time lag of ~110-125 ms between (differences in) EMG 
activity and (differences in) COM velocity. Therefore, it seems unlikely that increased 
SLRs in the (spastic) triceps surae have a direct, causal relation with the larger CoM ex-
cursions in PwHSP. Conversely, the relatively late instants of divergence between CoM 
trajectories of PwHSP and healthy controls more likely correspond with the enhanced 
triceps surae activity that was observed in our PwHSP at 220-320ms post perturbations. 
In this (post-LLR) time window, the PwHSP generally demonstrated sustained triceps 
surae activity, whereas control subjects showed strong inhibition of these muscles (i.e. 
below background activity levels). As TA activity has to overcome the triceps surae ac-
tivity to recover balance following toes-up perturbations, the sustained triceps surae (i.e. 
antagonist) activity must be considered detrimental for balance control. 
The observation of sustained triceps surae activity in the post-LLR time window in the 
PwHSP was an unexpected finding, and the mechanisms underlying this lack of inhibi-
tion can only be speculated upon. One suggestion may be related to the degeneration 
of the long descending tracts as a key neuropathological feature of the disease 11,28,103. 
Dendrites of motoneurons have voltage dependent channels that provide the capacity 
to generate persistent inward currents. It has been demonstrated that, due to a lack of 
descending input, large persistent inward currents make the spinal cord hyperexcitable, 
which may lead to a self-sustained firing of motoneurons after muscle activation 118-120. 
The evoked activity post perturbation in the spastic triceps surae of PwHSP may cause 
a self-sustained firing of motoneurons, causing further prolongation of muscle respons-
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es. An alternative (and not mutually exclusive) suggestion for the prolonged triceps 
surae activity could be a lack of reciprocal inhibition in the lower leg muscles, which has 
previously been demonstrated in PwHSP 121. Following toes-up perturbations, activity of 
TA muscles is required for maintaining balance. This mechanism normally leads to inhi-
bition of the triceps surae (which we indeed observed in the healthy controls), but may 
have been defective in the PwHSP. A different notion is a possible neurophysiological 
relationship between excessive SLRs and muscle activity during the post-LLR window, 
but the fact that we found no group differences in the MLR and LLR time windows 
seems to argue against this possibility. It must be mentioned, though, that all these 
suggested explanations for the (newly identified) sustained triceps surae activity remain 
speculative, as our study was not designed to elucidate the neural processes involved. 
In addition to the results on triceps surae activity, the lack of between-group differenc-
es in tibialis anterior activity may be considered as another HSP-related abnormality. 
Given the enhanced triceps surae activity in the PwHSP compared to controls, greater 
activity of TA – as the agonist muscle for recovering balance - would be expected to 
compensate for that. However, the absence of differences in TA activity suggests that 
the PwHSP had difficulties recruiting such compensatory activity (and thus corrective 
torques), which may also have contributed to their lower recovery success rates. In the 
present group of PwHSP, however, muscle strength of ankle dorsiflexors was normal 
(MRC = 5; see table 1), which suggests that the rate of TA recruitment may be more of 
a problem than its absolute strength.
Our results suggest that sustained muscle activity in the post-LLR window may help 
explain the observed difficulties that the PwHSP experienced in recovering from toes-
up perturbations. Although rotational perturbations do not occur often in daily life, 
sustained muscle activity may also compromise other postural tasks for which quick 
inhibition is important. This could be the case for larger balance perturbations that 
necessitate stepping to recover. Any perturbation to balance evokes an automated 
postural response, which leads to bilateral activation of leg muscles for counteract-
ing the perturbation-induced CoM excursions. When the CoM excursions exceed the 
boundaries of the base of support and a compensatory step is needed to recover, 
making this step requires rapid inhibition of postural muscle activity in the stepping 
leg. Future research should identify which neural mechanism underlies the sustained 
triceps surae activity in PwHSP, and whether this sustained activity may indeed contrib-
ute to poor balance control.
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A limitation of this exploratory study is that the group of PwHSP was relatively small 
(inherent to the rarity of the disease) and heterogeneous (despite our restriction to 
‘pure’ HSP phenotypes). We, therefore, chose not to adjust the statistical criterion 
for multiple testing, as this would introduce a substantial risk of type II (false-nega-
tive) errors. Although multiple testing at uncorrected alpha levels bears a risk of type I 
(false-positive) errors, we would like to emphasize that we observed a consistent pat-
tern of significant between-group differences in the SLR and post-LLR time-windows 
for both the soleus and gastrocnemius muscles. In addition, the direction of this effect 
in the SLR window was coherent with the underlying pathophysiological mechanism 
and with results from a previous study in HSP 24. Hence, it is deemed unlikely that the 
present results represent false-positive outcomes. Another limitation is that we did not 
measure corrective ankle torques. Such data would have allowed us to appreciate 
the mechanical effects of the HSP-related differences in triceps surae activity more 
directly. Furthermore, it remains difficult to provide conclusive evidence for cause-
and-effect relationships from discrete perturbations due to the complex interplay of 
the various systems involved in balance control. Interestingly, a powerful new com-
putational method (closed-loop system identification technique) has recently been 
proposed to identify such causal relationships from imposed continuous mechanical 
perturbations and recorded responses at the level of EMG, joint torques and body sway 
122. The application of this method may provide further insight into the mechanisms 
underlying defective balance control in PwHSP. 
Conclusion
 
The present results confirm that balance control is impaired in PwHSP. These bal-
ance impairments, however, do not seem to be directly related to hyperexcitable 
short-latency stretch reflexes of spastic triceps surae muscles. Rather, they seem to 
be due to lack of triceps surae activity suppression in the post long-latency reflex 
time window. Further research into the neural underpinnings of defective balance 
control in HSP should particularly focus on the possible role of impaired reciprocal 
inhibition and/or enhanced (self-sustained) firing of the motoneurons that innervate 
the triceps surae. 
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Appendix
FIGURE APPENDIX 1. Overall EMG activity (averaged over 4 intensities) of the participants 
that underwent all perturbation intensities for each post-perturbation time window in (A) SOL, 
(B) GM and (C) TA. Black bars represent data of HSP patients, grey bars of the of the control 
group. Asterisks mark significant differences between the groups. SOL, Soleus; GM, Gastrocne-
mius; TA, Tibialis anterior.
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STARTREACT DURING GAIT INITIATION IN HSP PATIENTS
Abstract 
Corticospinal lesions cause impairments in voluntary motor control. Recent findings 
suggest that some degree of voluntary control may be taken over by a compensatory 
pathway involving the reticulospinal tract. In humans, evidence for this notion mainly 
comes from StartReact studies. StartReact is the acceleration of reaction times by a 
startling acoustic stimulus (SAS) simultaneously presented with the imperative stim-
ulus. As previous StartReact-studies mainly focused on isolated single-joint move-
ments, the question remains whether the reticulospinal tract can also be utilized for 
controlling whole-body movements. 
To investigate reticulospinal control, we applied the StartReact paradigm during gait 
initiation in 12 healthy controls and 12 patients with ‘pure’ hereditary spastic paraple-
gia (HSP; i.e. retrograde axonal degeneration of corticospinal tract). Participants per-
formed three consecutive steps in response to an imperative visual stimulus. In 25% 
of 16 trials a SAS was applied. We determined reaction times of muscle (de)activation, 
anticipatory postural adjustments (APA) and steps. 
Without SAS, we observed an overall delay in HSP patients compared to controls. 
Administration of the SAS accelerated tibialis anterior and rectus femoris onsets in 
both groups, but more so in HSP patients, resulting in (near-)normal latencies. Soleus 
offsets were accelerated in controls, but not in HSP patients. The SAS also acceler-
ated APA and step reaction times in both groups, yet these did not normalize in the 
HSP patients.
The reticulospinal tract is able to play a compensatory role in voluntary control of 
whole-body movements, but seems to lack the capacity to inhibit task-inappropriate 
muscle activity in patients with corticospinal lesions.
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Introduction
Patients with an upper motor neuron syndrome (UMNS; e.g. stroke, spinal cord in-
jury, cerebral palsy, hereditary spastic paraplegia) have impaired voluntary motor 
control due to absent or reduced corticospinal output to the alpha motoneurons 
in the spinal cord. As a result, volitional movements like gait initiation or reaching 
while standing are impaired in these patients 123-125. Such movements are typically 
preceded by anticipatory postural adjustments (APAs) to optimize postural control 
during movement 126,127. Corticospinal pathways are strongly involved in the control 
of these APAs 128. As a consequence, UMNS patients show smaller APA magnitudes 
and delayed APA latencies compared to healthy controls 123-125,129,130.
Interestingly, recent findings in animals and humans suggest that some degree of 
voluntary motor control may be taken over by the reticulospinal tract as a compen-
satory neural pathway 1,37,39,131-134. In humans, evidence for the potential utility of this 
compensatory pathway for voluntary movements comes from studies that evaluated 
the StartReact effect. StartReact refers to the phenomenon that reaction times are 
greatly accelerated when a startling stimulus is presented simultaneously with an 
imperative stimulus for executing the requested movement. The exact mechanisms 
underlying StartReact are, however, still under debate, as the extent of the reaction 
time acceleration seems to depend on various factors. For instance, the StartReact 
effect is more likely to occur when there is a high level of motor preparedness and 
a strong familiarity with the task 36,135-137. Furthermore, the mechanism underlying 
StartReact appears to depend on the type of action. For example, SAS-induced dex-
terous hand movements likely engage transcortical pathways, whereas subcortical 
pathways are more involved in mediating SAS-induced locomotor actions and pos-
tural adjustments 135-137. Although the exact neural structures that are involved in the 
StartReact effect are not uncontested, there is ample evidence that StartReact during 
standing and walking is conveyed by the reticulospinal tract 2,36,138,139.
A previous StartReact study from our group in patients with hereditary spastic para-
plegia (HSP) has substantially contributed to the notion of compensation by the re-
ticulospinal tract 1. In its pure form, HSP is clinically characterized by bilateral muscle 
spasticity and weakness in the legs, whereas the arms commonly remain unaffected 
10,27,28. The main underlying pathological feature in HSP is axonal degeneration of the 
corticospinal tract 11, particularly affecting the distal parts of the longest descend-
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ing axons 12. This degeneration is reflected in lengthened central motor conduction 
times to the leg muscles upon transcranial magnetic stimulation, e.g. amounting to 
150% of reference values from healthy subjects 1. Indeed, reaction times of volun-
tary ankle dorsiflexion movements were substantially delayed compared to those of 
healthy individuals, yet the presentation of a startling acoustic stimulus (SAS) acceler-
ated reaction times to equivalent values in HSP patients and healthy controls 1. This 
finding points at an intact reticulospinal system in HSP, and this system may be instru-
mental for allowing these patients volitional motor control of the lower extremities in 
the presence of a dysfunctional corticospinal tract. 
Previous studies that demonstrated intact StartReact effects on voluntary move-
ments in various groups of patients with UMNS invariably included simple reaction 
tasks of isolated ankle, hand, wrist or elbow movements performed in a seated posi-
tion 1,38,134,140,141. In contrast, the one study that investigated the StartReact effect in a 
standing reach task failed to demonstrate a significant SAS-induced acceleration of 
the requested movement in stroke patients 123. These discrepant results cast some 
doubt on the potency of compensatory reticulospinal control for executing com-
plex, multisegmental movements. To shed more light on the potential utility of the 
reticulospinal system for controlling such movements, we studied the StartReact 
effect during gait initiation in patients with pure HSP. The APA prior to gait initiation 
involves concerted tibialis anterior (TA) muscle activation and soleus (SO) inhibition 
of the stepping leg to move the centre of pressure of the ground reaction forces 
backwards and towards the stepping leg in order to accelerate the centre of mass 
forwards and towards the stance leg 127,142.
In a gait initiation task in healthy young individuals, it was previously demonstrated 
that muscle onsets and offsets as well as APA and step onsets were substantially 
accelerated when a SAS was presented simultaneously with the imperative signal 
143. Based on the majority of StartReact studies in UMNS patients, we hypothesized 
that HSP patients, compared to healthy controls, would demonstrate delays in all 
gait initiation parameters when responding to the imperative stimulus alone, but that 
the presentation of a SAS would result in greater acceleration of muscle onsets and 
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Materials and Methods 
Ethical approval
The study was approved by the regional medical ethics committee (Commissie 
Mensgebonden Onderzoek Arnhem-Nijmegen) and was conducted in accordance 
with the Declaration of Helsinki. All subjects gave written informed consent before 
the experimental procedures. 
Participants 
Twelve patients with autosomal dominant forms of HSP (9 men, 3 women; mean 
age 51 years, range 27-71 years) and 12 aged-matched healthy controls (9 men, 3 
women; mean age 53 years, range 27-71) participated. The patients were recruited 
from the rehabilitation outpatient clinic of our expert centre for genetic movement 
disorders. All patients fulfilled the diagnostic clinical criteria for “pure” HSP 28. 
Clinical assessment
Clinical assessments were performed prior to the experiment. Muscle tone of the 
triceps surae (TS) (ankle dorsiflexion with knee both flexed and extended), TA (an-
kle plantarflexion), rectus femoris (RF) (knee flexion with hip extended) and biceps 
femoris (BF) (knee extension with hip flexed) was assessed bilaterally using the Mod-
ified Ashworth Scale (0-5), with higher scores indicating more hypertonia 144. Muscle 
strength was assessed bilaterally using the Medical Research Council (MRC) scale 
(0-5) for the TS, TA, RF and BF muscles, with lower scores indicating more muscle 
weakness 51. Vibration sense was tested bilaterally at the medial malleolus and at 
the first metatarsophalangeal joint using the semiquantitative tuning fork (0-8; Rydel 
Seiffer, Neurologicals, Poulsbo, Washington), with lower scores indicating more sen-
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TABLE 1. Clinical characteristics of HSP patients
      Median (range)
Rectus femoris MAS 1 (1-2)
MRC 4 (3-5)
Biceps femoris MAS 1 (0-2)
MRC 4.25 (3-5)
Tibialis anterior MAS 0 (0-1)
MRC 4 (3-5)
Triceps surae MAS: knee extended 1 (0-3)
knee flexed 1 (0-3)
MRC 4 (3-5)
forefoot vibration sense 3 (0-6)
ankle vibration sense 4 (1-6)
All values are means of values for the left and right body side. Vibration sense was  
tested using a semiquantitative tuning fork (scale range 0 – 8; Rydel Seiffer, Neurologicals,  
Poulsbo, Washington). MAS: Modified Ashworth scale (scale range 0-5). MRC: Medical 
Research Council scale (scale range 0-5).
Experimental design 
Familiarization
The subjects received three SAS while standing to familiarize them with the stimuli. 
The SAS were given through binaural earphones and consisted of 50 ms white noise 
(1500 Hz) with an intensity of 120 dB (measured by Investigator 2260 and Artificial 
Ear B&K 6cc type 4152, Bruel and Kjaer, Nærum, Denmark). The SAS was generated 
by a custom-made noise generator. 
Gait initiation
The participants stood in front of a box consisting of two blocks with light-emitting 
diodes (LED). Illumination of the first LED represented a warning signal and illumina-
tion of the second LED represented the imperative stimulus. Warning periods (1-3.5 
s) and inter-trial periods (6-10 s) were variable and random. The participants were 
instructed to stand on the two force plates with their weight equally distributed be-
tween the legs. Equal loading of both legs was visually checked online by the primary 
investigator from the force plate signals. In the case of clear deviation from a sym-
metrical loading pattern, the subjects were instructed to adjust the loading based on 
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verbal feedback from the primary investigator. As soon as the imperative stimulus 
was presented, the participants had to start walking as fast as possible and perform at 
least three steps (one trial), starting with their preferred leg. The preferred leg was de-
fined as the leg with which the participant would kick a football. The participants per-
formed a total of 16 trials; in 25% of these trials a SAS was presented simultaneously 
with the imperative stimulus using a synchronous analog pulse to the LED box and 
the startle generator. Prior to the task, the participants performed four practice trials.
Data collection
Electromyographic (EMG) (ZeroWire, Aurion, Italy) data were collected from both 
sternocleidomastoid (SCM) muscles and TA, RF and SO muscles of the preferred leg 
of the participant. The EMG electrodes were placed according to Seniam guidelines 
144. EMG signals (sampled at 2000 Hz) were consecutively band-pass filtered at 20-
450 Hz (zero-lag, second order Butterworth filter), rectified and low-pass filtered at 
30 Hz (zero-lag, second order Butterworth filter). 
Ground reaction forces under both feet were recorded at a sample rate of 2000 Hz 
by two force plates (60x180 cm each; AMTI Custom 6-axis composite force plat-
form, USA), which were embedded in the surface.
Reflective markers were placed at anatomical landmarks on the heel, ankle and toe 
of both feet. Marker positions were recorded by an 8-camera 3D motion analysis 
system (Vicon Motion Systems, United Kingdom) at a sample rate of 100 Hz. 
Data analysis
Data analyses were all conducted by the primary investigator. For all signals baseline 
activities and the respective standard deviations (SD) were calculated over 500 ms 
prior to the imperative stimulus. The baseline activity was subtracted from all signals. 
The ensemble average EMG traces of the TA, RF and SO EMG were calculated sepa-
rately for trials with and without a SAS. We determined muscle onset latencies for TA 
and RF. We defined the onset as the first instant that a signal exceeded the threshold 
of 2 SD above baseline activity (figure 1a), which was determined by a semi-automat-
ic computer algorithm. 
For determining SO offsets, we chose to apply a somewhat more liberal criterion 
(figure 1b). This was done because, compared to the baseline activity of TA and RF, 
the tonic SO activity at baseline demonstrated greater fluctuations, resulting in large 
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standard deviations. A threshold of -2 SD would therefore have resulted in SO off-
sets being identified relatively late. We first identified when SO activity went below a 
threshold of -2 SD, and then worked backwards to find the instant where the EMG 
signal exceeded the mean baseline activity –1 SD. This instant was taken as the SO 
offset. All onset and offset latencies were visually approved or corrected 1,23,41.
FIGURE 1. Representative TA and SO EMG signals of the stepping leg in a healthy control 
participant during gait initiation. TA onset and SO offset are indicated by a dot. Note that the 
SO baseline is fluctuating much more than the TA baseline. Therefore, TA muscle onset was 
determined as the instant where the signal exceeded 2 SD above baseline activity, whereas 
SO muscle offset was determined as the last instant where the EMG signal went below -1 SD 
before going below -2 SD for at least 50ms.
 
For each trial, it was determined whether an anticipatory postural adjustment (APA) 
occurred prior to the step. To define a weight shift as an APA the force under the 
stepping leg had to exceed 5% of the total body weight. In addition, the difference 
between the vertical loading underneath the stepping and stance leg was calculated. 
The difference had to rise above the threshold of 2 SD above the mean difference 
500ms prior to the imperative stimulus. This moment was defined as the APA onset. 
In addition, for each APA, the maximum increase in vertical force under the stepping 
leg was determined and normalized for body weight (BW) 146. 
For step onsets, 3D vectors (x,y and z direction) of the heel and toe markers of 
the stepping leg were calculated for each trial. The step onset was defined as the 
first instant when one of the two vectors rose above the threshold of 2 SD above 
baseline (calculated over 500ms prior to the imperative stimulus). Step length was 
determined for each trial separately using the horizontal displacement of heel and 
toe markers 146. 
For each trial with a SAS, we determined whether a startle reflex occurred in SCM. A 
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startle reflex was defined as short latency response in any of the SCM muscles start-
ing within 130 ms following the SAS. 
Statistical analysis
All outcome measures were tested using repeated-measures ANOVA. Group (HSP 
patients - healthy controls) was used as the between-subjects factor and SAS (SAS 
- no SAS) was used as the within-subjects factor. For parameters with interaction 
effects, post-hoc analysis was done to determine the 95% confidence interval (CI) 
of the mean difference between patients and controls for SAS and no SAS trials 
separately. Furthermore, we tested for differences in APA occurrences between the 
two groups using a chi-squared test. We used the chi-squared test also to test for 
differences in occurrence of startle reflexes between HSP patients and controls in 
SAS trials. 
As a secondary analysis, we tested for differences in onset latencies between SAS 
trials with a startle reflex (SCM+) and SAS trials without a startle reflex (SCM-), for those 
participants who presented both. A repeated measures ANOVA was used with startle 
reflex (SCM-- SCM+) as within-subjects factor and group (HSP patients - healthy con-
trols) as between-subjects factor. This secondary analysis was performed because 
there is an ongoing debate on whether the StartReact effect critically depends on 
the occurrence of a startle reflex. As such, this analysis was used to determine the 
potential impact of our decision of analyzing all SAS trials (as opposed to only includ-
ing SCM+ trials) on our primary results and conclusions. Note that for all our other 
analyses, all SAS trials were included.
Statistical analyses were performed using IBM SPSS Statistics Version 20 for Win-
dows. For all analyses, the α level was set at 0.05. 
Results 
 
EMG onset and offset latencies
The EMG pattern of the stepping leg during gait initiation was characterized by 
near-simultaneous TA activation, RF activation and SO inhibition in healthy controls, 
whereas activation of RF followed shortly after near-simultaneous TA activation and 
SO inhibition in HSP patients (see figure 2). 
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FIGURE 2. Mean EMG onset/offset latencies (SE) during gait initiation. * Indicates post-hoc 
significant difference between trials with and without a SAS. + Indicates post-hoc significant 
differences between groups with and without a SAS. n.s. = not significant.
Without SAS, TA onsets during gait initiation occurred earlier in controls (119 ± 14 
ms) than in HSP patients (158 ± 43 ms). Administration of the SAS accelerated these 
onsets in both groups (SAS, F
(1,22) 
= 92.216, p < 0.001), as shown in figure 2A. Yet, with 
the addition of the SAS we observed a larger acceleration in TA onsets in the HSP 
group (89 ± 25 ms) compared to controls (75 ± 13 ms; SAS x group, F
(1,22)
 = 4.454, p 
= 0.046; group, F
(1,22)
 = 8.384, p = 0.008). The mean delay in HSP patients was sig-
nificant without a SAS (95% CI: 12-66 ms, p = 0.010), but with a SAS the onsets were 
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With regard to RF onset latencies, the HSP patients showed an overall delay com-
pared to controls (group, F
(1,22)
 = 29.254, p <0.001; figure 2B). The SAS accelerated 
RF onsets in both the control group (118 ± 17 ms to 74 ± 10 ms) and HSP group (189 
± 56 ms to 100 ± 17 ms; SAS, F
(1,22)
 = 55.663, p < 0.001). Although the SAS-induced 
acceleration was significantly greater in HSP patients than in the controls (SAS x 
group, F
(1,22)
 = 6.388, p = 0.019), the delay in RF onsets in the HSP patients compared 
to healthy controls remained significant with a SAS (mean 26 ms, 95% CI: 14-38 ms, 
p < 0.001).
The SO offset without SAS was also delayed in HSP patients (143 ± 31 ms) compared 
to controls (111 ± 18 ms; SAS, F
(1,22)
 = 19.388, p < 0.001; figure 2C). The SAS accel-
erated the SO offsets, but in contrast to the results for TA onsets, the SAS-induced 
acceleration was greater in healthy controls than in HSP patients. Therefore, with 
addition of the SAS, the SO offsets in healthy controls (66 ± 15 ms) occurred earlier 
than in HSP patients (129 ± 43 ms; SAS x group, F
(1,22)
 = 5.687, p = 0.026; group, F
(1,22)
 
= 23.469, p < 0.001). Without a SAS, the mean delay in HSP patients was 32 ms (95% 
CI: 10-53 ms, p = 0.006), which delay increased to 64 ms in the SAS trials (95% CI: 
35-92 ms, p < 0.001).
Anticipatory postural adjustments
APAs were detected in 87% of the trials in HSP patients, whereas APAs were detected 
in all the trials of the healthy controls (F
(1,393)
 = 20.855, p < 0.001). The HSP patients 
had delayed APA onsets both without SAS (231 ± 23 ms) and with SAS (152 ± 31 ms) 
compared to the control group (without SAS: 189 ± 26 ms; with SAS: 129 ± 26 ms; 
group, F
(1,22)
 = 11,62, p = 0.003; figure 3A). The SAS significantly accelerated APA on-
sets (SAS, F
(1,22)
 = 154.299, p < 0.001), yet without differential effects between the two 
groups (SAS x group, F
(1,22)
 = 2.693, p = 0.115). 
APA amplitudes were smaller in HSP patients compared to healthy controls, both 
without SAS (control: 26 ± 5, HSP: 19 ± 8% BW) and with SAS (control: 27 ± 4, HSP: 
18 ± 7% BW; group: F
(1,22) 
= 12.355, p = 0.002; figure 3B). There was no effect of the 
SAS on APA amplitudes in either group (SAS, F
(1,22)
 = 0.016, p = 0.901; SAS x group, 
F
(1,22) 
= 2.247, p = 0.148).
Step onset and step length
Step onsets in HSP patients were delayed compared to healthy controls (group, F
(1,22)
 
= 19.898, p < 0.001), as shown in figure 3C. The SAS accelerated step onsets in both 
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in healthy controls (515 ± 57 to 434 ± 64 ms) and in HSP patients (645 ± 83 to 587 
± 118 ms; SAS, F
(1,22)
 = 28.507, p < 0.001). There was no differential effect of the SAS 
between HSP patients and healthy controls (SAS x group, F
(1,22) 
= 0.801, p = 0.381). 
No effects of the SAS were found on step length (SAS, F
(1,22)
 = 1.168, p = 0.291; SAS x 
group, F
(1,22)
 = 1.375, p = 0.254; figure 3D). In both without SAS and with SAS condi-
tions, HSP patients made shorter steps (38 ± 10 and 36 ± 9 cm) than healthy controls 
(51 ± 6 and 51 ± 8 cm; group, F
(1,22)
 = 16.877, p < 0.001). 
FIGURE 3. Mean onset latencies (SE) during gait initiation (left graphs) and mean anticipatory 
postural adjustment amplitudes and step lengths (right graphs). * Indicates significant differ-
ence between trials with and without a SAS. + Indicates significant differences between groups 
with and without a SAS. n.s. = not significant.
Startle reflex
The occurrence of the startle reflex in SCM during SAS trials was 64% HSP patients 
and 65% in healthy controls (c2
(1,93)
 = 0.000, p = 0.989). There were no differences in 
TA onset between the SCM- trials and SCM+ trials in either HSP patients (117 ± 14 and 
110 ± 13 ms) or healthy controls (85 ± 4 and 85 ± 4 ms; SCM, F
(1,14)
 = 0.715, p = 0.412, 
SCM x group, F
(1,14)




































































a. anticipatory postural adjustment onset b. anticipatory postural adjustment amplitude
c. step onset d. step length
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Discussion
 
The aim of the present study was to gain more insight in the potency of the reticu-
lospinal tract to act as a compensatory pathway for executing voluntary complex, 
multisegmental movements. Therefore, we investigated the effects of StartReact on 
gait initiation in HSP patients. Compared to healthy controls, the HSP group respond-
ed to the imperative visual stimulus alone with delayed TA and RF onsets, SO offsets, 
as well as APA and step onsets. Pairing the imperative stimulus with a SAS resulted 
in earlier onsets in TA, RF, APA and step onsets both in healthy controls and HSP 
patients. The SAS-induced acceleration in APA and step onsets was similar between 
groups, whereas a significantly greater StartReact effect was observed in TA and RF 
onset latencies in the HSP patients than in the controls, resulting in (near)-normal 
TA and RF onsets in the HSP group. In response to the visual stimulus alone, we 
observed TA onsets and SO offsets at approximately the same time. In the healthy 
controls, the SAS similarly accelerated TA onsets and SO offsets, such that the rela-
tive timing between these events was not affected. Yet, remarkably, no SAS-induced 
acceleration in SO offsets was observed in the HSP patients. 
Our study adds to the existing body of knowledge on StartReact effects in patients 
with upper motor neuron lesions 1,123,140,141,147 by demonstrating that patients with HSP 
showed greatly accelerated reaction times in a gait initiation task, as an example 
of a common voluntary whole-body movement. Without a SAS, there was a dif-
ference in TA onset between HSP patients and healthy controls, probably due to a 
delayed corticospinal conduction time. With the SAS, the normalization of TA onsets 
in HSP patients suggests that these patients now used the same neural pathway as 
healthy controls (i.e. the reticulospinal tract) to generate the SAS-induced move-
ments, irrespective of whether acceleration of reaction times may have been limited 
by physiological floor effects. It is important to mention that the observed SAS-in-
duced reaction times in this study (75-89ms) are in the same order of magnitude as 
those previously reported during both voluntary ankle dorsiflexion and gait initiation 
in various populations 1,143,146. In addition, our SAS-induced TA onsets are in line with 
previously reported startle reflex onsets in TA 1,148, which further supports the notion 
that the SAS-induced response is conveyed by the reticulospinal tract.
This finding complements previous work on single-joint movements. In our previous 
study in HSP patients, delayed onset latencies of TA activity and ankle dorsiflexion 
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movements were observed in a single-joint reaction task, yet with a SAS the patients’ 
reaction times were comparable to those of healthy individuals 1. Similarly, in stroke 
survivors, onset latencies of isolated elbow flexion and hand extension movements 
were delayed without a SAS, whereas these reaction times were also normalized 
with the SAS 140,141. To our knowledge, only one previous study has investigated the 
StartReact effect in a voluntary whole-body movement in a group of UMNS patients. 
During forward standing reaches with the paretic arm, people with stroke demon-
strated delayed onsets of both the anticipatory postural adjustment (APA) and the 
focal reaching movement compared to healthy control subjects. Administration of a 
SAS led to a significant reduction in reaction times in the controls. In contrast, in the 
people with stroke the SAS did not speed up APA onsets, whereas it even caused a 
further delay in reaching onsets 123. The discrepancy between these and our present 
findings may be related to damage of cortical areas responsible for motor prepara-
tion (e.g. pre-motor cortex, supplementary motor cortex) after stroke, whereas HSP 
(in its pure form) does not affect neurons originating from these secondary motor 
areas. As the StartReact phenomenon typically depends on the requested move-
ment being readily prepared when the SAS is administered, (partial) sparing of these 
cortical motor preparation areas seems imperative, with the degree of sparing likely 
becoming more critical as the task becomes more complex.
In this study, we found no difference in SAS-induced onset latencies between SCM+ 
and SCM- trials, which is consistent with previous StartReact studies that includ-
ed lower-extremity movements 1,23,36,135. In contrast, small but significant differences 
have been demonstrated in several studies that focused on upper extremity move-
ments 140,149,150. Based on these results it was previously suggested that a true Start-
React effect could only occur when a startle reflex in SCM was also elicited. Yet, at 
present, startle reflexes and acceleration of motor responses by a startling stimu-
lus are considered to be dissociated phenomena 36. The small difference between 
SCM+ and SCM- trials that has been reported by some authors is likely explained 
by the presence of a startle reflex in SCM being a marker of preparedness, with a 
higher level of preparedness in SCM+ trials leading to shorter reaction times 36,135,137. 
Although it remains elusive why this effect is not observed in lower extremity move-
ments, our results confirm that the presence of a startle reflex is not conditional for 
the occurrence of the StartReact effect. 
An unexpected finding of the present study was the lack of acceleration of soleus 
inhibition in the HSP patients upon administration of the SAS. In contrast, the SAS did 
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accelerate SO offsets in the healthy controls, which result is in agreement with the 
observations from a previous study that investigated the StartReact phenomenon 
in a gait initiation task in healthy young participants 143. In that study, SO offsets and 
TA onsets during gait initiation were both accelerated to latencies of ~50-70 ms 
by a SAS 143,151, which is consistent with the latencies observed in our healthy con-
trol group. StartReact effects on muscle inhibition have also been demonstrated in 
healthy young participants in a reaction time paradigm where they had to actively in-
hibit a baseline elbow flexion force with and without a SAS 151. Hence, it appears that 
our HSP patients differ from healthy participants in their lack of SAS-induced inhibi-
tory motor control. As both SO inhibition and TA activation are known to contribute 
to the generation of the APA 127, the observed disparity in excitatory and inhibitory 
StartReact effects in the HSP patients may also explain why their APA onsets were not 
accelerated to healthy control levels with the SAS.
The results of the current study raise the question which mechanism(s) may underlie 
the absent StartReact effect on muscle inhibition in the HSP patients. Here we can 
only speculate, as our study was not designed to address this unexpected finding. 
One suggestion may be that inhibitory control of the reticulospinal tract on spinal 
motoneurons is less potent than its excitatory effects. This relative difference be-
tween inhibitory and excitatory strength would be in line with previous observations 
in cats, where it has been shown that the reticulospinal tract has fast-conducting ex-
citatory (activating) fibers that project directly onto motoneurons, while inhibitory re-
ticulospinal projections merely appeared to be indirect (i.e. via interneurons) 152. Yet, 
under this assumption, one would expect SAS-induced differences in relative timing 
of TA onsets and SO offsets in the healthy controls as well, which we did not observe.
Another possibility is that HSP differentially affects the dorsal and medial fascicles of 
the reticulospinal tract. Animal studies have suggested that inhibitory commands are 
predominantly conducted by the dorsal reticulospinal tract (which runs closely to 
the corticospinal tract 153) , whereas the medial reticulospinal tract mainly conducts 
excitatory commands from the reticular formation 154,155. Hence, the lack of SAS-in-
duced acceleration in SO offsets may be due to affliction of the dorsal reticulospinal 
tract, while the medial reticulospinal may remain unaffected in the presently studied 
genotypes of HSP. Yet, we are unaware of any (post-mortem) studies in patients with 
HSP in support of this hypothesis. 
A third and perhaps most plausible mechanism is that the inhibitory SAS-induced 
CHAPTER 5
96
STARTREACT DURING GAIT INITIATION IN HSP PATIENTS
command may lack strength to overcome the tonic calf muscle activity that is pres-
ent when standing upright. Indeed, calf muscle tone is typically higher in UMNS pa-
tients compared to healthy controls. Due to the lack of descending inputs in UMNS, 
muscle activity can cause motoneurons to activate voltage-dependent persistent 
inward currents. These persistent inward currents can lead to self-sustained firing of 
motoneurons, resulting in a long-lasting involuntary enhancement of muscle activity 
118 that may override the effect of the inhibitory SAS-induced reticulospinal com-
mand. However, there is no direct evidence in support of this suggestion and further 
research is warranted to elucidate the mechanisms underlying defective StartReact 
effects on muscle inhibition in HSP. 
The present findings may shed new light on the functional utility of the reticulospi-
nal tract for bypassing defective corticospinal control. Animal studies have provided 
strong evidence for the potential of a compensatory role of the reticulospinal tract 
in recovery of upper-extremity motor function (for review: see Baker 39) and lately 
also of lower-extremity function. For instance recovery of function after complete 
corticospinal lesions was shown to coincide with an increased output from the retic-
ulospinal system as measured with intracellular recordings 37,132,133,156. Also in humans 
after stroke, the notion of reticulospinal contributions to functional recovery is gain-
ing support, particularly concerning those with severe damage to the primary motor 
cortex and/or the corticospinal tract 39,157-160. However, reticulospinal motor control 
has limitations compared to corticospinal control due to the greater dispersion of 
reticulospinal projections on spinal motor neurons 161, limiting the degree of refined 
fractionated movements. The results of the present study suggest that reticulospinal 
motor control may also be inferior because this system lacks the capacity to inhibit 
task-inappropriate muscle activity. Yet, the exact mechanisms remain elusive and 
can only be speculated upon. Together, these considerations may explain why in 
HSP patients spasticity and lack of refined motor control are often more prominent 
impairments than muscle weakness 75. During our task of gait initiation, the function-
al disadvantages of defective soleus inhibition on, for instance, step onset appeared 
to be rather minimal, however poor inhibitory control may be more detrimental to 
performance in other postural tasks, such as postural perturbations. Further research 
is needed to fully understand the potential and limitations of compensatory reticulo-
spinal motor control in upper motor neuron syndrome.
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PART 3
CLINICAL MANAGEMENT: FUNCTIONAL EFFECTS  
OF BTX-A IN PATIENTS WITH PURE HSP 

Which changes in ankle kine(ma)tics following BTX-A 
treatment and subsequent stretching of the calves 
contribute to increased comfortable speed in patients 
with pure hereditary spastic paraplegia?
SUBMITTED AS
van Lith BJH, van Bon GEA, Geurts ACH, Weerdesteyn V. Which changes in ankle kine(ma)
tics following BTX-A treatment and subsequent stretching of the calves contribute to increased 




EFFECTS OF BOTULINUM TOXIN ON ANKLE KINE(MA)TICS IN HSP PATIENTS
Abstract 
Background
Botulinum toxin type A (BTX-A) is a common treatment for focal spasticity. Patients 
with pure Hereditary Spastic Paraplegia (HSP) constitute a good clinical model to 
investigate the functional effects of BTX-A treatment, because their lower limb spas-
ticity is often more prominent than muscle weakness or sensory loss. In a group 
of patients with pure HSP, we previously showed increased comfortable gait speed 
after BTX-A treatment and subsequent stretching of the calves, but the underlying 
mechanisms remained unclear.
Research question
How do changes in ankle kinematics and kinetics following BTX-A treatment and 
subsequent stretching of the calves lead to increased comfortable gait speed in pa-
tients with pure HSP?
Methods
Sixteen patients with troublesome calf spasticity, confirmed by surface electromy-
ography during gait, were treated with bilateral BTX-A injections in the triceps surae 
and performed daily self-administered stretching exercises for 18 weeks. In 13 par-
ticipants, spatiotemporal variables and ankle kinematics and kinetics could be deter-
mined by instrumented gait analyses before intervention (baseline) and 4 (T1) and 18 
(T2) weeks thereafter. 
Results
Stride length and comfortable gait speed were larger at T1 and T2 compared to base-
line (p<0.05), whereas cadence did not change significantly. Peak ankle power and 
positive work during late stance improved at T1 and T2 (p<0.05), while negative work 
during early-midstance did not significantly change, nor did ankle angles (maximal an-
kle dorsiflexion and plantarflexion; maximal ankle range of motion), peak ankle torque, 
or the ground reaction force angle in the plane of progression at peak ankle power. 
Significance
BTX-A treatment and subsequent stretching of the calves in patients with pure HSP 
and proven troublesome calf spasticity during gait may enhance comfortable gait 
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speed by allowing more efficient use of calf muscle strength during push-off, leading 
to increased stride length. 
Introduction
Intramuscular injections with botulinum toxin type A (BTX-A) are a common treatment 
for focal spasticity, but evidence for the efficacy of treatment on walking capacity is 
rather limited. This may be due to the confounding effects of co-existing impairments, 
such as loss of muscle strength and somatosensation, which are highly prevalent in 
the patient groups studied (e.g. stroke and cerebral palsy (CP)) 162,163. Patients with pure 
Hereditary Spastic Paraplegia (HSP) constitute a good clinical model to investigate 
the functional effects of BTX-A treatment, because of their progressive bilateral lower 
limb muscle spasticity, while leg muscle strength and somatosensation are often pre-
served 27. Therefore, functional effects of BTX-A injections can be investigated relatively 
unconfounded by paresis or somatosensory impairment. A previous study from our 
group investigated the effects of BTX-A treatment and subsequent stretching of the 
calves in a group of patients with pure HSP. It was shown that – after the combined 
treatment – there was a substantial reduction of calf muscle tone, which coincid-
ed with a slight decrease in calf muscle strength during clinical examination (Medical 
Research Council (MRC) scale), although quantitative assessment of muscle strength 
showed no significant change. These effects at the level of the calf muscle resulted in 
a 10% gain in comfortable gait speed as well as in subjective gait benefits for most pa-
tients, without affecting antero-posterior balance capacity 9. Although an overall bene-
ficial functional effect was found, the question remained how the observed increase in 
comfortable gait speed after BTX-A treatment and subsequent stretching of the calves 
came about. Therefore, the focus of the current paper is on the ankle kinematics and 
kinetics before and after this combined treatment to better understand the observed 
beneficial effects in gait speed. 
Generally, the presence of calf muscle spasticity in patients with upper motor neuron 
syndrome leads to a gait pattern referred to as ‘toe walking’, which is characterized by 
initial midfoot or forefoot contact, early heel rise, lack of push-off power, toe dragging 
and limited step length 164. A midfoot or forefoot landing may be caused by premature 
calf muscle activity during the swing phase, often accompanied by lack of activity of 
the ankle dorsiflexors, leading to an abnormal (often reversed) roll-off motion of the 
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ankle and foot 112,165. BTX-A treatment of the calves may enhance ankle dorsiflexion an-
gles at initial contact and improve the first rocker, as was shown in people with stroke 
and children with CP 166,167. In the case of an initial heel strike, premature calf muscle 
activity early after loading may counteract normal ankle dorsiflexion movement during 
roll-off 165,168, leading to increased negative work (i.e., energy absorption) at the an-
kle joint 169. A reduction in mid stance calf muscle activity following BTX-A injections, 
which has previously been reported in people with stroke 170,171, may thus improve the 
second rocker and reduce energy absorption. Indeed, in patients with stroke and CP, 
larger ankle dorsiflexion angles 166,167,172-174 and a lower peak in energy absorption at the 
ankle 173 were observed following BTX-A treatment of the calf muscles. Lastly, during 
late stance, calf muscle spasticity coincides with reduced ankle power and slower 
ankle plantarflexion movement 165, which hampers forward propulsion. In such cases, 
BTX-A treatment might – on the one hand – facilitate active push-off if muscle tone is 
reduced, while – on the other hand – it may reduce voluntary muscle strength, which 
would limit push-off power during the third rocker. Yet, previously reported effects of 
BTX-A treatment of the calves on peak ankle power are inconsistent 166,173,175-177, which 
calls for further study.
The purpose of the current study was to identify how changes in ankle kinematics 
and kinetics after BTX-A treatment and subsequent stretching of the calf muscles led 
to an increase in comfortable gait speed in patients with pure HSP as observed in our 
previous study 9. We expected that the combined treatment would lead to a decrease 
in negative work during the loading and/or midstance phase of gait as a consequence 
of improved ankle dorsiflexion movement. In addition, we expected a slight decrease 
in positive work during late stance as a consequence of a possible decrement in calf 
muscle strength. However, we hypothesized that the decrease in negative work would 
outweigh the decrease in positive work, which would explain the observed increase 
in comfortable gait speed. For correct interpretation of the results, we also compared 
ankle kinematics and kinetics during gait of our patients with HSP with those of healthy 




In short, the inclusion criteria for patients were: (1) a pure form of autosomal dom-
CHAPTER 6
105
EFFECTS OF BOTULINUM TOXIN ON ANKLE KINE(MA)TICS IN HSP PATIENTS
inant HSP; (2) aged between 18 and 75 years; (3) calf muscle spasticity (Modified 
Ashworth Scale (MAS) score 1-2); (4) bilateral premature calf muscle activity during 
the loading and/or midstance phase of gait as determined by surface EMG; (5) bal-
ance- and/or gait-related activity limitations in daily life; (6) Functional Ambulation 
Categories (FAC) score 5 113; (7) passive ankle range of motion (ROM) more than 10° 
dorsiflexion with an extended knee, and (8) normal or near-normal calf and tibialis 
anterior muscle strength (MRC score 4-5) 114. In addition, 10 healthy controls with the 
same age and sex distribution were included to provide reference data 9. All subjects 
gave their written informed consent prior to participation. The study was approved 
by the regional medical-ethical committee and conducted in accordance with the 
Declaration of Helsinki. 
Intervention
Each patient was treated with one cycle of bilateral BTX-A injections (Dysport®) in 
the calf muscles of each leg, either 500 U (when MAS 1) or 750 U (when MAS 2), 
distributed evenly over the three heads of the triceps surae: soleus (5 sites) and 
medial (2 sites) and lateral (2 sites) heads of gastrocnemius. Furthermore, participants 
were instructed to perform stretching exercises of the calf muscles for approximately 
10 minutes, twice daily, during the 18-week study period. During this period, every 2 
weeks, patients were asked by the primary investigator whether they did their daily 
exercises to check adherence to the protocol. For a more detailed description of the 
intervention, we refer to our previous paper 9.
Design
The gait assessments of the patients with HSP were performed one week before 
treatment (baseline; T0), 4 weeks after treatment (T1), and 18 weeks after treatment 
(T2). T1 was set at 4 weeks after treatment, because at this time interval the physio-
logical effects of BTX-A on spasticity were expected to have reached a maximum 178. 
The effects of BTX-A were expected to diminish progressively until about 18 weeks 
after the injections. The healthy control subjects performed the gait assessment just 
once and were compared to the baseline data of the patients. 
Gait assessment
We used the instrumented gait analysis data as obtained in the previous study 9. Gait 
was evaluated barefoot and without the use of walking aids on a 10 meter walkway. 
All patients wore a safety harness attached to an overhead railing that prevented 
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them from falling. The subjects with HSP walked at an individually preferred (‘com-
fortable’) speed. Healthy control subjects were instructed to walk at low velocity in 
order to match their gait speed to the average speed of the patients. 
During the gait assessments, kinematic data were recorded by a 6-camera 3D mo-
tion analysis system (Vicon MX, Oxford Metrics, Oxford, UK) at a sample rate of 100 
Hz. Reflective markers were placed at anatomical landmarks according to the full-
body PlugInGait configuration 179. Simultaneously, ground reaction forces (GRFs) 
were recorded from two force plates (40 x 105 cm AMTI® force plate, Watertown, 
MA, USA), embedded in the middle part of the 10 meter walkway, at a sampling rate 
of 1000 Hz. Subjects walked back and forth repeatedly in order to obtain at least 5 
valid measurements for each leg (i.e. a complete support phase on one force plate 
without the opposite foot touching the same plate). 
Data analysis
For each trial, existing of one gait cycle for the left and one for the right leg, we de-
termined the following variables:
Spatiotemporal characteristics: gait speed, stride length and cadence (based on ki-
nematic data).
Kinematics: the maximal ankle dorsiflexion and plantarflexion angles and the total 
ankle ROM across the gait cycle (figure 1B); we also determined the angle of the 
foot with the horizontal (in the plane of progression) at initial contact, with positive 
angles representing a heel landing and negative angles representing a midfoot/fore-
foot landing. 
Kinetics: peak ankle torque (figure 1D), peak ankle power (figure 1F), and negative 
work (A1; energy absorption; figure 1F) during the early and midstance phase, and 
positive work (A2; energy generation; figure 1F) during the late stance phase; we 
further calculated the GRF angle at maximal ankle power, defined as the angle of the 
force with the ground (in the plane of progression), with 90° representing a vertical 
force and smaller angles indicating a force directed more horizontally. 
For each subject, the ensemble averages for ankle angles, ankle torques and ankle 
powers in the sagittal plane of all trials were calculated for each leg separately. Sub-
sequently, values for ankle kine(ma)tic outcomes were identified from these ensem-
ble averages, resulting in one value for the left and one value for the right leg. There-
after, these values were averaged resulting in a single value per variable per subject.
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FIGURE 1. Representative ensemble averages of the ankle angle (a and b), ankle torque (c and 
d), and ankle power (e and f) trajectories in the sagittal plane of a representative patient (left 
column) and control subject (right column), with the kine(ma)tic variables of interest. Ankle 
kinetics were normalized for body weight. Area under the curve: A1 = negative work; A2 = 
positive work.
Statistical analysis
The effects of the combined treatment were assessed using a repeated measures 
ANOVA with time (T0-T1-T2) as within-subjects factor. In the case of a significant 
time effect, post-hoc paired t-tests were used. In addition, we performed indepen-
dent t-tests to compare the gait variables between groups. Statistical analyses were 
performed using IBM SPSS Statistics Version 20 for Windows. For all analyses, the α 
level was set at 0.05.
Results
Of the 16 patients included in our previous paper 9, three patients were unable to 
deliver the full series of gait assessments due to technical problems (n=2) or because 
the gait assessments were too burdensome (n=1). Hence, the three consecutive gait 
assessments of 13 patients were used in this study, together with the single assess-
ments of 10 healthy controls. 
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TABLE 1. Demographic characteristics of the patients with HSP and the healthy control subjects.
  HSP Control
N 13 10
Age (mean ± SD) 48.46 ± 12.80 46.10 ± 11.82 
Sex (male/female) 10/3 6/4
 
Time effects in HSP
The data of the patients are summarized in table 2. Gait speed differed between 
the assessments (F(2,24)=5.626, p=0.010), with higher speeds at T1 (t(12)=-2.960, 
p=0.012) and T2 (t(12)=-2.835, p=0.015) compared to baseline (figure 2A). Stride 
length was also different between the assessments (F(2,24)=5.914, p=0.008), as 
strides were longer at T1 (t(12)=-2.687, p=0.020) and T2 (t(12)=-3.123, p=0.009) (fig-
ure 2B) than at baseline. There were no time effects for cadence (F(2,24)=2.635, 
p=0.124).
The ankle angles showed no differences between the assessments (maximal dor-
siflexion: F(1.16,13.87)=0.734, p=0.426; maximal plantarflexion: F(2,24)=0.414, 
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TABLE 2. Outcomes for within-subjects comparisons
Bold values indicate statistical significance. *Sphericity not assumed, Greenhouse-Geisser test 
used. GRF angle: angle of the ground reaction forces with respect to the horizontal in the 
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Although peak ankle torque did not differ between the assessments (F(2,24)=1.288, 
p=0.294), there was a significant difference for peak ankle power (F(2,24)=7.958, 
p=0.002), with increased peak powers at 4 weeks (t(12)=-3.215, p=0.007) and 
at 18 weeks (t(12)=-3.648, p=0.003) after BTX-A treatment (figure 2C). No differ-
ences between the assessments were found for negative work (F(2,24)=2.834, 
p=0.079; figure 2D). In contrast, positive work did differ between the assessments 
(F(2,24)=4.104, p=0.029), with higher positive work at T1 (t(12)=-2.784, p=0.017) and 
T2 (t(12)=-2.241, p=0.045) compared to baseline (figure 2E). There were no time 
effects for GRF angle at maximal ankle power (F(2,24)=0.886, p=0.426). 
 
FIGURE 2. Gait velocity (A), stride length (B), peak ankle power (C), negative work (D) and posi-
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Group differences between HSP and control
Table 3 summarizes the group results for all variables. The preferred gait speed of pa-
tients at baseline was similar to the slow gait speed of healthy controls (t(21)=1.035, 
p=0.312). Patients walked with shorter stride lengths (t(21)=2.990, p=0.007) than 
healthy controls, while cadence was higher in patients compared to controls, but 
the latter difference did not reach significance (t(21)=-1.559, p=0.134).
No group difference was found for maximal ankle dorsiflexion angle (t(14.586)=-1.357, 
p=0.195), but patients had lower maximal ankle plantarflexion angles than healthy con-
trols (t(21)=-2.979, p=0.007). As a result, the total ankle ROM was lower in patients 
compared to controls (t(19.299)=2.947, p=0.008). Furthermore, foot angles at initial 
contact were smaller in patients than in healthy controls (t(21)=5.843, p<0.001).
TABLE 3. Outcomes for between-subjects comparisons
 HSP-T0 Controls Independent samples t-test
 (mean ± SD)  
Gait speed (m/s) 0.93 ± 0.19 1.00 ± 0.11 t(21)=10.035, p=0.312
Stride Length (m) 1.07 ± 0.15 1.24 ± 0.10 t(21) = 2.990, p = 0.007
Cadence (strides/s) 0.87 ± 0.10 0.81 ± 0.06 t(21) = -1.559, p = 0.134
Maximal ankle  
dorsiflexion (°)
17.19 ± 4.96 15.22 ± 1.45 t(14.586) = -1.357, p = 0.195*
Maximal ankle  
plantarflexion (°)
4.70 ± 6.65 11.50 ± 3.12 t(21) = -2.979, p = 0.007
Ankle ROM (°) 21.89 ± 5.01 26.73 ± 2.75 t(19.299) = 2.947, p = 0.008*
Foot angle at initial 
contact (°)
11.91 ± 3.37 19.40 ± 2.26 t(21) = 5.843, p < 0.001
Peak ankle torque 
(Nm/kg)
1.24 ± 0.20 1.48 ± 0.09 t(17.270) = 3.844, p = 0.001*
Peak ankle power  
(W/kg)
1.99 ± 0.60 2.80 ± 0.40 t(21) = 3.630, p = 0.002
Negative work (J/kg) 0.17 ± 0.05 0.19 ± 0.04 t(21) = -1.116, p = 0.277
Positive work (J/kg) 0.18 ± 0.04 0.25 ± 0.03 t(21) = 4.850, p < 0.001
GRF angle (°) 79.54 ± 4.00 75.39 ± 1.87 t(21) = -3.026, p = 0.006
Bold values indicate statistical significance. *Equal variances not assumed. GRF angle: angle of 
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Both peak ankle torque and peak ankle power were lower in patients compared to 
healthy controls (t(17.270)=3.844, p=0.001 and t(21)=3.630, p=0.002, respectively). 
No group difference was observed for negative work (t(21)=-1.116, p=0.277), but pa-
tients generated less positive work than controls (t(21)=4.850, p<0.001). Lastly, the 
GRF angles at maximal ankle power of patients were more vertically oriented than 
those of controls (t(21)=-3.026, p=0.006). 
Discussion
The results of this study do not corroborate our hypothesis that the increase in com-
fortable gait speed observed after BTX-A treatment and subsequent stretching of 
spastic calf muscles in patients with HSP was associated with reduced negative work 
during the loading and/or midstance phase of gait due to improved ankle dorsiflex-
ion movement. Only one previous study has addressed changes in midstance kinet-
ics after BTX-A injections in the calves and reported a decrease in peak negative work 
in children with spastic CP 173. This treatment was, however, combined with a 1.5±0.5 
months rehabilitation program for at least three days a week, which makes it difficult 
to compare the results with the current findings. The lack of changes in ankle dorsi-
flexion angles that we observed is also not in line with several studies in patients with 
stroke and CP that did report improved ankle dorsiflexion movements after BTX-A 
treatment (for review, see 180,181). However, in the majority of studies that investigated 
both ankle dorsiflexion angles and gait speed 167,171-177,182-184, improvements in dorsiflex-
ion angles were not accompanied by an increase in gait speed 167,172-174,176,183,184, where-
as another study reported higher gait speeds in the absence of improvements in 
ankle dorsiflexion angles 171. Hence, it seems unlikely that improved ankle dorsiflexion 
movement during the stance phase of gait and/or reduced energy absorption at the 
ankle importantly underlie improvements in gait speed following BTX-A treatment.
Surprisingly, we did not find a decrease but an increase in positive work (+11% at T1) 
during the late stance phase of gait after BTX-A treatment in our patients, which co-
incided with improved peak ankle power (+16% at T1), increased stride length (+5% 
at T1), and increased comfortable gait speed (+9% at T1), while cadence remained 
constant. A previous study on BTX-A treatment of the calf muscles in patients after 
stroke showed similar results, with an increase in both peak power and gait speed 
177. Indeed, in healthy people greater late-stance ankle power generation is strongly 
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associated with higher gait speed 185, which suggests that a similar mechanism may 
have been at work in our present study. Yet, it may not be the only mechanism un-
derlying improvements in gait speed, as another study on BTX-A treatment of the 
calves in children with CP reported a higher gait speed in the absence of greater 
peak ankle power 175. 
When the patients with pure HSP in our study were compared to healthy controls, 
several kinematic and kinetic variables were deviant, such as ankle plantarflexion 
angle, peak ankle torque, peak ankle power, positive work and the GRF angle at 
maximal ankle power, which underlines the potential for improvement of the ankle 
dynamics in our patients. The observed improvement of ankle dynamics after BTX-A 
treatment in the present study may – nonetheless – be considered as counterin-
tuitive, given the fact that BTX-A causes a presynaptic block of the neuromuscular 
junctions. This might coincide with some loss of maximal muscle strength besides a 
reduction of muscle tone. Indeed, in our previous study 9, we observed a slight tem-
porary decrease in calf muscle strength on clinical examination (MRC scale), but this 
result was not confirmed by quantitative muscle strength assessment. Hence, the 
loss of calf muscle strength after BTX-A treatment (if any) may be negligible. In con-
trast, the current study shows that peak ankle power and positive work during late 
stance actually increased after BTX-A treatment. Since peak ankle torque remained 
constant, the observed increase in peak ankle power (torque · angular velocity) sug-
gests enhanced ankle plantarflexion velocity underlying the improved ankle dynam-
ics. Possibly, muscle tone reduction due to BTX-A injections provides a better basis 
for efficient muscle recruitment, leading to faster concentric calf muscle contraction 
during push-off 165. This notion would imply that the common fear of clinicians that 
BTX-A treatment of calf muscles may induce clinically troublesome loss of knee sta-
bility or reduced push-off power during gait might not be justified, but more well-fo-
cused research is needed to further underscore this notion. 
Interestingly, the observed improvements of positive work, peak ankle power, stride 
length and gait speed were not restricted to the first assessment 4 weeks after BTX-A 
treatment, but were all retained at the second assessment 18 weeks after treatment. 
This pattern of results implies that improvements in ankle dynamics after BTX-A treat-
ment for calf muscle spasticity may reach beyond the typical ‘period of BTX-A effec-
tiveness’ of three to four months. Possibly, the intensive stretching regime that was 
performed by the patients during the entire 18-week follow-up is responsible for this 
long-lasting result of BTX-A treatment, as repetitive muscle stretch may have a mod-
ulating (inhibiting) effect on muscle tone as well 186. 
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A limitation of this study is that we focused on the kinematics and kinetics of the 
ankle joint, where concurrent dynamic changes at the hips may have occurred 
that might have contributed to (or perhaps hampered) comfortable gait speed after 
BTX-A treatment of the calves. Indeed, it has been shown that generation of e.g. 
ankle and hip power are interrelated in healthy subjects 187. Another limitation is that 
the current study only investigated changes in ankle dynamics after one cycle of 
BTX-A treatment. The observed improvements may therefore not be generalized 
to the effects of multiple treatment cycles over several months or years, such as is 
common in clinical practice. The present results may not be generalized to other 
patient groups either. They do, however, warrant more extensive mechanistic and 
clinical research into the (long-term) functional effects of BTX-A treatment in order 
to obtain a better understanding of why and how this treatment may be functionally 
beneficial to patients with spastic gait disorders. 
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Abstract
Objective 
To investigate the functional effects of bilateral botulinum toxin A (BTX-A) treatment 
and subsequent stretching of spastic hip adductors on gait and reactive lateral step-
ping responses in patients with pure hereditary spastic paraplegia (HSP).
Design
Explorative pre-post intervention study 
Patients
Twenty-five patients with pure HSP
Methods
Patients were treated with bilateral BTX-A injections in the hip adductors and per-
formed daily self-administered stretching exercises for 16 weeks. Before the inter-
vention (T0), and 6 (T1) and 16 (T2) weeks thereafter, we assessed gait width, gait 
speed, and leg angles at first stepping-foot contact after lateral balance perturba-
tions, as well as the corresponding success rates of reactive lateral steps. 
Results
Compared to baseline, gait width increased by 12.6% and 9.7% and comfortable gait 
speed by 8.3% and 11.5% at T1 and T2, respectively. In known perturbation directions, 
leg angles increased by 5.9% at T1 and 8.0% at T2, while success rates increased from 
70% at baseline to 90% at T1 and T2. No effects were found for maximal gait speed 
or lateral stepping responses in unknown perturbation directions.
Conclusions
BTX-A treatment and subsequent stretching of the hip adductors may improve gait 
and reactive lateral stepping in patients with pure HSP.
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Introduction
Patients with pure hereditary spastic paraplegia (HSP) show a slow, retrograde axonal 
degeneration of the corticospinal tract, which leads to bilateral progressive lower ex-
tremity spasticity. Although muscle strength and somatosensation are often affected 
as well, the degree of paresis and sensory loss is usually milder than in other condi-
tions with spastic paraparesis (e.g. spinal cord injury or multiple sclerosis) 8,9. Hip ad-
ductor spasticity is often prominently present in patients with pure HSP. Besides loss 
of gait propulsion and balance deterioration in the plane of progression,8,188 patients 
are usually troubled by frontal-plane imbalance as well, to which hip adductor spas-
ticity is suggested to be an important contributing factor 75. This may be explained by 
spasticity of the hip adductors leading to forced, spontaneous narrowing of the base 
of support while standing and walking (‘scissoring’). In addition, HSP patients may ex-
perience difficulties stepping sideways to recover from a lateral balance perturbation, 
as the hip abductors have to overcome the involuntary activity of the spastic hip ad-
ductors. The small base of support in combination with the presumed side-stepping 
difficulties likely increase the risk of falling in HSP patients. 
Botulinum toxin type-A (BTX-A) injections are commonly used for reducing spasticity 
in HSP patients9,65,76,93,189, although BTX-A is still on off-label prescription in HSP for 
all commercially available toxins. BTX-A treatment of the hip adductors, calf muscles 
and hamstrings has been suggested to lead to functional improvements in balance 
and gait capacities 75,189. However, despite the high prevalence of hip adductor spas-
ticity in HSP patients, there are no studies that have systematically investigated the 
effects of BTX-A injections in these muscles, neither on clinical indicators of spas-
ticity, nor with respect to balance and gait capacity. In a few previous studies with 
limited numbers of HSP patients, the hip adductors were injected in some of the par-
ticipants (n=5 to 12), yet often in combination with other muscle groups (i.e. calves, 
tibialis posterior, iliopsoas and rectus femoris) 65,93,94. Furthermore, these studies did 
not include stretching exercises following BTX-A treatment, as recommended by 
international consensus 5. Hence, the specific effects of BTX-A injections in the hip 
adductors with subsequent stretching exercises remain to be established. 
In this exploratory study, we focused on the effects of BTX-A injections in spastic 
hip adductors and subsequent stretching exercises in patients with pure HSP, using 
two primary outcomes: (1) gait width and (2) the quality of sideways reactive step-
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ping responses following lateral balance perturbations. In addition, comfortable and 
fast gait speed, success rates of the lateral stepping responses, and various clinical 
(physical and functional) tests served as secondary outcome measures. The physio-
logical effect of BTX-A usually reaches its maximum 6 weeks after the injections 178 
and diminishes progressively until about 16 weeks after the injections. Therefore, we 
hypothesized that reduced hip adductor tone would translate in improvements in 
both gait width and lateral stepping at 6 weeks post treatment, whereas a reduction 
of these effects was expected at 16 weeks after treatment. 
Methods
Participants
Participants were recruited from all patients with HSP and hip adductor spasticity 
known at the expert centre for genetic movement disorders of our university hospi-
tal. In addition, active recruitment took place through the national patient organisa-
tion “Spierziekten Nederland”. Inclusion criteria were: (1) a ‘pure’ form of autosomal 
dominant HSP (either genetically proven, or based on family history); (2) 18 years or 
older; (3) bilateral hip adductor spasticity (Modified Ashworth Scale (MAS) score 1-4); 
(4) balance- and/or gait-related activity limitations in daily life; (5) able to walk > 50 m 
independently with (adapted) shoes and/or orthoses (but without walking aids such 
as crutches or a walker); and (6) comfortable gait velocity > 0.4 m/s. Participants 
were excluded if they suffered from cognitive impairments or from any comorbidity 
affecting their gait capacity. In addition, the last BTX-A treatment of the hip adductors 
should have been administered longer than 6 months before the first measurement. 
Regular BTX-A treatments of other muscle groups should have been performed ei-
ther within 3 to 4 weeks or longer than 4 months before the first measurement in 
order to have either an optimal or otherwise an absent effect of these prior injections 
during the study period. 
For participants recruited at the outpatient departments, all inclusion criteria were 
checked by the attending physician. Participants who responded to the recruitment 
letters via the patient organisation were interviewed by telephone by the primary 
investigator to check inclusion criteria 1, 2, and 4, whereas inclusion criteria 3, 5 and 
6 were checked by a physiotherapist at the first visit for the study. Out of 75 patients, 
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25 patients fulfilled the inclusion criteria and were included. Their demographic and 
clinical characteristics are listed in Table 1. 
 
TABLE 1. Patient characteristics at T0






AD, genotype not  
confirmed 8
   Median (range)
Tibialis anterior MAS 0 (0-1)
MRC 5 (2-5)
Triceps surae MAS knee extended 2.5 (1-4)
knee flexed 2.5 (0-4)
MRC 5 (2-5)
Hip adductors MAS 3 (1-4)
MRC 5 (2-5)
Hip abductors MRC 5 (2-5)
BBS 49.5 (27-56)
   Mean (range)
Age 53.5 (26-72)
Hip abduction ROM 38.8 (20.0-52.5)
6MWT 367.5 (196-515)
TUG 11.1 (6.3-23.0)
ABC   49.83 (17-95.3)
 
AD: autosomal dominant inheritance; MAS: Modified Ashworth Scale; MRC: Medical Research 
Council scale; BBS: Berg Balance Scale; ROM: range of motion; 6MWT: 6-min Walk Test; TUG: 
Timed Up and Go test; ABC: Activities-specific Balance Confidence scale
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Ethics statement
All subjects gave their written informed consent prior to participation. The study was 
approved by the regional medical-ethical committee and conducted in accordance 
with the Declaration of Helsinki. Due to lack of prior research on gait width and 
quality of reactive sidesteps in patients with HSP, no formal power calculation could 
be performed. Given the exploratory nature of our study, a required number of 25 
patients seemed optimal, feasible and justified, and was agreed upon by the medical 
ethical committee.
Intervention
Each participant was treated with bilateral BTX-A injections in the hip adductors by 
one of three rehabilitation physicians of our university hospital. A solution of 100 U 
Xeomin® per 5 ml saline 0.9% was used. A dose of 150 or 200 U per leg was inject-
ed, depending on the degree of hypertonia (Modified Ashworth Scale (MAS) 1: 150 
U; MAS ≥2: 200 U). The BTX-A was distributed over the gracilis, adductor magnus 
and adductor longus muscles according to table 2. Muscle selection was based on 
muscle volume and its moment arm with respect to the hip joint. Thigh length was 
measured from the pubic bone to the medial femoral condyle and thigh length per-
centages were calculated from the pubic bone (see Figure 1). All BTX-A injections 
were placed under ultrasound guidance.
 
FIGURE 1. Schematic view of injection locations in percentages thigh length from the pubic 
bone to the medial femoral condyle. At the indicated thigh lengths, BTX was injected into 
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TABLE 2. Distribution of botulinum toxin per leg 
Percentage Units/ml
  thigh length* MAS 1 MAS ≥2
Gracilis 15% 15/0.75 20/1.00
35% 15/0.75 20/1.00
60% 15/0.75 20/1.00
Adductor Magnus 15% 30/1.50 40/2.00
35% 30/0.75 40/2.00
Adductor Longus 15% 30/1.50 40/2.00
 35% 15/0.75 20/1.00
* Upper leg length was calculated from pubis bone to medial femoral condyle.  
Thigh-length percentages were expressed from pubis.
During the 16-week study period, participants were instructed to perform stretching 
exercises of the hip adductors (with the hips both flexed and extended) for approx-
imately 10 minutes, three times per day, and to log their exercises in a diary. The 
exercises were individually demonstrated and instructed by a physiotherapist at the 




For instrumented gait assessment, the GAITRite system was used (CIR Systems, Inc., 
Sparta, NJ), which is a 4.88 meters long carpeted walkway that contains pressure 
sensors that detect the position of each footfall 190. Participants started at one end 
of the GAITRite and were instructed to walk three times across the walkway with 
(adapted) shoes and/or orthoses at their preferred speed. Subsequently, they walked 
three times across the walkway at their maximal speed without risking a fall. For each 
step, gait width was determined by the GAITRite system (which is stored as ‘stride 
width’) and exported to Microsoft Excel. For each participant, the median gait width 
of all steps was calculated to avoid a disproportional influence of a single outlying 
step. Gait width was determined for both the preferred (primary outcome) and maxi-
mal gait speed. In addition, the mean preferred and mean maximal gait speed of the 
three trials was calculated.
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Instrumented dynamic balance assessments
For instrumented dynamic balance assessments, the Radboud Falls Simulator was 
used (RFS). The RFS is a moveable platform (240 x 174 cm; BAAT, Enschede, The 
Netherlands 6) that can translate in multiple directions. In this way, perturbations can 
be imposed that mimic natural situations. In this study, only sideways perturbations 
were used, where a leftward platform translation resulted in a rightward balance 
perturbation and vice versa. In the remainder of this text, we consistently refer to the 
direction of the balance perturbations. 
At the start of each measurement, participants were instructed to sustain all per-
turbations by making a single lateral step without grabbing the handrails, while the 
perturbation direction was known to the participants. All participants wore a safety 
harness attached to the ceiling that prevented them from falling. In addition, a railing 
system was present at both sides that participants could grab in the case of a fall. At 
the first measurement (T0), participants were exposed to increasing perturbation in-
tensities that started at 0.125 m/s2 and were increased by at least 0.125 m/s2 between 
trials. The maximum perturbation intensity that each participant could successfully 
sustain with a single step at least once out of three trials (without falling or grabbing 
the railing system) defined the individual limit of stability. To familiarize them with the 
test situation, during the subsequent measurements (T1 and T2), participants were 
again exposed to at least 15 incremental perturbation intensities until their individual 
limits of stability were reached. 
During all measurements each participant was twice (randomly) exposed to five 
leftward and five rightward perturbations at their individual limits of stability. During 
the first 10 perturbations, the perturbation direction was known to the participant, 
whereas during the last 10 trials the perturbation direction was unknown. These 20 
trials were used for statistical analysis.
During all balance assessments, kinematic data were recorded by an 8-camera 3D 
motion analysis system (Vicon Motion Systems, UK) at a sample rate of 100 Hz. 
Reflective markers were placed at anatomical landmarks according to the full-body 
PlugInGait configuration 179. For all trials in which the participant succeeded to make 
a sidestep following the perturbation, the leg angle (primary outcome) was calculat-
ed at the instant of stepping-foot contact, as the body configuration at step contact 
appears to critically determine the successfulness of balance recovery responses 
191. The leg angle was defined as the angle between the absolute vertical and a line 
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connecting the mid-pelvis and the ankle marker of the stepping foot. The medians of 
the five right and five left leg angles were calculated to avoid a disproportional influ-
ence of a single outlying value. These medians were averaged for each person into 
a single leg angle score for the perturbations with known and unknown directions 
separately. Furthermore, the success rates of the lateral stepping responses were cal-
culated for the perturbations with known and unknown directions separately. A trial 
was scored as successful if the participant maintained balance with a single sidestep.
Physical tests
Muscle strength of the hip adductors and hip abductors was assessed with the Med-
ical Research Council (MRC) scale (0-5) with lower scores indicating more muscle 
weakness 51. Muscle tone of the hip adductors was assessed using the MAS (0-5) with 
higher scores indicating more hypertonia 49. Furthermore, passive range of motion 
(ROM) on hip abduction was measured using a goniometer. All outcomes were av-
eraged for both sides into a single score.
Functional tests
Functional balance was assessed barefooted with the Berg Balance Scale (BBS, range 
0-56) 192. The Timed Up and Go (TUG) test) 193 was performed with (adapted) shoes 
and/or orthoses, but without other walking aids. Endurance was assessed with the 
6-min Walk Test (6MWT),194 during which all walking aids were allowed. Lastly, the 
Activities-specific Balance Confidence (ABC) scale 195 was obtained as a subjective 
measure of mobility and balance. 
Procedure
All outcome measurements were performed on the day of treatment prior to the 
injections (baseline; T0), 6 (±1) weeks after treatment (T1), and 16 (±1) weeks after 
treatment (T2). T1 was set at 6 weeks after treatment, because at this point in time 
the physiological effects of BTX-A on spasticity were expected to have reached a 
maximum 178. The effects of BTX-A were expected to diminish progressively until 
about 16 weeks after the injections. Hence, T2 was set at 16 weeks post treatment to 
test the possible presence of a long-term effect of the combined treatment. The in-
strumented assessments were taken by the primary investigator. All other tests were 
assessed by an independent physiotherapist. 
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Statistical analysis
All instrumented (parametric) outcome measures were tested using repeated-mea-
sures ANOVA. The primary outcomes gait width and sidestep leg angle were tested 
using time (T0 – T1- T2) as within-subjects factor. For gait width and gait speed, also 
gait condition (preferred – maximal) was introduced as a within-subjects factor. We 
applied Bonferroni corrected post-hoc tests in the case of a significant main effect 
of time. All other (non-parametric) outcome measures (physical and functional tests) 
were analyzed with a Friedman’s test using time (T0 – T1 – T2) as a within-subject 
factor. Wilcoxon’s tests were used for post-hoc comparisons in the case of a signifi-
cant time effect. All statistical analyses were performed using IMB SPSS Statistics Ver-
sion 22 for Windows. The α-level was set at 0.05 for all analyses, with no adjustment 




From the total of 25 patients included in the study, three patients were lost between 
the first (T0) and the second measurement (T1): one patient suffered from increasing 
shoulder complaints that were already present before the first visit. One patient was 
lost due to spontaneous severe back pain, which had also repeatedly occurred in the 
past. A third patient left the study due to personal circumstances. No other adverse 
events occurred during the study.
Instrumented gait assessments
Table 3 summarizes the group results for all measurements. There was a significant 
time effect on gait width (F(2,42)=6.143, p=0.005). Gait width increased by 12.6% 
from baseline to T1 (p=0.021), and this improvement persisted at T2 (9.7%; p=0.022) 
(see figure 2a). There was no effect of gait condition on gait width (F(1,21)=1.229, 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 3. Outcomes measures
a = T0<T1/T2, T1=T2; b = T0<T1<T2; c = T0 < T1, T0 = T2, T1 = T2; d = T0 > T2 > T1; e = 
T0/2 > T1, T0 = T2; f = T0<T2<T1. MAS: Modified Ashworth Scale; MRC: Medical Research 
Council scale; ROM: range of motion; BBS: Berg Balance Scale; TUG: Timed Up and Go test; 
6MWT: 6-min Walk Test; ABC: Activities-specific Balance Confidence scale; dir = direction 
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There was also a significant time effect on gait speed (F(2,42)=5.458, p=0.008) as 
well as a significant time x gait condition interaction (F(2,42)=5.399, p=0.008). Com-
pared to baseline, the preferred gait speed had increased by 8.3% at T1 (p=0.001) 
and by 11.5% at T2 (p<0.001). In contrast, no significant changes from baseline were 
observed in the maximal gait speed (figure 2b). 
 
FIGURE 2. Gait width (a) and gait speed (b) at three measurements (T0, T1, T2) for preferred 
and maximal gait speed (gait condition). *indicates significant post-hoc effects of time for gait 
width. #indicates significant post-hoc effects of time on preferred gait speed.
Instrumented balance assessments
Changes in leg angles across time could only be statistically tested if side steps were 
made at all measurements (T0-T2). As some participants failed to make any side 
steps (i.e. only made cross steps) or grabbed the railing system before stepping, a 
total of 19 participants could be included in the analysis of trials with known pertur-
bation direction and 13 in the analysis of trials with unknown directions. The mean 
limit of stability was 2.135 m/s2 (range 0.375 m/s2 - 4.375 m/s2).
For the known direction perturbations, the leg angle showed a main effect of time 
(F(2,36)=12.053, p<0.001). There was an increase of 5.9% in leg angle from base-
line to T1 (p=0.003), which persisted at T2 (8.0%; p=0.001). In contrast, leg angle 
for the unknown direction perturbations did not show a significant effect of time 
(F(2,24)=0.107, p=0.899) (see figure 3a). 
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FIGURE 3. Leg angle (a) and success rate (b) at three measurements (T0, T1, T2) for known 
and unknown perturbation directions. #indicates significant post-hoc effects of time in known 
perturbation directions. *indicates significant effect of time.
 
For the known direction perturbations, there was a significant effect of time on suc-
cess rate (χ2(2)=12.559, p=0.002). Compared to the 70% success rate at baseline, 
participants were more successful at T1 (90%; p=0.007), which result tended to per-
sist at T2 (90%; p=0.075). For the unknown direction perturbations, no significant 
effects of time were found (χ2(2)=4.388, p=0.111) (see figure 3b). 
Physical tests
Hip adductor muscle tone showed a significant time effect (χ2 (2)=33.890, p<0.001). 
The MAS scores decreased from baseline to T1 (p<0.001), and subsequently in-
creased from T1 to T2 (p=0.001), although they did not reach the baseline values 
(T0 vs T2, p=0.001). Hip adductor muscle strength also showed a significant ef-
fect of time (χ2)=15.800, p<0.001), as the MRC scores decreased from baseline to 
T1 (p=0.005), and increased from T1 to T2 (p=0.003) to baseline values (T0 vs T2, 
p=0.480). Hip abductor muscle strength did not significantly differ between the three 
measurements (χ2(2)=4.957, p=0.084). Furthermore, there was a significant time ef-
fect on hip abduction ROM (F(2,42)=31.613, p<0.001), which increased from baseline 
to T1 (p<0.001) and decreased from T1 to T2 (p=0.001), although it was still above 
baseline values at T2 (T0 vs T2, p<0.001).
Functional tests
Because the 6MWT was too demanding for five participants, the analysis was per-
formed on the remaining 17 participants. This analysis showed no significant effect 
of time on the 6MWT (F(2,32)=2.498, p=0.098). Likewise, the BBS (χ2(2)=4.031, 
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p=0.133), TUG (F(2,42)=0.198, p=0.821, and ABC scale (F(2,42)=2.048, p=0.142) did 
not show significant time effects either.
Discussion 
The aim of this study was to evaluate the effects of BTX-A treatment and subsequent 
stretching of the hip adductors on gait and balance capacities in patients with pure 
HSP. The results support our hypothesis that bilateral BTX-A injections in and subse-
quent stretching of the hip adductors improve both gait width and lateral stepping 
responses in known perturbation directions coinciding with reduced hip adductor 
tone 6 weeks after treatment compared to baseline. These functional effects were 
retained, although some recurrence of hip adductor muscle tone was found 10 
weeks later. In addition, comfortable gait speed increased 6 weeks post injections, 
which effect was even a bit stronger after 16 weeks. In contrast, maximal gait speed 
and lateral stepping responses in unknown perturbation directions did not respond 
to the treatment nor did other functional tests (BBS, TUG, 6MWT, ABC scale). 
Besides a prolonged reduction in hip adductor muscle tone lasting up to 16 weeks 
after treatment, we observed a similar and substantial improvement in hip abduction 
ROM (on average 13.3°) and a temporary reduction of hip muscle strength (on av-
erage 1 point on the MRC scale, 6 weeks after treatment). These findings are in line 
with several previous studies 9,65,93,94,178,188,189. The mean improvement of muscle tone 
at 6 weeks post injections was 1.5 point on the MAS, which can be considered sub-
stantial and clinically relevant 196. Interestingly, the observed temporary loss of mus-
cle strength did not seem to have a detrimental effect on balance and gait capacities, 
since functional tasks improved (or remained stable) 6 weeks after treatment. This 
result is in agreement with a previous study from our group9 and suggests that loss 
of muscle strength after BTX-A injections in spastic muscles is probably of relatively 
short duration and without noticeable functional disadvantage. 
The observed improvement of gait width was on average 1.1 and 1.5 cm for com-
fortable and maximal walking speed, respectively, and was probably the direct re-
sult of reduced hip adductor tone and improved hip abduction ROM. Remarkably, 
this effect was found even though comfortable gait speed improved in parallel. It is 
conceivable that a higher gait speed might coincide with faster leg swing and, thus, 
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aggravate velocity-dependent hip adductor spasticity, but this effect apparently did 
not occur. Instead, the reason why comfortable gait speed improved may be that 
reduced hip adductor tone allowed patients to make larger and/or faster steps. In a 
prior study of patients with spastic paraparesis of various origins, BTX-A injections in 
the hip adductors also led to increased gait velocity 197. In addition, previous studies 
of patients with HSP in which hip adductors were injected with BTX-A in combination 
with other muscle groups showed increased gait speed as well 65,93,94. These findings 
have important clinical implications as reduced spontaneous gait speed is one of 
the most frequent problems reported by patients with HSP 56. Notably, maximal gait 
speed did not improve after treatment, which is in agreement with the notion that 
the hip adductors are not the key muscles for gait propulsion 198. Nevertheless, gait 
width during walking at maximal gait speed improved even stronger than during 
comfortable walking, indicating the robustness of the treatment effects on widening 
the base of support while walking. The observed effect size for gait width in this study 
may seem small, but it constitutes a 10-15% increase compared to baseline. Hence, 
the observed increase in gait width of 1.1-1.5 cm may well be clinically relevant in 
terms of improved frontal-plane balance, but this conclusion needs to be supported 
by future studies.
To our knowledge, the effects of bilateral BTX-A injections on reactive lateral step-
ping responses have not been investigated before. In the present study, we only ob-
served beneficial effects on stepping responses to perturbations in known directions. 
Interestingly, no improvements of stepping leg angle or success rate were observed 
upon perturbations in unknown directions. As hip adductor spasticity decreases, 
less muscle activity of the hip abductors is supposedly needed to make a lateral 
step. One explanation for the observed discrepancy between known and unknown 
perturbation direction may be that the individual maximal perturbation intensity at 
baseline was based on tests with a known perturbation direction. As a consequence, 
the perturbation intensities might have been too high for the participants following 
perturbations in unknown directions. This may also (partly) explain the much lower 
number of participants able to sustain perturbations with unknown compared to 
known directions. Another reason might be that reactive steps following unexpected 
perturbations are relatively strongly influenced by delayed postural responses that 
occur in patients with HSP,23,75 because patients cannot compensate by an anticipa-
tory ‘central set’ if the direction is unknown. Nevertheless, the improved balance ca-
pacity following perturbations in known directions suggests that hip adductor spas-
ticity indeed impairs the quality of lateral stepping responses and, thus, is a relevant 
treatment target from a frontal-plane balance perspective.
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The fact that the beneficial effects on muscle tone, gait width, comfortable gait 
velocity, lateral balance persisted until 16 weeks after treatment seems to challenge 
the common opinion that the biological effects of BTX-A have worn off after this 
time interval. It may, therefore, be that the stretching component of the treatment 
protocol was responsible for the observed long-term effects.
Study limitations and future perspectives
A limitation of the present exploratory study in patients with HSP is the relatively 
small sample size and the lack of a control condition, while the rather stringent inclu-
sion and exclusion criteria limit the generalisability of our findings. Nevertheless, this 
study provides indications for the beneficial effects of bilateral BTX-A injections in the 
adductor longus, adductor magnus and gracilis muscles and subsequent stretching 
of these muscles on gait width, comfortable gait speed, and reactive lateral stepping 
in known perturbation directions, whereas maximal gait speed, gait endurance, and 
clinical balance scores appear to be less responsive in these patients. Future research 
should preferably be multi-centered to increase the number of participants and use 
a randomized controlled design. Gait width and gait speed would be valuable and 
responsive outcome measures in such trials. The instrumented balance assessments 
used in the present study are, however, less suitable for multi-center studies as they 
require further development of clinically affordable systems. Clinically applicable as-
sessments to validly test the quality of (lateral) reactive stepping responses are there-
fore urgently needed. As HSP is a chronic and progressive condition, it would also be 
relevant to conduct longitudinal, comparative cohort studies to investigate whether 
repetitive cycles of BTX-A treatment of spastic hip adductors improve the life-time 
functional ambulation prognosis in these patients. 
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SUMMARY AND GENERAL DISCUSSION
Summary
The overall aim of this thesis was to gain more insight into the experienced (motor) 
problems and objectifiable motor control deficits in patients with pure forms of he-
reditary spastic paraplegia (HSP), and to evaluate the functional effects of spasticity 
treatment with botulinum toxin type A (BTX-A) in these patients. In the first part, 
we provided an overview of the pathophysiology, functional diagnosis, and clinical 
management of balance impairments and falls in patients with HSP, based on the lit-
erature and clinical experience within the Expert Centre for Rare and Genetic Move-
ment Disorders of the Radboud University Medical Center (part of the European 
Reference Network for Rare Neurological Diseases (ERN-RND)). Next, we zoomed 
in on the experienced complaints, activity limitations and loss of motor capacities 
by means of a web-based survey amongst patients with HSP in the Netherlands. In 
the second part, we investigated some of the underlying motor control deficits in 
patients with pure HSP related to balance control and gait initiation. In the third part, 
we examined the functional effects of BTX-A treatment and subsequent stretching 
of specific spastic muscle groups on balance and gait capacities in patients with pure 
HSP. Here, the main findings of this thesis are summarized. In the section ‘general 
discussion’ of this chapter, the results are placed in a broader perspective and direc-
tions for future research are provided.
Part 1: Daily problems of living with HSP
 
Pathophysiology, functional diagnosis and clinical management
Although balance impairments and falls are both common and devastating in patients 
with HSP, the underlying mechanisms and possible clinical strategies have received 
very little attention in the literature. In chapter 2, we provided a narrative review that 
elaborates on the pathophysiology, functional diagnosis, and clinical management 
of balance impairments and falls in patients with HSP. Four important intrinsic risk 
factors for balance impairments and falls were identified: spasticity, contractures, 
muscle weakness, and loss of proprioception. Of these, loss of proprioception and 
delayed postural responses were considered to be key in causing balance problems, 
in addition to muscle contractures causing abnormal biomechanical constraints (e.g. 
pes equinus). The influence of spasticity itself on balance control is probably less 
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strong, but spasticity was considered to be an important risk factor for the develop-
ment of muscle contractures. The influence of muscle weakness on balance prob-
lems seems to be limited but, together with the slowness of postural responses, it 
was thought to contribute to impaired feet-in-place as well as to impaired stepping 
reactions in response to postural perturbations. Based on the four identified risk fac-
tors and their interactions, diagnostic and treatment options were discussed.
Experienced complaints, activity limitations and loss of motor capacities
In chapter 3, we investigated the experienced complaints, activity limitations, and 
loss of motor capacities in patients with pure HSP. Treatment in these patients is 
often focused on reducing spasticity and its physical consequences but, in order to 
optimally address individual patients’ needs, we need to better understand their ex-
perienced complaints, activity limitations, and loss of motor capacities. To this end, 
we developed and distributed an HSP-specific web-based questionnaire amongst 
Dutch patients with HSP. Of 166 respondents, 109 participants with presumably pure 
HSP experienced the greatest burden from muscle stiffness and limited standing 
and walking activities, while 72% reported leg and/or back pain. Thirty-five and 46% 
reported to use walking aids (e.g. crutches) indoors and outdoors, respectively. Fif-
ty-seven percent reported a fall incidence of at least twice a year (‘fallers’), and in 51% 
a fall had led to an injury at least once. Seventy-three percent reported fear of falling. 
Duration of spasticity and incapacity to rise from the floor were positively associat-
ed with being a ‘faller’, whereas non-neurological comorbidity and wheelchair use 
were negatively associated. Higher age, experienced gait problems, not being able 
to stand for 10 minutes, and incapacity to open a heavy door showed a negative as-
sociation with being a ‘walker without aids’ (>500m). The results emphasize the large 
functional impact of spasticity on the lives of people with pure HSP and contribute 
to a better understanding of possible targets for rehabilitation.
Part 2: Motor control mechanisms in patients with 
pure HSP
 
Influence of hyperexcitable stretch reflexes of the calves on balance control
In chapter 4, we studied the role of hyperexcitable short-latency stretch reflexes 
(SLRs) of the triceps surae muscles on balance control. We exposed 16 patients with 
pure HSP and 9 healthy controls to ‘toes-up’ support-surface perturbations at several 
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intensities, imposed by a rotational platform. Surface electromyography (EMG) data 
were recorded from the gastrocnemius, soleus and tibialis anterior muscles, and 
center-of-mass trajectories (CoM) were recorded based on 3-D motion analysis. We 
hypothesized that exaggerated SLRs in the triceps surae would lead to difficulties in 
sustaining ‘toes-up’ perturbations, which would be reflected by an early divergence 
of the CoM trajectories in patients with HSP compared to those of control subjects. 
We found that the HSP group performed worse in recovering from the perturba-
tions and, as expected, showed hyperexcitable SLRs (40-80ms post perturbation) 
compared to the control group. In later phases of the postural responses (220-320 
ms post perturbation), we observed sustained triceps surae activity in patients with 
HSP where, in contrast, control subjects showed a suppression of this activity. Only 
this latter difference in late triceps surae activity corresponded with the instant of 
divergence of CoM trajectories between patients and controls. Therefore, our hy-
pothesis was not confirmed. Instead, the results corroborated the notion that lack 
of late triceps surae suppression may be more important than hyperexcitable early 
SLRs in causing defective balance control after ‘toes-up’ perturbation in patients with 
pure HSP.
Differential control of muscle activation and inhibition during gait initiation
Corticospinal lesions cause impairments in voluntary motor control. Previous find-
ings suggested that some degree of voluntary control may be taken over by a com-
pensatory pathway involving the reticulospinal tract. In humans, evidence for this 
notion mainly comes from StartReact studies. StartReact is the acceleration of re-
action times by a startling acoustic stimulus (SAS) simultaneously presented with 
the imperative stimulus. Previous studies on StartReact mainly focused on isolated 
single-joint movements. In chapter 5, we therefore investigated whether the retic-
ulospinal tract can also be utilized for controlling whole-body movements. Twelve 
healthy participants and 12 patients with pure HSP performed three consecutive 
steps in response to an imperative visual stimulus. In 25% of the trials, a SAS was 
applied. We determined reaction times of muscle (de)activation, anticipatory pos-
tural adjustments (APAs) and steps. Without a SAS, we observed an overall delay in 
patients with HSP compared to controls. Administration of the SAS accelerated mus-
cle onsets in both groups, but more so in the HSP group, resulting in (near-)normal 
latencies. In contrast, muscle offsets were accelerated in the control group, but not 
in the HSP group. APAs and step reaction times were accelerated in both groups, but 
did not normalize in the HSP group. Our results suggest that the reticulospinal tract 
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seems to be able to play a compensatory role in complex whole-body movements, 
such as during gait initiation. However, this compensation appears to be suboptimal, 
as it lacks the capacity to inhibit task-inappropriate muscle activity. 
Part 3: Functional effects of BTX-A in patients with 
pure HSP 
 
Functional effects of BTX-A treatment and subsequent stretching of the calf muscles
A previous study from our group showed an increased comfortable gait speed after 
BTX-A treatment and subsequent stretching of the triceps surae muscles in 15 pa-
tients with pure HSP and with EMG-confirmed troublesome calf muscle spasticity 
during gait analysis. However, the kinematic and kinetic mechanisms underlying this 
improvement remained unclear. In chapter 6 we investigated how changes in ankle 
kinematics and kinetics after the BTX-A treatment led to an increase in comfortable 
gait speed in this group. Gait analysis data of 13 patients before treatment and 4 and 
18 weeks thereafter were used to investigate the changes in ankle kine(ma)tics. For 
correct interpretation of the results, data were compared with those of 10 healthy 
age- and sex-matched controls walking at similar speeds. It was found that, parallel 
to improved gait speed and stride length, peak ankle power and positive work during 
the late stance phase improved following treatment, whereas no effects were ob-
served on ankle kinematics or negative work during the early-midstance phase of 
gait. These results suggest that BTX-A treatment and subsequent stretching of the 
calves in patients with pure HSP may enhance comfortable gait speed by allowing 
more efficient use of residual calf muscle strength during push-off, leading to in-
creased stride length.
Functional effects of BTX-A treatment and subsequent stretching of the hip ad-
ductors
In chapter 7, we investigated the effects of BTX-A treatment and subsequent stretch-
ing exercises of the hip adductors on balance and gait. Patients with pure HSP often 
suffer from hip adductor spasticity, causing reduced gait width and a narrow base 
of support. In addition, they experience difficulties stepping sideways when recov-
ering from lateral balance perturbations. A small base of support and the presumed 
side-stepping difficulties likely increase the risk of falling in HSP. Botulinum toxin 
type-A (BTX-A) injections are commonly used to reduce spasticity in patients with 
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HSP, but no studies have systematically investigated the effects of BTX-A treatment 
and subsequent stretching of the hip adductors on gait and balance. In this study, 25 
patients with pure HSP and clinically established hip adductor spasticity were treat-
ed with bilateral BTX-A injections in the hip adductors and performed daily self-ad-
ministered stretching exercises for 16 weeks. The results indicated that, after BTX-A 
administration, there was a sustained increase (both 6 and 16 weeks post treatment) 
in comfortable gait speed and gait width. Furthermore, patients showed sustained 
improvement of reactive lateral stepping responses (both success rate and quality of 
stepping), but only when the perturbation direction was known. This study provided 
the first evidence of beneficial effects of BTX-A treatment and subsequent stretching 
of spastic hip adductors to improve functional balance and gait in patients with pure 
HSP. 
General discussion
In this thesis, we have used pure HSP as a clinical model to investigate the effects 
of spasticity on balance and gait and to understand the functional effects of botu-
linum toxin type A (BTX-A) treatment on these motor capacities. Indeed, as argued 
in chapter 2, spasticity is the cardinal feature of pure HSP, whereas muscle strength 
is often relatively preserved. The latter observation can be explained by the fact that 
the reticulospinal tract is able to compensate for loss of voluntary muscle activation 
by the corticospinal tract; a notion supported by the results of chapter 5. However, 
these results also indicate that the quality of this compensatory voluntary motor 
control is suboptimal due to impaired inhibitory capacity of the reticulospinal tract. 
Together with the well-known impaired selectivity of spinal motor neuron activation 
through the reticulospinal tract 161, the feature of abnormally prolonged muscle ac-
tivation probably underlies some of the characteristic ‘positive symptoms’ related to 
spasticity, such as abnormal muscle co-contractions, associated reactions, or even 
dystonia. In addition to these and other positive symptoms (such as hyperexcitable 
muscle stretch reflexes, increased muscle tone upon stretch, and spontaneous mus-
cle spasms), the so-called ‘negative symptoms’ (e.g. muscle weakness, slowness of 
movement) and ‘secondary symptoms’ (e.g. intrinsic muscle stiffness, muscle con-
tractures) complete the clinical picture of the spastic paresis (figure 1). This picture is 
never simple and may actually be very diverse amongst different groups of patients 
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with spastic paresis and even within the same group of patients, such as those with 
pure HSP. 
 
FIGURE 5. Schematic overview of primary (positive and negative) and secondary (biomechan-
ical changes) symptoms of spastic paresis. Note that – with regard to motor control – the 
different types of symptoms interact with each other. 
 
Where both paresis and spasticity are usually severe (and bilateral) in people with 
(near-)complete spinal cord injury and may also be severe (and unilateral) in peo-
ple with a cerebral hemisphere lesion (e.g. stroke), people with HSP often show 
predominant spasticity with relatively mild paresis due to the intactness of the cor-
tico-reticulospinal pathway and other neuronal pathways tracts descending from or 
via the brainstem 1,36,37. Yet, secondary symptoms such as increased intrinsic muscle 
stiffness and muscle shortening are frequently severe and, together with the slow-
ness of voluntary muscle activation and of postural responses, greatly determine the 
clinical picture of balance and gait problems in people with pure HSP. As spasticity, 
muscle stiffness, muscle contractures, and slowness of movement often differ in 
their severity and spatial distribution, they result in a complex clinical picture that is 
highly variable among individual patients, even if these patients all show phenotypes 
of so-called ‘pure HSP’. This group also shows a large heterogeneity in the underly-
ing genetic deficits 199. Hence, it is not surprising that people with pure HSP may still 
show different gait patterns as well as different patterns of postural imbalance, which 
makes it a challenging condition for clinicians in terms of functional diagnosis and 
clinical management (see chapter 2). 
CHAPTER 8
142
SUMMARY AND GENERAL DISCUSSION
The results of our survey (chapter 3) illustrate the variety in experienced complaints, 
activity limitations and loss of motor capacities in patients with pure HSP. Coherent 
with the above, muscle stiffness, balance and gait problems, and falls were indicated 
as most prominent issues by the majority of the participants. Yet, several other symp-
toms and impairments were reported as well, with impact on functional indepen-
dence and quality of life, such as a high burden from (leg and/or back) pain, (mental 
and/or physical) fatigue, fear of falling, and autonomic dysfunction. Likely, chronic 
pain and fatigue will negatively affect balance and gait capacities and increase fall 
risk, which  provides an argument for targeted treatment of these symptoms. Also, 
fear of falling should be a specific target from a therapeutic perspective, as it is well 
known that it is strongly associated with fall risk and often results in physical inac-
tivity, deconditioning, morbidity and, ultimately, mortality 200. Even autonomic dys-
function might be associated with balance and gait problems and falls, for instance, 
because urinary urge may cause people to urgently seek a bathroom and take risks. 
It is evident that all problems mentioned above interact in a complex way in the life 
of an individual with HSP, but the remainder of this general discussion will be focused 
on the motor deficits, balance and gait problems, and their respective treatments. 
We will do so from the perspective of four topics of debate that are relevant for all 
people with spastic paresis, but with an emphasis on those with HSP. First, the func-
tional impact of positive versus negative and secondary symptoms of spastic paresis 
will be discussed. Second, we will address the interplay between corticospinal versus 
cortico-reticulospinal systems in the voluntary motor control of people with HSP. 
Third, we will focus on standing balance and compare feet-in-place responses with 
reactive stepping in response to postural perturbations in people with HSP. Lastly, 
we will address the functional (net) effects of neuromuscular blockade through in-
tramuscular BTX-A injections regarding, on the one hand, muscle tone and, on the 
other hand, muscle strength in people with HSP. 
Functional impact: positive versus 
negative and secondary symptoms of spastic paresis
Spasticity was originally defined by Lance (1980) as a velocity-dependent increase in 
muscle resistance against passive stretch, resulting from hyperexcitable phasic and 
tonic stretch reflexes 201. Yet, spastic muscles are also characterized by intermittent 
or sustained involuntary activation without an apparent stretch upon the muscles, 
as was recognized in the definition by Pandyan et al in 2005 202. Hence, although 
the term ‘spasticity’ is commonly used in clinical practice, it remains hard to define 
CHAPTER 8
143
SUMMARY AND GENERAL DISCUSSION
and understand what spasticity exactly is and, also, what its functional impact is 
in the context of the complete set of symptoms of spastic paresis. Indeed, both 
definitions of ‘spasticity’ neglect the concurrent and almost inevitable negative and 
secondary symptoms. This is remarkable, because the positive, negative and second-
ary symptoms of spastic paresis strongly interact regarding their functional impact 
(see Figure 1). For example, positive symptoms, such as muscle overactivity during 
movement or at rest, may lead to reduced stretch and mobilization of the affected 
muscles, resulting (in the long term) in secondary symptoms such as non-neurogen-
ic stiffness, adaptive shortening, and eventually muscle contracture. Reversely, there 
is ample evidence that structurally shortened muscles become more sensitive to 
stretch, as they reach their threshold for a specific degree of muscle stretch earlier, 
which may aggravate the already increased stretch reflexes. This interaction leads 
to what has been referred to in the literature as the ‘vicious circle of the stretch-de-
pendent spastic paresis’ 203. Also the positive and negative symptoms interact with 
each other. For example, loss of motor selectivity (or increased muscular ‘synergism’) 
is regarded as a typical negative (deficit) symptom of spastic paresis. Yet, reduced 
motor selectivity probably contributes to specific positive (excess) symptoms such 
as abnormal and prolonged co-contractions and associated reactions. Conversely, 
when an antagonist muscle exhibits a co-contraction due to loss of motor selectivity, 
the effective strength of the agonist muscle will be reduced, which aggravates the 
negative symptoms. As a result, the functional impact of positive, negative and sec-
ondary symptoms is strongly intertwined, rendering it almost impossible to clearly 
distinguish their individual effects clinically. Overall, it is believed that the functional 
impact of the negative and secondary symptoms may even be larger than that of the 
typical positive symptoms. Nonetheless, spasticity is considered to be an important 
risk factor for the development of secondary symptoms, as it predisposes to a short-
ened position of the affected muscles. It is also possible that increased muscle tone 
negatively affects the contractile properties of the affected muscles, which would 
imply that it might directly influence the negative symptoms. In fact, evidence for the 
latter notion was found in chapter 6, where we reported that the use of BTX-A in the 
calf muscles actually improved peak ankle power and positive work during the late 
stance phase of gait.  
The complex interaction between the different symptoms of spastic paraparesis 
makes it hard to quantify spasticity. Spasticity is often assessed with clinical (ordinal) 
scales that are based on sensing the resistance against (fast) passive stretch imposed 
upon muscles, e.g. the (modified) Ashworth Scale (MAS) 49 and the Tardieu test 204. 
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However, muscle resistance is not only a consequence of neurogenic mechanisms 
such as activated tonic stretch reflexes, but may also be due to non-neurogenic 
mechanisms such as increased muscle stiffness. Because neurogenic and non-neu-
rogenic mechanisms cannot easily be discerned in clinical practice 205, many cli-
nicians and researchers prefer the more neutral term ‘hypertonia’ above the word 
‘spasticity’ when expressing the outcome of clinical scales such as the MAS. In the 
same vein, the perceived resistance to passive motion (PRPM) test has been pro-
posed as an adaptation to the MAS 206. The underlying pathophysiologic mechanisms 
of non-neurogenic muscle stiffness are not yet well understood. On the one hand, 
changes in the contractile elements of the muscles have been proposed, such as 
a reduction in the number of sarcomeres and subsequent lengthening of the sar-
comeres 207-209. On the other hand, there is growing evidence that non-contractile 
muscle elements may play a critical role, i.e. stiffening of extracellular matrix and in-
crease in collagen 210. With regard to the neurogenic mechanisms underlying muscle 
stiffness, it becomes increasingly clear that these are strongly influenced by body po-
sition, activity, and even context. Indeed, posture may influence the vestibulospinal 
drive and, thus, modulate the activity of spinal reflexes and motoneuron activation. 
Physical activity, such as gait, may overrule abnormal resting tone or require com-
pensatory recruitment of cortico-reticulospinal pathways causing non-selective and 
prolonged muscle co-activations. The (psychological) context may be either safe 
and familiar or challenging and unfamiliar, which may have a huge impact on the su-
praspinal modulation of spinal activity through stress-related mechanisms. These in-
sights have gradually shifted the emphasis of assessing spasticity with clinical scales 
to the quantification of muscle activity using electromyography (EMG) during func-
tional tasks, such as gait. However, EMG itself does not differentiate between normal 
and abnormal muscle activity, unless the electrical signals are clearly abnormal (e.g. 
short, ‘spiky’, bursts of activity). In the same vein, ‘abnormal’ (e.g. premature) timing 
of muscle activity may be a normal adaptation to an abnormal gait pattern. For in-
stance, spastic gait is often characterized by forefoot landing, which may coincide 
with early activation of the calf muscles at the end of the swing phase. But such 
premature activity is also required if forefoot landing is used as a strategy to deal with 
impaired ankle dorsiflexion. The same holds for abnormally prolonged muscle ac-
tivity. For instance, spastic gait may coincide with prolonged activation of the tibialis 
anterior muscle during midstance, yet this is rarely ‘spastic’ but rather a functional 
compensation to facilitate foot roll-off in the case of stiff calf muscles. The bottom 
line is that ‘spasticity’ is such a complex phenomenon that it can only be understood 
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in individual patients when taking into account all positive, negative and secondary 
symptoms, as well as body posture, physical activity, and (psychological) context, 
and when integrating this information with data from instrumented movement anal-
ysis and from profound knowledge of human motor control. 
Voluntary motor control: corticospinal versus cortico-reticulospinal control in HSP
The corticospinal tract originates largely (but not solely) from the primary motor cor-
tex and is the dominant descending pathway for voluntary motor control in humans. 
It is the primary tract for voluntary muscle activation and force production. Further-
more, it has a function in the presynaptic inhibition and modulation of spinal reflexes 
and for reciprocal inhibition of antagonist muscles, leading to the capacity to make 
precise and selective voluntary movements (i.e., fine motor control) 37,211,212. The de-
gree to which muscles are dependent on corticospinal innervation depends on their 
location in the human body. Distal muscles of the hand and ankle-foot are much 
more dependent on direct innervation by the neurons from the lateral corticospinal 
tract than proximal muscles of the shoulder and pelvic girdles, which is why they are 
more vulnerable to unilateral brain injury and least responsive to functional training. 
Axial muscles of the trunk and neck are almost exclusively innervated by neurons 
from the medial corticospinal tracts 211,212. Because these medial tracts are intimately 
and bilaterally intertwined at different levels of the brainstem and spinal cord, the 
axial muscles are least vulnerable to one-sided brain injury and most responsive to 
functional training. Because HSP involves bilateral degeneration of the corticospinal 
tracts and because the longest neurons are most susceptible to this degeneration, it 
is not surprising that the clinical picture of pure HSP is characterized by loss of selec-
tive motor control and slowness in the lower extremities, complicated by enhanced 
and poorly modulated spinal stretch reflexes and abnormal muscular co-contrac-
tions. These problems are usually strongest in the distal muscles controlling the an-
kles and feet, but – in more advanced cases –  may ascend up to the thigh, pelvic, 
and even the lower trunk muscles.  
In the case of a selective deficit of the corticospinal tract, such as in pure HSP, it 
is known that the cortico-reticulospinal tract may play a role as a compensatory 
neural pathway 39,132,134 . Spinal motor neurons to the extremities may be activated 
particularly by the lateral reticulospinal tract originating from the reticular formation 
in the brainstem. Normally, this tract is considered to support the control of gross 
and (more or less) ‘automatic’ movements such as locomotion and balance main-
tenance as well as to modulate muscle tone at rest and during movement. In HSP, 
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the lateral reticulospinal tract may become more dominant to also control voluntary 
single- and multi-joint movements and to assist in generating sufficient force. The 
compensatory role of the cortico-reticulospinal system for defective corticospinal 
control has previously been investigated in animals. When the corticospinal tract 
was lesioned in primates, motor function recovered after a while and the primates 
were even capable again of climbing in their cages. Intracellular recordings showed 
that the cortico-reticulospinal systems was involved in the functional recovery after 
administering corticospinal lesions 37. 
In humans, evidence for the compensatory role of the reticulospinal tract after corti-
cospinal injury mainly comes from StartReact studies. The StartReact effect involves 
the early ‘release’ of a prepared motor response from the brainstem, evoked by a 
startling stimulus (usually a loud sound) and conveyed through the reticulospinal 
tract,. Compared to other upper motor neuron disorders, HSP is a suitable model 
to investigate this compensatory role of the cortico-reticulospinal tract, given the 
selective deficit of the corticospinal tract in HSP . Indeed, our group has previously 
reported that during single-joint movements (voluntary ankle dorsiflexion) as well 
as during reactive balance responses to a moving platform, people with HSP and 
healthy subjects showed similar reaction times of the (lower) leg muscles if the pri-
mary stimulus was combined with a startling acoustic stimulus (SAS), whereas people 
with HSP were clearly slower (20-40ms) without a SAS 1,23. These results strongly sup-
port the potential of an intact cortico-reticulospinal tract compensating for a defec-
tive corticospinal tract, as the SAS presumably triggered the release of the requested 
prepared response at the brainstem level. In chapter 5 of this thesis, we have been 
able to show that a SAS is also able to facilitate voluntary whole-body movements, 
such as during gait initiation, in a similar manner and to a similar extent (i.e. normal-
ization). Remarkably, however, the SAS was not able to normalize the offset latencies 
of the soleus muscle, which implies that the reticulospinal tract lacks the capacity to 
inhibit task-inappropriate muscle activity.  
Thus, the cortico-reticulospinal system may play an important compensatory role in 
the voluntary motor control of people with HSP, but this compensation comes with 
several functional limitations. First, dependence on this bypass route leads to delayed 
voluntary and automatic responses in normal daily life situations, when there is no 
well-timed SAS available. Together with delayed afferent proprioceptive signals char-
acteristic of pure HSP, this explains why normal, fast and accurate, balance control 
(both feet-in-place and stepping responses) appears to be slowed down and less 
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accurate in these people, causing progressive postural imbalance during many daily 
life activities such as rising from a chair, standing, walking, turning, squatting, stair 
climbing et cetera. Second, the reticulospinal tract has different projections onto 
the spinal motoneuron pools compared to the corticospinal tract 161. Indeed, retic-
ulospinal neurons typically favor the innervation of extensor muscles of the lower 
limbs (and flexor muscles of the upper limbs). As a result, people with HSP often have 
relatively preserved muscle strength in the leg extensor muscles, whereas the flexor 
muscles (tibialis anterior, hamstrings) are weaker. This inborn innervation preference 
probably explains why people with HSP typically show signs of hyperreflexia and 
hypertonia in the muscles that typically subserve the so-called ‘extension pattern’ of 
the lower limbs: dorsal lower leg muscles (calves, tibialis posterior, toe flexors) and 
medioventral thigh muscles (quadriceps, adductors). In addition, since the axons of 
the reticulospinal tract branch way more extensively to motoneuron pools at various 
levels of the spinal cord than the direct corticospinal neurons 152,213, more muscles are 
activated simultaneously, leading to a loss of motor selectivity and, thus, loss of fine 
motor control. Third, as the reticulospinal tract is probably not able to adequately 
compensate for the loss of reciprocal inhibition by the corticospinal tract, abnormal 
muscular co-activation of agonists and antagonist is often observed during function-
al tasks in people with HSP, a phenomenon that probably interacts with the incapac-
ity of the reticulospinal tract to inhibit task-inappropriate muscle activity.  
Overall, despite the fact that the cortico-reticulospinal system is able to compensate 
for the loss of direct corticospinal control in terms of voluntary muscle activation and 
force production, this compensation comes with a cost: apparent slowness of (al-
ternating) movements, loss of motor selectivity, and abnormal muscular co-contrac-
tions that all impair the quality of motor control. Although a well-timed SAS is able 
to resolve the initiation slowness of single- and multi-joint, automatic and voluntary 
activities, this knowledge is not easily applicable in a clinical tool that can be used 
in daily life. To what extent intramuscular administration of BTX-A might be able to 
modulate abnormal muscular co-contractions will be discussed later.
Standing balance: feet-in-place responses versus reactive stepping in HSP 
Strategies for standing balance are typically categorized into ‘feet-in-place’ strategies 
and ‘stepping’ strategies. When - after a postural perturbation - balance cannot be 
maintained within the existing base of support (BOS) (i.e., with a feet-in-place strat-
egy), a stepping strategy is necessary in order to change the BOS in such a way that 
the accelerated center of body mass (COM) can be displaced over a larger trajec-
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tory to keep it within the boundaries of the altered BOS 214. Stepping strategies may 
be either voluntary and, thereby, anticipatory (e.g. when making self-initiated move-
ments), or they may be involuntary and reactive (e.g. in response to unexpected ex-
ternal postural perturbations). In this paragraph, we will compare the characteristics 
of feet-in-place responses with reactive stepping upon external perturbations. For 
both types of postural responses, a correct timing and amplitude of muscle acti-
vation and subsequent muscle deactivation is necessary. When the human body is 
perturbed in the sagittal plane, e.g. by a sudden  movement of the support surface, 
the first line of defense is a reflexive symmetrical muscle activation, called the auto-
matic postural response (APR), which is presumably conveyed by the reticulospinal 
tract 215. When this initial response is unable to keep the COM within the BOS, the 
next strategy is to make a step in the direction of the perturbation, which requires 
that many of the activated muscles within the APR in the stepping leg are deactivated 
to allow this leg to move forward or backward. This stepping strategy may be more 
dependent on the corticospinal tract 106. For example, after losing balance in the 
forward direction, which dorsiflexes the ankles, typically the calves and hamstrings 
are eccentrically activated to generate a plantar-flexing ankle torque in order to de-
celerate the falling body and keep the feet in place (the so-called ‘ankle strategy’). If, 
however, balance cannot be maintained with a feet-in-place strategy, the calves and 
hamstrings must be quickly deactivated and the antagonists (i.e., tibialis anterior and 
rectus femoris) concentrically activated to ensure a successful step forward as part 
of the stepping strategy (and vice versa for balance perturbations in the backward 
direction). For lateral body perturbations, it is equally complex but in a different way. 
Upon a sideways perturbation, the initial strategy will be to eccentrically recruit the 
hip abductors on the ipsilateral side to decelerate the imposed weight shift as part of 
a so-called ‘weight-shifting strategy’. If, however, balance cannot be maintained with 
such a feet-in-place strategy, the ipsilateral leg must be quickly unloaded which re-
quires a prolonged and strong activation of the hip abductors. Subsequently, strong 
concentric activation of the hip abductors is needed to make successful side step. 
In all these instances, any delay in the timing and amplitude of the protective mus-
cle activations or in the timing and extent of muscle deactivations will result in an 
impaired capacity to maintain static and dynamic balance 216.  An important question 
is to what extent impaired balance control in patients with HSP can be attributed to 
spasticity. This seems to be different for feet-in-place responses compared to reac-
tive stepping.
A previous study on the influence of spasticity on balance in people with HSP 
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showed that calf muscle tone (assessed with the MAS) was associated with an im-
paired capacity to execute feet-in-place strategies, but only after rotational ‘toes-up’ 
platform perturbations. These types of perturbation stretch the calf muscles, but a 
reactive stretch response must be strongly suppressed to avoid the calves pulling 
the body further backwards. Remarkably, the resistance to other types of platform 
perturbation (rotational ‘toes down’ or translational forward or backward) was not 
associated with lower leg muscle tone 22. In chapter 3 of this thesis, we provid-
ed evidence that the typical short latency stretch reflexes (SLRs) after ‘toes-up’ per-
turbations, although increased in amplitude, could not be held responsible for the 
divergence of the COM trajectory in the backward direction compared to healthy 
controls. Instead, the timing of divergence of COM trajectories suggest insufficient 
suppression of late calf muscle activity (from ̴500ms post perturbation onset) to 
play a key role. In the case of translational body perturbations in the sagittal plane, 
some degree of involuntary muscle activation following stretch might even have a 
theoretical benefit for recovering balance with a feet-in-place strategy. For example, 
losing balance in the forward direction may lead to stretch-induced activation of the 
calves and hamstrings, which assists in decelerating the forward COM movement. 
Since most balance perturbations in daily life are translational (rather than rotational), 
the stretched and (subsequently) involuntarily activated muscles might be protective 
against balance loss, provided they are deactivated in time, although the magnitude 
of this effect is probably very small. Taken together, sensorimotor deficits other than 
hyperreflexia or enhanced muscle tone upon stretch are likely to play the most im-
portant role in the causation of balance problems in people with HSP. As addressed 
in chapter 2, muscle contracture, muscle stiffness, muscle weakness, loss of pro-
prioception, and delayed postural responses are all probably more influential with re-
gard to feet-in-place balance control than hyperreflexia or hypertonia, although the 
latter do have functional impact as risk factors for muscle stiffness and contracture. 
Indeed, when for instance the calf muscles become stiffer or lose length, they tend 
to pull the body backward while standing with the heels on the ground, causing a 
form of ‘retropulsion’. In addition, an impaired capacity to deactivate muscles timely 
and appropriately may have a detrimental effect on the capacity to execute feet-in-
place strategies (see chapter 3). 
Compared to feet-in-place postural responses, reactive stepping seems to be rela-
tively severely impaired in people with HSP. This can be explained in several ways. 
First, reactive stepping responses have to be made fast in order to be successful, and 
the required activation of agonist muscles may easily elicit a counteracting stretch 
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response of spastic antagonist muscles (e.g. the hamstrings during forward step-
ping, and the hip adductors during lateral stepping). As a result, the prime movers 
have to overcome the involuntary muscle activation due to spasticity. Second, im-
paired muscle deactivation is likely to aggravate the consequences of hyperexcitable 
stretch reflexes during reactive stepping, because the  antagonist spastic muscle 
activity is prolonged due to inappropriate suppression. Figure 2 shows the average 
gastrocnemius muscle activity of the stepping leg in 12 trials of an individual with HSP 
versus a healthy control subject during reactive stepping after a forward perturbation. 
The grey line clearly indicates the prolonged, inappropriate muscle activity.  
 
FIGURE 2. Preliminary ensemble average gastrocnemius muscle activity of the stepping leg in 
a person with pure HSP and a healthy control subject during a reactive forward stepping task. 
Time zero is the peak muscle activity. Note that the person with HSP shows prolonged muscle 
activity compared to the control subject. 
Third, effective reactive stepping probably depends on the corticospinal tract, which 
is the defective neural system in people with pure HSP. Instead, the reticulospinal 
tract - primarily responsible for feet-in-place postural responses - is spared. Overall, 
in people with pure HSP, reactive stepping responses are likely to be more impaired 
than feet-in-place responses, in terms of both amplitude and timing of the postural 
responses. Hence, clinically, a specific focus on improving reactive stepping strat-
egies in people with HSP is of utmost importance. To what extent intramuscular 
administration of BTX-A might be able to improve reactive stepping will be discussed 
in the next paragraph.
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Spasmolysis: influence of BTX-A on muscle tone versus muscle strength in HSP 
BTX-A inhibits the acetylcholine release from the presynaptic neuromuscular termi-
nals. It acts on the extrafusal muscle fibers, producing the muscle contraction, as 
well as on the intrafusal muscle fibers within muscle spindles, regulating the affer-
ent responses to muscle stretch. Hence, focal intramuscular BTX-A injections may 
reduce the effects of efferent neural signals towards the targeted muscles, but also 
the afferent responses from these muscles upon stretch (i.e., the phasic and tonic 
stretch reflexes) 4. In patients with spastic paresis, efferent signals to the muscles may 
be either voluntary or involuntary (e.g. in the case of associated reactions, co-con-
tractions, or spastic dystonia) as argued in the beginning of this discussion. BTX-A 
injections are specifically meant to reduce the positive symptoms of spastic paresis 
but, inherent in their working mechanism, they cannot discriminate between intend-
ed / appropriate (volitional) versus unintended / inappropriate (involuntary) muscle 
activation. As a consequence, spasticity can be treated with BTX-A, but this treatment 
may – at least theoretically – also lead to loss of peak muscle strength. In addition, 
BTX-A injections cannot selectively reduce a specific part of the muscle activation 
pattern. On a theoretical basis, in the case of hyperexcitable tonic stretch reflexes, 
BTX-A injections may be intended mainly to decrease the peak of neuromuscular ac-
tivation but, through its generic working mechanisms on efferent nerve fibers, BTX-A 
treatment will likely reduce the amplitude of the entire muscle activation pattern (see 
Figure 3). 
 
FIGURE 3. Schematic representation to describe the part of the EMG signal BTX-A is aimed at 
and the part of the EMG signal that is effected by BTX-A injections. *Part of the signal BTX-A is 
aimed at. #Part of the signal that is influenced by BTX-A.
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Hence, BTX-A may slightly shorten the duration of muscle activation by bringing the 
small activation amplitude at the start and the end of the muscle contraction below 
a critical value. In this way, BTX-A injections might also have a small influence on the 
timing of muscle activations. 
Hence, the question is justified whether the unselective effect of BTX-A on neu-
romuscular activation may lead to a clinically relevant loss of muscle strength in 
patients with pure HSP. In chapters 6 and 7, we observed an increase in comfortable 
gait speed after BTX-A injections in the calf and hip adductor muscles, respectively, 
despite a small (temporary) loss of maximal muscle strength on clinical examination. 
With regard to balance control, a previous study from our group showed no bene-
ficial or detrimental effects of BTX-A treatment of the calves on feet-in-place pos-
tural responses 9, whereas chapter 7 of this thesis showed improved lateral reactive 
stepping after BTX-A injections in the hip adductor muscles when the direction of 
perturbation was known. Hence, from an overall perspective, the impact of BTX-A 
treatment on effective muscle strength seems limited or even negligible. A possible 
explanation for this finding is that maximal muscle strength of agonist muscles is 
hardly needed during regular functional tasks, such as standing and walking. In ad-
dition, loss of (maximal) muscle strength of a spastic antagonist muscle will improve 
the effective strength of a non-spastic agonist muscle. Indeed, if timely deactivation 
of antagonist muscles is critical for specific functional tasks, a lower activation am-
plitude after BTX-A treatment may support task execution. Remarkably, in chapter 6, 
we found evidence for the notion that BTX-A treatment may actually have a benefi-
cial effect on the mechanical efficiency and contraction velocity of the calf muscles 
during the late stance phase of gait 165, as indicated by improved peak ankle power 
and positive work, perhaps by lowering the muscle tone just before ‘push-off’. This 
needs to be corroborated by further research.
To sum up, in people with pure HSP, the (net) functional effect of a reduction of mus-
cle tone versus a reduction of (maximal) muscle strength through BTX-A treatment 
seems to be beneficial for comfortable gait speed and reactive stepping, while it 
seems to be neutral for feet-in-place postural control and maximal gait speed. How-
ever, it is important to acknowledge that these conclusions are based on the studies 
reported in chapters 6 and 7, in which we included patients with relatively preserved 
muscle strength. It is still possible that patients with more severe muscle weakness 
and/or muscle fatigue might experience a net detrimental effect of  BTX-A injections 
on the performance of functional tasks, such as standing and walking. Hence, the 
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severity of the negative symptoms of spastic paresis should be taken into account in 
individual patients, which supports the adage to ‘start low and go slow’ when initiat-
ing BTX-A treatment in people with spastic paresis. If the goal of BTX-A treatment is 
to improve motor control, a thorough clinical examination of all symptoms of spas-
tic paresis is key. Preferably, this should be extended with a neurophysiological and 
biomechanical assessment of functional activities (e.g. by instrumented gait analysis) 
to identify the right muscular targets for BTX-A treatment and support individual goal 
setting. 
It is important to mention here that BTX-A treatment in patients with HSP can also be 
installed to reduce spasticity-related focal pain and/or stiffness complaints without 
the aim to improve function. In addition, BTX-A injections can be indicated to facili-
tate the performance of muscular stretching exercises to prevent or reduce muscle 
contractures and maintain function in the long term. For these indications, the pos-
sibility of a slight temporary loss of (maximal) muscle strength after BTX-A treatment 
is usually accepted by the patient and the clinician without further consideration.
Directions for future research 
This results of this thesis emphasize the need for future studies that investigate the 
underlying mechanisms and treatment of balance and gait problems in people with 
pure HSP. In order to improve motor control, these studies should focus on all (posi-
tive, negative, and secondary) symptoms of spastic paresis and take into account the 
influence of body posture, physical activity, and context as well. From a clinical point 
of view, it seems to be most critical to improve dynamic balance capacity and reduce 
muscular stiffness and slowness of the lower extremities during voluntary activities 
such as gait. Merely focusing on a neurophysiological reduction of muscle tone 
will have limited functional impact. Maintaining muscle compliance and adequate 
muscle length through physical exercises and muscle stretching seems to be key to 
preserve balance capacity and mobility as long as possible.  
With regard to spasticity, impaired muscle deactivation seems to play a critical role in 
causing some of the balance and gait deficits in people with HSP, particularly during 
functional tasks that require fast alternating movements, such as playful leisure and 
sports activities. Therefore, further research is needed to better understand the func-
tional implications of impaired muscle deactivation and how muscle deactivation 
might be improved during functional tasks, including the effect of BTX-A treatment. 
In addition, future research should further explore the potential and limitations of 
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compensatory cortico-reticulospinal motor control and how cortico-reticulospinal 
control could be optimized to improve balance and gait capacities. 
As for balance control, especially fast reactive stepping responses are impaired in 
people with pure HSP, most prominently if the direction of perturbation is unknown 
(see chapter 7). These situations require fast muscle activations of agonists and de-
activation of antagonist, without being able to use anticipatory strategies. Future 
studies should, therefore, focus on how reactive stepping strategies may be im-
proved, for instance by dynamic balance training on a moving platform. In addition, 
pro-active stepping strategies should be improved, for instance by gait adaptability 
training on an instrumented treadmill. The recently initiated Move-HSP study 217 is an 
example of the latter type of training. If such training would prove to be successful, it 
could have a significant impact on fall risk and social participation. 
Lastly, the working profile of BTX-A treatment in people with spastic paresis should 
be studied in more depth to better understand how extrafusal and intrafusal neu-
romuscular blockade affects muscle activation and deactivation during functional 
activities. Apart from single cycle experiments, longitudinal studies with repetitive 
BTX-A cycles should be conducted to compare the added functional effects of this 
treatment compared to regular exercises, including muscle stretching. These longi-
tudinal studies should preferably make use of easily applicable tools for patients to 
monitor their complaints and functioning on a daily basis over a prolonged time peri-
od. In this perspective, our group has started a feasibility study aimed at investigating 
the surplus value of an online monitoring tool for patients with spastic paresis that 
can be read out by clinicians as well to determine the (long-term) efficacy of BTX-A 
treatment, including possible side effects. Such a monitoring tool may also facilitate 
shared decision making with regard to the indication, timing, and targets of BTX-A 
treatment in people with spastic paresis.  
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SAMENVATTING IN HET NEDERLANDS
Dit hoofdstuk geeft een beknopte Nederlandse samenvatting en is vooral gericht op 
lezers zonder achtergrondkennis. De resultaten worden gedetailleerd samengevat 
en bediscussieerd in het hoofdstuk ‘Summary and general discussion’. 
Hereditaire spastische paraplegie (HSP) is een groep van progressieve erfelijke aan-
doeningen die wordt gekenmerkt doordat de motorische zenuwbanen vanuit de 
hersenen naar de benen (corticospinale zenuwbanen) zijn aangedaan. Hierdoor 
hebben mensen met HSP tijdens hun leven vaak toenemend last van stijfheid (spasti-
citeit) en zwakte van de beenspieren, waardoor loop- en balansproblemen ontstaan 
die geleidelijk verergeren. Er worden twee groepen HSP onderscheiden: pure HSP 
en complexe HSP. Pure HSP wordt vooral gekenmerkt door spasticiteit en zwakte 
van de beenspieren. Mensen met complexe HSP hebben vaak ook nog andere symp-
tomen zoals cognitieve problemen, spraakproblemen of motorische problemen van 
de armen. In dit proefschrift werd onderzoek gedaan naar mensen met pure HSP. 
Het doel van dit proefschrift was om meer inzicht te krijgen in de ervaren (motori-
sche) problemen en motorische stoornissen van mensen met pure HSP en om de 
effecten van behandeling van spasticiteit met botulinetoxine op de balans- en loop-
vaardigheid bij deze mensen te testen. In het eerste deel geven we een overzicht 
van de pathofysiologie, functionele diagnostiek en het klinisch handelen gericht op 
balansproblemen en valproblematiek bij mensen met HSP, gebaseerd op de litera-
tuur en op de klinische ervaring binnen het Radboudumc Expertisecentrum voor 
Erfelijke Bewegingsstoornissen. Tevens hebben we onderzoek gedaan naar de er-
varen klachten en motorische beperkingen door middel van een digitale vragenlijst, 
afgenomen bij mensen met pure HSP in heel Nederland. In het tweede deel hebben 
we onderzoek gedaan naar een aantal onderliggende mechanismen van de balans-
problematiek en het (starten met) lopen bij mensen met pure HSP. In het derde deel 
hebben we de effecten getest van behandeling met botulinetoxine, gevolgd door 
rekoefeningen, van specifieke spastische spiergroepen op de balans- en loopvaar-
digheid bij mensen met pure HSP. 
Deel 1: Dagelijkse problemen van het leven met HSP
 
Pathofysiologie, functionele diagnostiek en klinisch handelen
Ook al zijn balansproblemen en vallen veelvoorkomend en een groot probleem bij 
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mensen met HSP, de onderliggende mechanismen en mogelijke behandelstrategie-
en zijn beperkt onderzocht. In hoofdstuk 2 hebben we op basis van bestaande li-
teratuur en eigen klinische expertise een overzicht gemaakt van de pathofysiologie, 
functionele diagnostiek en het klinisch handelen gericht op balans- en valproblema-
tiek bij mensen met HSP. Vier belangrijke intrinsieke factoren voor balansproblemen 
en vallen werden geïdentificeerd: spasticiteit, contracturen, spierzwakte, en verlies 
van proprioceptie. Van deze factoren worden verlies van proprioceptie en daarmee 
samenhangende vertraging van evenwichtsreacties beschouwd als belangrijkste 
oorzaak voor de balansproblemen, samen met de ontwikkeling van spierverkortin-
gen en gewrichtsdeformaties zoals spitsvoeten. De invloed van spasticiteit op de 
balansproblematiek wordt als minder groot beschouwd, maar spasticiteit wordt wel 
benoemd als belangrijke risicofactor voor de ontwikkeling van spierverkortingen. De 
unieke invloed van spierzwakte op de balansproblemen lijkt relatief gering maar, sa-
men met de traagheid van evenwichtsreacties, kan deze wel bijdragen aan een ver-
zwakking van de statische en dynamische balanshandhaving. Gebaseerd op de vier 
geïdentificeerde risicofactoren en hun interacties werden diverse diagnostische- en 
behandelingsopties bediscussieerd. 
Ervaren klachten en motorische beperkingen
In hoofdstuk 3 hebben we de ervaren klachten en motorische beperkingen van 
mensen met pure HSP onderzocht. Behandeling van deze mensen is vaak gericht op 
het verminderen van spasticiteit en de fysieke gevolgen hiervan, maar om aan indi-
viduele behoeften te voldoen is het belangrijk om beter te begrijpen wat patiënten 
zelf ervaren. We hebben daarom een digitale HSP-specifieke vragenlijst ontwikkeld 
en verstuurd naar patiënten met HSP in heel Nederland. Het bleek dat de meeste 
mensen de grootste hinder ervoeren van spierstijfheid en van beperkingen in het 
uitvoeren van staande en lopende activiteiten. Daarnaast gaf bijna driekwart van de 
deelnemers aan last te hebben van been- en/of rugpijn. Respectievelijk 35% en 46% 
van de mensen gebruikte binnenshuis en buitenshuis loophulpmiddelen (zoals een 
stok). 57% gaf aan minimaal 2 keer per jaar te vallen en werd geïdentificeerd als 
‘valler’. Bij 51% had een val minimaal 1 keer tot een blessure of verwonding geleid 
en 73% was bang om te vallen. De duur van de ervaren spasticiteit (in jaren) en het 
onvermogen om op te staan van de grond waren positief geassocieerd met het 
de identificatie als ‘valler’, terwijl niet-neurologische co-morbiditeit en het gebruik 
van een rolstoel hiermee negatief geassocieerd waren. Een hogere leeftijd, ervaren 
loopproblemen, het niet kunnen staan gedurende 10 minuten, en onvermogen om 
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een zware deur te openen waren negatief geassocieerd met (> 500m) kunnen lopen 
zonder loophulpmiddel. Deze resultaten benadrukken de grote impact van HSP op 
het dagelijks leven en dragen bij aan het beter stellen van behandeldoelen bij de 
revalidatie van deze mensen. 
Deel 2: Onderliggende motorische stoornissen bij 
mensen met pure HSP
 
De invloed van verhoogde rekreflexen van de kuiten op balanshandhaving
Spastische spieren hebben als eigenschap dat zij een versterkte motorische res-
pons tonen als reactie op spierrek (rekreflex). In hoofdstuk 4 hebben we de rol van 
(verhoogde) rekreflexen van de kuitspieren op de balanshandhaving onderzocht bij 
mensen met pure HSP en bij gezonde vrijwilligers. Mensen moesten een roterende 
balansverstoring ondergaan , waarbij met verschillende snelheden de tenen naar 
boven werden gekanteld en de kuiten werden gerekt. Mensen met HSP waren hierbij 
minder goed in staat om hun balans te handhaven en lieten – zoals verwacht –
hogere rekreflexen zien dan gezonde vrijwilligers. Maar ook in een latere fase van de 
evenwichtsreactie werd verhoogde spieractiviteit van de kuiten geobserveerd bij de 
mensen met HSP, terwijl deze late activiteit bij gezonde vrijwilligers tijdig en effectief 
werd onderdrukt. Dit late verschil in spieractiviteit tussen mensen met HSP en ge-
zonden kwam overeen met het moment dat er ook een verschil werd gevonden in 
het bewegingstraject van het lichaamszwaartepunt tussen de twee groepen. Deze 
bevindingen suggereren dat een verstoorde de-activering van late kuitspieractiviteit 
belangrijker is dan een versterking van de vroege rekreflexen voor het veroorzaken 
van balansproblemen bij mensen met pure HSP.
Spieractivering versus spierde-activering tijdens starten met lopen
Schade aan de zenuwbanen vanuit de hersenen naar het ruggenmerg c.q. de cor-
ticospinale banen leidt tot verstoringen in de aansturing van willekeurige bewegin-
gen. Bevindingen uit eerder onderzoek suggereren dat een bepaalde mate van wil-
lekeurige aansturing overgenomen zou kunnen worden door zenuwcircuits die via 
de hersenstam verlopen c.q. het cortico-reticulospinale baansysteem. Bij mensen is 
dit vooral getest door middel van het StartReact effect. Het StartReact effect is de 
versnelling van de reactietijd van een willekeurige beweging die optreedt als – tegelij-
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kertijd met de primaire stimulus – een schrikreactie wordt ontlokt, veelal door middel 
van een hard geluid. Er wordt verondersteld dat de willekeurige beweging dan primair 
wordt aangestuurd via de hersenstam. Eerder onderzoek werd vooral uitgevoerd op 
basis van enkelvoudige bewegingen van één gewricht. In hoofdstuk 5 hebben we 
getest of het hersenstamcircuit ook kan worden gebruikt om complexe bewegingen 
te initiëren, waarbij coördinatie van meerdere lichaamssegmenten nodig is. Deelne-
mers moesten na het verschijnen van een visuele stimulus zo snel mogelijk starten 
met lopen. Zonder een schrikgeluid waren de reactietijden van mensen met HSP ver-
traagd vergeleken met gezonde vrijwilligers. Indien tegelijkertijd met de visuele sti-
mulus een schrikgeluid werd aangebonden, bleek de spieractivering van beide groe-
pen versneld, maar verhoudingsgewijs méér bij de mensen met HSP, waardoor de 
reactietijden even snel werden in beide groepen. Spierde-activering werd eveneens 
versneld door gelijktijdige aanbieding van een schrikgeluid, maar alleen bij de gezon-
de vrijwilligers. Deze resultaten suggereren dat het hersenstamcircuit potentieel ook 
kan compenseren bij de initiatie van complexe multisegmentale bewegingen, zoals 
tijdens starten met lopen. Echter, deze compensatie is niet optimaal, aangezien dit 
circuit niet in staat lijkt te zijn tot adequate de-activering van spieren. 
Deel 3: Functionele effecten van botulinetoxine bij 
mensen met pure HSP
 
Functionele effecten van behandeling met botulinetoxine en rekoefeningen van 
de kuiten
Botulinetoxine wordt vaak gebruikt om spasticiteit te verminderen. Naast een ver-
mindering van spasticiteit kan er ook milde spierverzwakking optreden. In een eer-
dere publicatie van onze groep werd beschreven dat de comfortabele loopsnelheid 
toenam in een groep mensen met pure HSP na behandeling met botulinetoxine en 
aanvullende rekoefeningen van de kuitspieren. Echter, de onderliggende mechanis-
men die ten grondslag lagen aan de gevonden verbetering van loopsnelheid werden 
niet gerapporteerd. In hoofdstuk 6 hebben we onderzocht hoe in dezelfde groep 
patiënten eventuele veranderingen in bewegingsuitslagen, krachtenspel en energie-
ontwikkeling rond de enkels tot een hogere loopsnelheid na de behandeling hebben 
geleid. Gangbeeldanalyse liet zien dat er – naast een verbetering van loopsnelheid en 
een grotere schredelengte – sprake was van een grotere afzetkracht en meer ener-
gieontwikkeling rond de enkels tijdens de late standfase, terwijl er geen veranderin-
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gen optraden in bewegingsuitslagen of in de krachten of energieabsorptie tijdens de 
vroege en middenstandfase van het lopen. Deze resultaten suggereren dat behan-
deling met botulinetoxine, aangevuld met rekoefeningen van de kuiten bij mensen 
met pure HSP de loopsnelheid kan verhogen door een efficiënter gebruik van de be-
schikbare kuitspierkracht tijdens de afzetfase, leidend tot een grotere schredelengte.
Functionele effecten van behandeling met botulinetoxine en rekoefeningen van 
de heupadductoren
In hoofdstuk 7 hebben de we op soortgelijke wijze de functionele effecten van be-
handeling met botulinetoxine en aanvullende rekoefeningen van de heupadducto-
ren op de balans- en loopvaardigheid onderzocht bij mensen met pure HSP. De 
heupadductoren bevinden zich aan de binnenzijde van het bovenbeen. Mensen met 
HSP hebben vaak last van spasticiteit van de heupadductoren, waardoor de benen 
tijdens het lopen naar binnen neigen met een (te) smal gangspoor tot gevolg. Dit 
veroorzaakt balansproblemen. Mensen met HSP ervaren daarnaast vaak moeilijkhe-
den bij het zijwaarts stappen om hun balans te handhaven tijdens dynamische om-
standigheden. Een smal gangspoor en de veronderstelde problemen bij het zijwaarts 
stappen leiden waarschijnlijk tot een verhoogd valrisico. Intramusculaire injecties 
met botulinetoxine worden vaak gebruikt om spasticiteit te verminderen, maar er is 
nog geen onderzoek dat systematisch heeft onderzocht wat de functionele effecten 
zijn van behandeling van de heupadductoren bij mensen met pure HSP. De resul-
taten lieten zien dat er na behandeling een verhoogde comfortabele loopsnelheid 
en gangspoorbreedte was. Daarnaast lieten patiënten zien dat het zijwaarts stappen 
verbeterde zowel wat betreft het effect als wat betreft de kwaliteit van de stap. Dit 
laatste werd vastgesteld aan de hand van de beenhoek t.o.v. de verticaal, maar bleek 
alleen het geval tijdens de condities waarin de patiënten vooraf de richting van de 
balansverstoring kenden. Deze studie geeft de eerste aanwijzingen dat behandeling 
met botulinetoxine en aanvullend rekken van spastische heupadductoren de balans- 
en loopvaardigheid kan verbeteren bij mensen met pure HSP. 
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Een mooi moment! Het werk van de afgelopen jaren is samengevat in één proefschrift. 
Veel mensen hebben me geholpen om tot dit resultaat te komen. Mensen die ik 
graag persoonlijk wil bedanken. 
Allereerst wil ik alle mensen met HSP en de controledeelnemers bedanken die deel 
hebben genomen aan de onderzoeken. Bedankt dat jullie de tijd hebben genomen 
en bereid waren om deel te nemen aan de experimenten. Jullie hebben een waar-
devolle bijdrage geleverd aan de wetenschap. 
Sander, tijdens mijn stage vroeg je me of ik wilde starten met de FEBOCH-II studie. Jij 
kon niet beloven dat dit zou uitlopen tot een promotietraject maar wilde daar je best 
voor doen. Met de ambitie om te promoveren heb ik deze kans aangegrepen en ben 
ik gestart. Dankzij jou is dit een mooi promotietraject geworden. Het is een eer dat ik 
met jou heb mogen samenwerken en ik heb ontzettend veel van je geleerd. Zowel 
op klinisch als op wetenschappelijk gebied ben je me blijven verrassen en heb je me 
weten te inspireren met jouw brede kennis en kritische blik. Ondanks jouw drukke 
agenda heb ik altijd het gevoel gehad dat jij de tijd had om me te helpen waar nodig. 
Vivian, onze samenwerking begon al tijdens mijn stage. Ondanks dat ik zo laat aan 
kwam kloppen heb je perfect ingeschat welk stageproject bij me zou passen. Ik denk 
terug aan fantastische intensieve discussies en brainstormsessies waar we compleet 
verdwaalden in analyses en interpretaties. Ik vond dat echt een leuke tijd en was heel 
blij dat dit voortgezet kon worden tijdens mijn promotie. Jouw kennis op het gebied 
van balanscontrole en lopen is enorm. Ik was telkens verbaasd hoeveel beter het ar-
tikel weer werd door jouw feedback. Ik vond het heel mooi om te zien hoe jij zowel 
op hoofdzaak als op detail weer de juiste input gaf om me verder te helpen. Ik heb 
heel veel van je geleerd. 
Bart, ik ben blij dat jij mijn promotor bent geweest. Voor advies en vragen met be-
trekking tot neurologie kon ik op je rekenen. Jij kan heel goed de vertaalslag maken 
vanuit jouw expertise naar mijn onderzoeken en daar heb ik heel veel aan gehad. Ik 
heb bij vragen altijd bij je aan kunnen kloppen en je nam altijd de tijd voor me om 
alles uit te leggen. Ontzettend bedankt voor de snelle reacties en de inbreng vanuit 
jouw neurologische achtergrond. 
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Jorik, jouw verdediging is de eerste geweest die ik mee heb mogen maken. Dat was 
direct een goed voorbeeld. Leuk dat ik nu de eerste promovendus van jou als co-
promotor ben. Het was fijn met je samen te werken. Volgens mij hebben wij het net 
zo vaak over wetenschappelijke inhoud gehad als over complete onzin. Ik heb veel 
geleerd van de efficiëntie waarmee jij werkt en heb feedback altijd ontzettend snel 
en met hoge kwaliteit teruggekregen. Ik heb op jou kunnen rekenen. 
Ik had me geen beter promotieteam voor kunnen stellen dan ik nu gehad heb. Jullie 
hebben voor mij klaar gestaan en ik ben dankbaar dat ik met zulke goede mensen 
samen heb mogen werken. 
Leden van de manuscript-commissie, Prof. Dr. Pieter Medendorp, Prof. Dr. Bas Blo-
em, Prof. Dr. Herman van der Kooij, bedankt voor het kritisch beoordelen en goed-
keuren van mijn manuscript. Ik kijk er naar uit om met jullie in discussie te gaan. 
Zonder sponsoren was het niet mogelijk geweest de onderzoeken uit te voeren en 
had ik nooit kunnen promoveren. Graag wil ik contactpersonen Rob van der Linden 
van Merz Pharmaceuticals en Mary Verhoeven van Ipsen Farmaceutica BV enorm 
bedanken voor de prettige samenwerking. 
Hanneke en Allan, jullie wil ik graag bedanken voor het selecteren van mensen met 
HSP die voldeden aan de inclusiecriteria en natuurlijk voor het injecteren van de 
botulinetoxine injecties voor de FEBOCH-II studie. Jasper, met jou heb ik ook veel 
samengewerkt. Bedankt voor het afnemen van de klinimetrie en het uitleggen van de 
rekoefeningen die in het kader van het onderzoek uitgevoerd moesten worden. Daar-
naast wil ik Giel graag bedanken voor het helpen bij de metingen van de FEBOCH-II 
studie. Laura en Hans, jullie wil ik graag bedanken voor jullie bijdrage bij het opzetten 
en analyseren van de EXPAND-survey en voor jullie feedback op het artikel. Ook al 
mijn andere co-auteurs wil ik graag  bedanken voor hun waardevolle inbreng. 
Radboudroomies: Frank, Milou, Renee, Jolanda, Lotte Heutinck, Marian, Vera, Wout-
er, Digna, Mitchel, Anouk en Lotte van de Venis, bedankt voor de gezelligheid de af-
gelopen jaren op onze kamer en tijdens OZU’s. Ook tijdens congressen heb ik naast 
een leerzame ook een hele gezellige tijd met jullie gehad. 
Frank, we hebben de kamer gedeeld in Florida, maar ook in het kippenhok. Ik heb 
veel met en om jou moeten lachen en wat was het mooi om je in de zeik te nemen 
(maar dat gebeurde helaas andersom ook). Ik ben blij dat we nog steeds veel contact 
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hebben en wat mooi dat wij onze promotietrajecten in dezelfde week af mogen 
sluiten! Milou, ik vind het leuk dat ik veel met jou samen heb mogen werken. Buiten 
dat ik niet snel meer paellaschotel met je zou delen (aangezien er niets voor me 
overblijft) heb ik een ontzettend leuke tijd met je gehad de afgelopen jaren. Frank en 
Milou, ik ben blij dat jullie mijn paranimfen willen zijn.
Ook alle andere collega-onderzoekers en oud-collega’s op de afdeling wil ik bedan-
ken. Mariska, Laura, Rosanne, Joyce, Teo, Mariëlle, Rosemarie, Arjen, Sjoerd en Clau-
dia, ontzettend bedankt voor jullie gezelligheid en hulp afgelopen jaren. Geert, jou 
wil ik ook bedanken als redder in nood als de techniek te wensen overliet. Dorien en 
Laurien, ook jullie wil ik nog graag apart noemen. Dank voor jullie inzet de afgelopen 
jaren. Het was altijd gezellig om even bij jullie binnen te lopen. Corine, jij hebt me 
enorm geholpen bij het inplannen van de FEBOCH-II deelnemers. Het was een hele 
klus en ik ben nog steeds dankbaar dat je dit zo goed hebt kunnen regelen. 
Alle leden van het OZO, de Labmeeting en de Journal Club, zowel Radboud collega’s 
als mensen van het SMK, wil ik bedanken voor de samenwerking en de discussies die 
we gehad hebben. Ook mensen die ik tijdens cursussen ontmoet heb wil ik bedank-
en. Sven, veel succes met het afronden van jouw promotietraject!
Lonneke, bedankt voor de prachtige omslag en lay-out van dit proefschrift. Ik ben er 
heel blij mee!
Frank, ik wil je bedanken voor jouw vertrouwen in onze samenwerking. We zijn namens 
ROER met mooie projecten bezig en ik hoop dat wij onze samenwerking lang voort 
kunnen zetten. Bob, naast dat ik jou wil bedanken dat je me met Frank in contact hebt 
gebracht, heb ik ook veel gehad aan jouw adviezen tussen het tennissen door. 
Uiteraard ook dank aan mijn groep vrienden waar mijn opleiding mee begon: de 
Allstars. Toen ik jaren geleden startte met Bewegingswetenschappen had ik niet ver-
wacht dat dit ooit zou leiden tot een promotie. Ik heb een leerzame en leuke tijd met 
jullie gehad, met als hoogtepunt natuurlijk de ‘wok’-avonden.
Mijn vrienden wil ik bedanken voor de fijne afleiding tussen het werken door. Frank, 
Stefan, Marten, Dylan, Randy, Glenn, Tommy, Jules, Bas, Anke, Nina, Bregje en Hilde; 
bedankt voor de fijne afleiding tussen het werken door. Ik kijk terug op veel mooie 




Lieve schoonfamilie, Bart, Jeannette, Ruud, Kristel en Renske, ik heb me altijd heel 
erg welkom gevoeld bij jullie. Dank voor jullie interesse in mijn promotie de afge-
lopen jaren. Ik hoop dat we nog veel gezellige momenten en lachbuien gaan hebben 
samen. 
Lieve Bob en Bibi, ik ben enorm blij met jullie als broer en zus en de band die wij 
hebben. We zijn allemaal onze eigen weg gegaan, maar ik ben blij dat we nog zoveel 
contact hebben. Bob, niemand maakt mij meer aan het lachen dan jij. Ik hoop dat 
we nog veel van die momenten gaan krijgen met jou en Esmee. Bibi, ik vind het knap 
hoe jij alles geregeld krijgt en dat jij je nooit druk maakt. Jouw dagen zitten altijd 
bomvol, maar je weet toch tijd te maken. Bob en Bieb, ik ben trots op jullie! 
Lieve mama, op jou kan ik altijd rekenen. Je hebt de afgelopen jaren veel interesse 
gehad in wat ik aan het doen was. Daarnaast zorg je altijd voor gezelligheid en dat 
we veel leuke dingen doen, met als hoogtepunten onze vakanties met Bob en Bibi. 
Het maakt me bewust van wat écht belangrijk is in het leven. Hans, Marleen, Lisa en 
Geert, ook jullie wil ik ook bedanken voor gezellige momenten met de familie en de 
fantastische weekendjes weg. 
Lieve papa, bedankt voor jouw onvoorwaardelijke vertrouwen in mij. Ik ben blij dat je 
me altijd mijn eigen keuzes hebt laten maken en dat jij hier altijd achter hebt gestaan. 
Daar heb ik heel veel aan gehad. Vanaf halverwege mijn Bachelor tot aan het eind 
van mijn promotie heb ik ook voor jouw bedrijf mogen werken. Ik vond dit een leuke 
afwisseling naast het doen van onderzoek. Het is altijd fijn geweest tussendoor weer 
thuis te komen en ik heb genoten van onze etentjes met jou en Heleen. 
Lieve Renée, jij bent alles voor mij. Wat is het ontzettend fijn om met jou samen te 
zijn. Ik besef me heel goed dat ik geluk heb met jou. Jij maakt mijn leven mooier en 
leuker. We hebben inmiddels onze eigen huis en leven toe naar onze bruiloft. We 
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Courses and workshops Organizer Year ECTS
Basiscursus Regelgeving en 
Organisatie voor Klinisch  
onderzoekers (BROK)
Radboud university medical center 2015 1.5
Management voor Promovendi Radboud university 2016 2
Cambridge Advanced English Radboud in’to languages 2016, 
2017
3.4
Writing week Department of Rehabilitation, 






The Art of Presenting Science Radboud university 2017 1.5
Scientific Integrity Course Radboud university medical center 2017 0.6
Advanced Conversation Radboud university 2017 1.5
Reanimatiecursus Radboud university medical center 2017 0.15
ESP69 Causal Mediation  
Analysis
Erasmus MC 2017 0.5
Personal development week Department of Rehabilitation,  
Radboud university medical center
2018 1.3
Innovation and  
Entrepreneurship
Radboud university 2018 3
BROK herregistratie Radboud university medical center 2019 0.15
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Lectures and conferences Location Year ECTS
Congress on  
NeuroRehabilitation and  
Neural Repair of the Dutch 
Society for Neuro Rehabilitation 





Radboud research round:  




Society for Movement Analysis 
Laboratories in the Low Lands 
(SMALLL) congress
















Donders Discussions at the 
Donders Institute for Brain, 
Cognition and Behaviour
Nijmegen 2016 0.25
World Congress of the  
International Society of Posture 
and Gait Research (ISPGR)




Research data management according to FAIR principles
General information about the data collection
Research projects within this thesis involve human subject data. Written informed 
consent for collecting these data was obtained from the participants. Pre-existing 
data and new data were collected and stored at the Radboud university medical 
center, Nijmegen, the Netherlands. 
FAIR principles
Findable
Data were stored on the server of the department of Rehabilitation at the Radboud 
university medical center. Most data of the survey (chapter 3) were also stored in the 
online database management system Castor EDC. Paper CRF files were stored in the 
department’s archives. Documentation to describe the data sets is provided on the 
department’s server. Data sets stored at the department’s server can be found at Q:\
Research\044 HSP Startle and Q:\Research\056 FEBOCH II.
Accessible
All data will be available on request by contacting the staff secretary of the depart-
ment of Rehabilitation at the Radboud university medical center (secretariaatstaf.
reval@radboudumc.nl).
Interoperable 
Documentation was added to the data sets to make the data interpretable (Q:\Re-
search\044 HSP Startle\FAIR). The documentation contains links to publications, ref-
erences to the location of the data sets and description of the data sets. The data 
were stored in the following file formats: .xlsx (Microsoft Office Excel) and .mat (Mat-
lab, Mathworks, USA). No existing data standards were used such as vocabularies, 
ontologies or thesauri. 
Reusable
The data will be stored for at least 10 years and can therefore also be reused in this 
time period. There is no embargo on the accessibility of the data. 
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Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young sci-
entists. To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour 
established the Donders Graduate School for Cognitive Neuroscience (DGCN), 
which was officially recognised as a national graduate school in 2009. The Graduate 
School covers training at both Master’s and PhD level and provides an excellent edu-
cational context fully aligned with the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students 
in biology, physics, psycholinguistics, psychology, behavioral science, medicine and 
related disciplines. Selective admission and assessment centers guarantee the enrol-
ment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alum-
ni show a continuation in academia with postdoc positions at top institutes world-
wide, e.g. Stanford University, University of Oxford, University of Cambridge, UCL 
London, MPI Leipzig, Hanyang University in South Korea, NTNU Norway, University 
of Illinois, North Western University, Northeastern University in Boston, ETH Zürich, 
University of Vienna etc.. Positions outside academia spread among the following 
sectors: specialists in a medical environment, mainly in genetics, geriatrics, psychi-
atry and neurology. Specialists in a psychological environment, e.g. as specialist in 
neuropsychology, psychological diagnostics or therapy. Positions in higher educa-
tion as coordinators or lecturers. A smaller percentage enters business as research 
consultants, analysts or head of research and development. Fewer graduates  stay 
in a research environment as lab coordinators, technical support or policy advisors. 
Upcoming possibilities are positions in the IT sector and management position in 
pharmaceutical industry. In general, the PhDs graduates almost invariably continue 
with high-quality positions that play an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please 
visit: http://www.ru.nl/donders/graduate-school/phd/.

